Oncology and Carcinogenesis articles for China

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 1828

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
166 161.38
Metabolic Reprogramming Nanoplatform for Broad-Spectrum Lactate Suppression to Reverse High Intensity Focused Ultrasound-Induced Immunosuppression in Hepatocellular Carcinoma Therapy 1.00
A Genetically Engineered Macrophage-Derived Vesicular Nanodecoy Targeting the CD47/SIRPα Axis for Reinforced Tumor Radioimmunotherapy 1.00
Arginine Polymer-Based Nanoplatform Facilitates Oral Co-Delivery of Antibody/Antigen for Robust Oral Immunotherapy in Orthotopic Colon Cancer 0.92
Ferritin-Based Mild Magnetic Hyperthermia Therapy for Bladder Cancer: A Synergistic Anti-Inflammatory Strategy 1.00
Autophagy-Enhanced Nanoplatforms Eliminate Intracellular Bacteria and Block Bacteria-Driven Epithelial–Mesenchymal Transition for Tumor Metastasis Inhibition 1.00
Tuning J‑Aggregation Behavior of Fused Ring Acceptor Fluorophore within Nanoparticles for NIR-II Excitable Bioimaging with High Brightness 0.94
Injectable Binary-Amplified Cascade Hydrogels Suppress Post-Incomplete Microwave Ablation Relapse via Integrated Metallo-Metabolic-Immunomodulation 1.00
Ultrasound-Triggered Localized Surface Plasmon Resonance Enhances Electron Transfer for Melanoma Sonodynamic Therapy 1.00
Multistage Responsive NanoCRISPR Unleashes Cascade Amplified Endogenous Apoptosis and Inhibits Epithelial-Mesenchymal Transition Simultaneously for Suppressing Tumor Growth and Metastasis 1.00
Engineering of Immunoactive Hydrogels Complements Tumor-Treating Fields for Glioblastoma Therapy 1.00
Reengineered Albumin-Paclitaxel Nanoparticles Remodeling Tumor Cell Death Pathways for Prevention of Chemotherapy-Induced Breast Cancer Metastasis 1.00
A Bioinspired Exosomal Nanoplatform for Coordinated Sorafenib and MicroRNA Delivery to Sensitize Ferroptosis and Induce Immunoactivation in Triple-Negative Breast Cancer 1.00
Clickable Universal Tumor-Antigen Equipping Strategy for Remedial Chimeric Antigen Receptor T Cells to Destroy Solid Tumors 1.00
A Self-Assembled Irinotecan Nanomedicine Abrogates Steatohepatitis-Induced Liver Metastasis and Potentiates Antitumor Efficacy against Colorectal Cancer 1.00
Combinatorial Design of Fatty Acid-Incorporated Plasmid Lipid Nanoparticles Drives Dendritic Cell Hyperactivation for Enhanced Cancer Immunotherapy 1.00
Hydration-Driven Self-Gelling Particulate Embolic Agent for Precise and Stable Occlusion of Hemorrhagic Vessels with Collateral Circulation 1.00
Penetrate-Then-Gate Bioorthogonal In Situ Cancer Vaccination for Aligned Antigen Capture and Localized TLR7/8 Licensing 1.00
Injectable Trojan Horse Hydrogel Unleashing Penetrable and Immunostimulatory Nanomicelles for Postoperative Treatment of Glioblastoma 1.00
Excited-State-Guided Molecular Design System for Type I Photosensitizers 0.25
Engineered Bacillus Calmette-Guérin Mediated Immunotherapy of Triple-Negative Breast Cancer 1.00
Hierarchical Zeolitic Imidazolate Framework-8@Au Cluster Nanocarriers for In Situ Chimeric Antigen Receptor Macrophage Programming and Immunotherapy in Prostate Cancer 1.00
Multi-Ion Channel Nanomedicines Targeting Zinc Transporter 1/ATPase Copper Transporters Disrupt Copper/Iron Homeostasis to Enhance Tumor Immunotherapy 1.00
Dual Energy Depletion by Zinc/Copper Disruptor to Potentiate Cuproptosis and Pyroptosis for Enhanced Tumor Immunotherapy 1.00
Synergizing Pt–O–Mo Coupling and Electron Gradient: A Nanozyme Paradigm for Low-Dose Tumor Radiosensitization 1.00
Nanodiamond-Mediated Targeted Delivery of Nanobodies and Immunostimulatory RNA for Breast Cancer Therapy 0.63
Piezocatalytic Nanoplatform Drives Mg2+-Release-Amplified Ferroptosis-Immune Synergy for Tumor Microenvironment Reprogramming 0.89
In Situ Self-Reinforcing Fully Active Nanodrugs: Excitation/Oxygen-Free Redox Disruption Therapy through Metabolite-Driven Reactive Oxygen Species Cascades 1.00
Hierarchically Targeted Cu-Doped Carbon Dot/Kynurenic Acid@RM Platform for Restoring Mitochondrial Metabolism and Modulating Inflammation in Acute Pancreatitis 1.00
Iron Borate Nanobeams for Magnetic Resonance Imaging-Guided Boron Neutron Capture Therapy 1.00
A Self-Driving and Self-Reporting Petal-Like Au–Cu2O Metalloenzyme for Probing H2S-Mediated Cuproptosis 1.00
Engineered Bacteria-Driven Biohybrid Microrobots Potentiate IL-2 Immunotherapy by Evoking Pyroptosis 1.00
Carrier-Free Nano-Proteolysis Targeting Chimeras Enable Selective Protein Degradation and Enhance Photoimmunometabolic Therapy against Lung Adenocarcinoma 1.00
Molecular Engineering of Curcumin-Based Lysosome-Targeting Photosensitizers for Boosting Tumor Photoimmunotherapy via Ferroptosis/Pyroptosis Activation and Autophagy Inhibition 1.00
A Stretchable, Transparent, Photothermally Stimulated Laser-Induced Graphene Patch for Noninvasive Skin Tumor Treatment 1.00
Reprogramming Postablation Tumor Immune Microenvironment with Dual-Function Nanotherapeutic Immunomodulator for Synergistic Antitumor Immunity and Recurrence Suppression 1.00
Active Mechanics Governs Three-Dimensional Cell-in-Cell Formation 1.00
Photoactivatable Nanozyme-Integrated Microneedles Orchestrate a Self-Amplifying Immunogenic Cell Death–STING Signaling Circuit for Tumor Immune Rewiring 1.00
Triplet π-Conjugated Oligomer Nanoparticles with High Intersystem Crossing Efficiency for 808 nm Laser-Activated Photodynamic Therapy 1.00
Axially Polarized O–Fe–N4 Single-Atom Enzyme Drives Clearance of Tumor-Resident Intracellular Microbiota and Potentiates Immunotherapy 1.00
Bacteria-Derived Nanobody-Decorated Nanoplatform Restores T Cell Immunity Post-Radiotherapy 1.00
Tumor-Directed Disulfidptosis via Spatiotemporally Controlled Copper Bioorthogonal Activation 1.00
Microenvironment-Triggered Signal Amplification for Dual-Modal Fluorescence/MRI of Hepatocellular Carcinoma 1.00
A Biomimetic Microparticle Disrupting the Intracellular/Extracellular pH Homeostasis of Tumor Cells for Cancer Chemo-Immunotherapy 1.00
A Type I/II Photosensitizer with Lysosome-Targeting Capabilities Induces Immunogenic Cell Death in Cancer Cells to Enhance Tumor Immunotherapy 1.00
Engineered Self-Activatable Polymeric Nanozymes Precisely Eradicate Tumor-Associated Intramacrophage Bacteria to Potentiate Immunotherapy Based on Cluster of Differentiation 47 Blockade 0.90
Galloyl-Mediated Antigen Capture Coupled with Hypoxia-Responsive Reprogramming Drives Potent Photoimmunotherapy 1.00
circTNIK Promotes Carbon Nanotubes-Induced Lung Carcinogenesis via GRP78-Mediated Endoplasmic Reticulum Stress and Suppression of Type I Interferon Signaling 1.00
Metal–Phenolic Networks-Based Nanozyme Reprograms Tumor Metabolism and Immunosuppressive Microenvironment to Enhance Ferroptosis and Potentiate Cancer Immunotherapy 1.00
Probiotic-Driven Therapeutic Vaccine for in Vivo Reprogramming of Tumor Cells To Elicit Postoperative Antitumor Immunity 1.00
Reprogramming the Tumor Mechanical Microenvironment with Lactate Inhibition and Stimulator of Interferon Genes Activation to Potentiate Systematic Radio-Immunotherapy 1.00
Synergistic Gene Immunotherapy for Lung Cancer via Targeted Nanomedicine Restoring Genetic Tumor Suppression and Activating STING Pathway 0.88
An Intracellular Gelated Macrophage-Based Vaccine for Tumor Immunotherapy 1.00
Selective Depletion of Tumor-Associated Macrophages with Biomineralized Erythrocyte Nanoghosts to Boost Neoadjuvant Radioimmunotherapy 0.89
A Recombinant Targeted Bionanoparticle In Vitro Expressing a Gene-Editing Protein for Epidermal Growth Factor Receptor Mutant Lung Cancer 1.00
Anti-Protein-Adsorption Nano-Proteolysis Targeting Chimeras as a Potent Platform for Efficient Programmed Cell Death Ligand 1 Degradation 1.00
Charge-Reversal Near-Infrared II Polymeric Amphiphiles Enable Efficient Combinatorial Gene and Mild Photothermal Therapy for Osteosarcoma 1.00
Oxygen Self-Sufficient Ir–MnII/III Coordination-Assembled Nanoparticles Evoke Apoptosis and Ferroptosis for Boosting Hypoxic Melanoma Photoimmunotherapy 1.00
H2S-Activable BiFeO3–x Nanocatalysts for Ferroptosis-Driven Cancer Immunotherapy 1.00
Immunological Conversion of Solid Tumors Using an Outer Membrane Vesicle Based Checkpoint Nanoinhibitor for Cancer Immunotherapy 1.00
A “Jack-of-All-Trades” Phototheranostic System Enabled by Strategic Regulation of Ferroptosis and PANoptosis for Cancer Therapy 1.00
An Ultrasonic Probe-Fabricated Nanocapsule for Cytomembrane-Anchoring Photodynamic Therapy and In Situ Tumor Vaccine 1.00
Highly Active Strontium Peroxide Nanoparticles Induce Alkalization/Oxidation to Potentiate Cancer Immuno-Metabolic Therapy 1.00
Brain-Targeting Metal–Organic Framework Nanoplatform Reprogramming Ferroptosis Sensitivity of Glioblastoma 0.83
Dual-Powered Nanomotor In Situ Vaccine with Tumor-Confined Penetration and Acidity Neutralization Boosts Stimulator of Interferon Genes-Mediated Immunotherapy 0.92
NIR-II Multimodal Phototheranostics Synergized with Antigen-Specific Vaccines for Boosted Cancer Photoimmunotherapy 1.00
Albumin Nanoparticles Co-Loaded with Dual Drugs for Enhanced Ferroptosis-Based Cancer Therapy through Modulating Cholesterol Metabolism 1.00
Copper-Oxamate Coordination Polymers Reverse Cuproptosis Resistance in Nonsmall Cell Lung Cancer via Glycolysis Reprogramming 1.00
Adaptive Cytoskeletal Responses to Extracellular Environment Viscosity Modulate Cell Migration 1.00
Muscle-Targeted Nanocomposite Therapy Alleviates Age-Related Sarcopenia via Antioxidant and Metabolic Reprogramming 1.00
Ion-Pairing Therapeutic Agents to Overcome Immune Resistance for Enhancing Type I Near-Infrared Photodynamic Immuno/Chemotherapy 1.00
A Sonosensitizing Nanoshuttle for Synergistic Hypoxia Relief and Immune Activation To Strengthen Sonodynamic Immunotherapy Against Triple-Negative Breast Cancer 1.00
Enhancing Breast Cancer Immunotherapy by Suppressing Sympathetic Nervous System-Driven T-Cell Exhaustion and Promoting T-Cell Priming and Trafficking 0.93
NIR-II Photocatalytic-Triggered Pyroptosis via Built-In Electric Field-Enhanced Reactive Oxygen Species Generation in Au–Cu2O Nanodumbbells 1.00
Noncontact Environmental Radiation Sensitization via Photoresponse Processes Mediated by Nanostructured Ru-Based Photosensitizers with Near-Infrared Responsiveness 1.00
Dual-Membrane-Camouflaged Engineered Bacteria for Targeted Melanoma Therapy 1.00
Rapid Detection and Purification of Extracellular Vesicles for Hepatocellular Carcinoma Screening Using a Plasmonic Metasurface Integrated with the Kolmogorov–Arnold Network 1.00
Senescence-Primed Ferroptosis Enabled by a Metal–Organic Framework Nanoplatform for Enhanced Cancer Therapy 1.00
Multistage Biobarrier-Adaptive Peptide Radiosensitizer with Low-Dose X-ray Augments Glioblastoma Radiotherapy via Destabilizing Lysosomal Homeostasis 0.90
Extracellular Vesicle-Packaged MIR4435-2HG Facilitates Cigarette Smoke-Induced Bladder Cancer Progression through Enolase 1-Dependent Glycolytic Reprogramming 1.00
Tumor Mechanobiology-Inspired Nanomechanics: Piezo1 Mediated Tumor-Associated Macrophages Reprogramming and Exosome-Driven Immune Amplification 1.00
Ferric Ion-Release Nanoprobes for Hypoxia Magnetic Resonance Imaging and Radiotherapy Stratification in Solid Tumors 1.00
Engineered Dendritic Cell-Derived Vesicles for T-Cell-Targeted Magnesium Delivery and Metabolic Reprogramming 1.00
Efferocytosis-Mimicking Nanovesicle-Cross-Linked Hydrogel for Dual Immunomodulation and Angiogenesis to Prolong Allogeneic Skin Graft Survival 1.00
Pyroptosis-Inducing Nanoplatform with Plasmonic-Enhanced Phototherapy for Metastasis-Suppressive Cancer Immunotherapy 0.91
Engineering Microwave-Activatable Nanoenergic Converters with Energy Cascade Structures for On-Demand Microwave Dynamic Therapy 1.00
Near-Infrared-Triggered Photoresponsive Nanobombs Overcome Tumor Immunosuppression through Coordinated Pyroptosis Activation and Mitophagy Blockade 1.00
Engineered Probiotics Remodel the Tumor Immune Microenvironment 1.00
Cysteine Metabolism Reprogramming-Motivated Catalytic Immunotherapy for Orthopedic Biofilm Infections 1.00
Ultrasmall Manganese-Doped TiO2–x Overcomes the Efficacy–Safety Dilemma of Sonodynamic Therapy via Tumor Microenvironment-Responsive Reactive Oxygen Species Amplification and Clearance 1.00
Ultrasound-Visualized Cuproptosis in Glioblastoma via Endogenous Copper Sequestration and Nitric Oxide-Gas Controlled Release Using a Programmable Nanoliposomal Platform 1.00
Intracellular Disulfide Stress Induced Actin Dysfunction for Enhancing Radiotherapy Sensitivity and Eliciting Antitumor Immunity 0.85
Harnessing Synergistic Interplay of Twisted and Planar Structures for the Development of NIR-II Phototheranostic Agents 1.00
Mitochondria-Targeted Dual-Ion Perturbator Amplifies Cuproptosis for Enhanced Melanoma Immunotherapy and Accelerated Postoperative Wound Healing 1.00
Targeting Mitochondrial Oxidative Stress by Calcium/Copper/Elesclomol Tri-Overloaded Nanocages for Osteosarcoma Immunotherapy via Immunogenic Cell Death 1.00
In Situ Remodeling of Tumor Microenvironment via Specific Cancer-Associated Fibroblasts Subtype Engineering to Boost Antitumor Immunity 1.00
Metallosalphen-Covalent Organic Framework-Based Semiconducting Artificial Enzymes with Radio-Activable Antitumor Immunity for Suppressing Tumor Metastasis and Recurrence 0.88
Nanomotor-Promoted In Situ Vaccination for Deep-Seated Cancer Immunotherapy 1.00
Self-Adjuvanting Gel for Hierarchical Delivery to Tumors and Lymph Nodes in Liver and Colon Tumor Immunotherapy 1.00
Photosynthetic Plant-Derived Nanovesicles Precisely Amplify Photodynamic Effect by Light-Activated Oxygen Generation for Enhanced Cancer Photoimmunotherapy 1.00
Calreticulin Enhances Therapeutic Immune Responses of Dry Thermostat-Stressed Hepatocellular Carcinoma Cell Vaccine 0.91
Surface d-Band Modulation via Biodirected Mineralization Enables Nanoenzymes to Inhibit Radiation-Induced T-Cell Exhaustion and Potentiate Immunoradiotherapy 1.00
Spatiotemporally Controlled Nanomicelles for Synergistic Phototherapy and Immune Reprogramming in Triple-Negative Breast Cancer 1.00
Mito-Specific “Trojan Horse” Nanotherapy: Synergistic Antitumor Immunotherapy via Dual Modulation Mitochondrial Metabolism and Glycolysis 0.71
Nebulized Inhalation of Engineered Extracellular Vesicles to Destruct Pre-metastatic Niche and Inhibit Postoperative Lung Metastasis in a Mouse Model 1.00
Virus-Like Particle-Based Personalized Neoantigen Nano-Vaccine for Tumor Immunotherapy and Recurrence Prevention 1.00
Exploring the Potentials of Silver Nanoparticles in Overcoming Cisplatin Resistance in Lung Adenocarcinoma: Insights from Proteomic and Xenograft Mice Studies 0.83
Efficiently Reversing Immunotherapy Resistance in Lung Cancer by an Inhalable 2D Molybdenum Disulfide T Cell Hyperactivation Platform 0.88
Self-Delivery Nanomedicine for Selective Mitochondrial Copper Depletion and Oxidative Stress Amplification 1.00
Three-Dimensional Afterglow Luminescence–MRI Fusion Tomography with Magnetically Targeted Luminescent-Magnetic Nanoparticles for Deep-Seated Tumor Imaging 1.00
Oncolytic Hydrogel Enhances Immune Checkpoint Blockade by Generating In Situ Vaccine, Remodeling Tumor Physical and Metabolic Barriers 1.00
Mechanical Properties Measured by Atomic Force Microscopy Help Evaluate Different Constructions of Re-engineered Chimeric Antigen Receptor-T Models 1.00
Ultrasound-Mediated Piezocatalysis Triggers NO Release to Augment Targeted Immunotherapy of Pancreatic Cancer 1.00
A Spatiotemporally Controllable DNA Hydrogel Mesh for Focused Antimetastasis Therapy of Cancer 0.95
Ascorbic Acid-Derived Supramolecular Gels Induce Immunogenic Ferroptosis in Cancer Cells to Potentiate Tumor Immunotherapy 1.00
Anti-Triggering Receptor Expressed on Myeloid Cells 2-Conjugated Nanovesicles Loaded Vadimezan Reprogram Tumor-Associated Macrophages to Combat Recurrent Lung Cancer 1.00
Inhalable Fibroin Hybrid Liposomes for the Targeted Treatment of Lung Adenocarcinoma via Autophagy-Enhanced Ferroptosis 1.00
Exercise-Induced Stimulation of Self-Powered Nanofibers for Aspirin/Lysine Delivery in the Prevention of Denervated Muscle Atrophy 1.00
Nanotentacle-Armed Flexible Affinity Interface Enables Streamlined Capture, Labeling, and Release of Circulating Tumor Cells 1.00
Harnessing Nanotechnology for Cellular Health through Strategic Modulation and Nanoscale Control of Electron Mobility 1.00
Immune-Modulating Dual-Targeted Nanomaterials for Low-Temperature Photothermal–Photodynamic–Chemodynamic Therapy of Osteosarcoma Targeting Tumor and Endothelial Cells 1.00
Synergizing Ferroptosis Suppressor Protein 1 Gene Silencing and Photodynamic Therapy Based on Photosensitive Lipid Nanoparticles for Colon Cancer Immunotherapy 1.00
Tailoring Long-Lived Charge Separation Enables Efficient Light-to-Heat Conversion for Efficient Cancer Therapy 0.96
Quantitative and Reversible Regulation of Yes-Associated Protein Activity by Ultrasmall Nanoparticle-Mediated Magnetothermal Stimulation of F-Actin 1.00
Absolute Length Distribution of Human Telomeres with Single-Molecule Techniques 1.00
Hybrid-Ligand Metal–Organic Frameworks Enabling Radio–Radiodynamic–Chemodynamic Therapy Primes Checkpoint Blockade Immunotherapy in Hypoxic Tumors 1.00
Chiral Artificial Antigen-Presenting Cells Enhancing Tumor Immunotherapy: Evasion of Macrophage Uptake through Inhibition of Serum Protein Corona Formation 1.00
Prolonged Release of Bacillus Calmette–Guérin by Floating Microbubbles to Enhance Intravesical Immunotherapy for Bladder Cancer 1.00
Intranasal Delivery of HPV Therapeutic Vaccines for Enhanced Mucosal Immunization and Anti-Tumor Immunity 1.00
A Cyclized Bivalent Aptamer-Based Protein Degrader Targeting Receptor Tyrosine Kinases Overcomes Resistance to Inhibitors in Lung Cancer 1.00
NO-Driven Self-Propelled Nanomotors Augment Chemo-Immunotherapy and Transcatheter Arterial Embolization 0.33
Hybrid Cell Membrane-Functionalized Nanoagents Synergistically Enhance Cuproptosis-Mediated Immunotherapy by Dual Modulation of Glycolytic Metabolism and Tumor Microenvironments 0.85
Disulfidptosis Nanoinducer Interrupts Tumor Metabolic Privilege to Boost Sustained Immunotherapy 1.00
Gelatin Methacryloyl Xerogel Puncture Implants Loaded with Cu0.5Mn2.5O4 Nanoparticles Synergizes Cuproptosis and STING Activation for Enhanced Breast Cancer Immunotherapy 1.00
Using the Electronic Grab-Transport Mechanism to Construct Metal–Organic Frameworks with Type I/II Dual Sonodynamic Therapy Reinforcement 1.00
Noninvasive Activation of Local and Systemic Immunity with a Sequential-Targeting Sonodynamic Nanovaccine to Treat Glioblastoma 1.00
Charge Transfer-Mediated J-Aggregates of Azaindole Cyanine with 160 nm Absorption Redshift for Efficient NIR-II Photothermal Tumor Therapy 1.00
In Situ Ultrasound-Triggered Bioluminescence for Combined Sono/Photodynamic Immunotherapy 1.00
Overcoming Radiotherapy Resistance in Chordoma through the Synergistic Action of Selenium-Containing Nanoparticles and THZ1 0.97
Phosphorylated Neuropeptides Regulate Glioblastoma Proliferation and Invasion via Chiral Amino Acids 1.00
Immuno-Initiator Rectifies Immunodeficiency to Restore Immune Function and Potentiate Immunotherapy against IDH Mutant Glioma 1.00
Machine Learning-Assisted Multimodal Early Screening of Lung Cancer Based on a Multiplexed Laser-Induced Graphene Immunosensor 1.00
A Multifaceted Nanodrug Disrupts the Copper–Iron Homeostasis to Enhance Cancer Radiotherapeutic Effect 1.00
Oxygen-Generating Transdermal Nanoplatform Codelivering BRD4 Proteolysis-Targeting Chimera/Verteporfin/CaO2 Synergistically Remodels Immunosuppressive Melanoma Microenvironment to Potentiate Combination Immunotherapy 1.00
An Asynchronous-Regulated Nanosheet Cascade Amplifies Sonodynamic-Triggered Self-Enhanced DNA Damage for Intensive Tumor Immunotherapy 1.00
A Nitroreductase-Responsive Type I Photosensitizer with Aggregation-Induced Emission Characteristics for Precise Hypoxic Cancer Theranostics 1.00
Protein-Confined Rotor Strategy for Quantum Yield Enhancement in Supramolecular Photosensitizers toward Sentinel Lymph Node-Targeted Photodynamic Immunoactivation 1.00
Engineered Bacteria-Nanoparticle Conjugate Reprograms Immunosuppressive Niche via Dendritic Cell-Centric Innate-Adaptive Immune Coupling 1.00
Axially Chlorinated Carbon Nanodots for Hypoxia-Tolerant Neutrophil-Mimicking Photoenzymatic Cascade Therapy against Postoperative Tumor Recurrence 0.82
Peroxidase-Inspired Polyphthalocyanine Networks with Highly Efficient Sonocatalytic Activities for On-Demand Tumor Immunotherapies in Breast Cancers 0.92
Sulfur Vacancy-Rich Bi2S3–x–Pt Heterojunction with Multi-enzymatic Activities for Enhanced Sonodynamic Therapy 1.00
Nanodrug Modulates Premetastatic Niche and Suppresses Metastatic Lung Adenocarcinoma via Programmed Cell Death Ligand 1 Blockade and STING Pathway Activation 1.00
A Wireless Cytosensor Based on a Bionic Dandelion Isothermal Amplification System for Ultrasensitive Detection of Circulating Tumor Cells 1.00
Biodegradable and Piezoelectric Mn-Doped Hydroxyapatite for Sonodynamic Immunotherapy 1.00
Multienzymatic Hybrid Metalloenzymes Triggering Cascade Reactions-Regulated Tumor Redox Homeostasis and Immunosuppressive Microenvironment for Catalytic Immunotherapy 1.00
A Metal–Organic Framework-Based Immune-Regulating Nanocarrier Depot for Enhanced Combination Cancer Immunotherapy 1.00
Bacterial Membrane Vesicles as Heteroantigen Reservoirs for Potentiated Colorectal Cancer Immunotherapy 1.00
Combretastatin A4-Based Albumin Nanoparticles Remodeling the Tumor Immune Microenvironment to Enhance T Cell Immunotherapy in Colon Cancer 1.00
Nanoigniter-Integrated Microneedle Patches for Boosted Photothermal-Mediated Multimodal Therapy: In Situ Tumor Microenvironment Igniting Strategy 1.00
Self-Driving and Detachable Lab-Microrobots Tailor Drug Delivery for Closed-Loop Stimulation of the Antitumor Immune Cycle 1.00
Active Chemical Messenger-Driven Immune Activation via Electrochemical Patch for iIn-Situ/i Tumor Vaccination 0.75
Starting the Engine and Releasing the Brakes of T-Cell Responses: A Biomimetic Dendritic Cell Nanoplatform for Improved Glioblastoma Immunotherapy 1.00
Cognate Nanovaccine Promotes Tertiary Lymphoid Structures Function and Strengthens Immune Cell Cross-Talk by Targeting Exhausted T Cells in Nonimmunogenic Cancers 1.00
Disrupting Tumor Lactate Homeostasis to Sensitize Chemo-Immunotherapy Using a Glucose-Disguised Lactate Interceptor 1.00
Thermosensitive Resiquimod-Loaded Lipid Nanoparticles Promote the Polarization of Tumor-Associated Macrophages to Enhance Bladder Cancer Immunotherapy 1.00
Multimodal Regulation of Dendritic Cells via Mineralized Vaccines for Postsurgical Tumor Relapse Prevention 1.00
Spatiotemporally Controlled Co-Treatment of Lung Cancer and Pulmonary Immune-Related Adverse Events by Inhalable Albumin-Chaperoned Ultrathin MnOsub2/sub Nanosheets 1.00
47 45.79
Microenvironment-responsive piezoelectric nanoreactors integrate O2 and H2 generation for efficient tumor sonodynamic therapy 1.00
Endoplasmic Reticulum-Targeted Photodynamic Therapy Synergizes with Rapamycin to Induce Autophagic Cancer Cell Death 1.00
Thionated donor-acceptor naphthalimides as efficient heavy-atom-free triplet photosensitizers for type I/II ROS generation in hypoxia-immune photodynamic therapy 0.70
A Neuraminidase-Functionalized Injectable Hydrogel Depletes Sialic Acid to Disrupt the Tumor–Osteoclast Cycle and Suppress Breast Cancer Bone Metastasis 1.00
Modulation of Intrabone Distribution of Anionic Polypeptide Nanocarriers through Hydrophobic Modification for the Treatment of Acute Myeloid Leukemia 1.00
Bimetallic rare earth nanoplatform amplifies DNA damage to trigger necroptosis and immune cascade for potent durable antitumor therapy 1.00
Tumor in-situ Self-Assembling Gold Nanorods for Photothermally Enhanced Radiotherapy Enabled by Multilevel Radiosensitization Mechanisms 1.00
Glutathione-Depleting Mitochondria-targeting Nanodrugs for Stress Amplification and Immune Activation via Synergistic Photodynamic Therapy and Cuproptosis 1.00
A pH-responsive polymeric nanovaccine with efficient endosomal escape and potent antitumor immunity for cancer treatment 1.00
Bovine serum albumin-stabilized nano-delivery system potentiates targeted anti-angiogenic therapy and synergistic photo-immunotherapy to restrict lung cancer metastasis 0.82
Cascade-targeting oxygen-self-supplying nano-photosensitizer for enhanced photodynamic immunotherapy of triple-negative breast cancer 1.00
Endoplasmic Reticulum-Targeting Prodrug Nanoassemblies for Potent Ferroptosis Therapy via Concurrent Glutathione Depletion and Arachidonic Acid Accumulation 1.00
Fluorinated Polymeric Nanoplatform Relieves Tumor Hypoxia and Enhances Chemo-Sonodynamic Therapy 1.00
Poly (ADP-ribose) polymerase 1-targeted photosensitizer as a dual-activator of pyroptosis and the STING pathway for enhanced cancer photoimmunotherapy 1.00
Absorbable microspheres co-delivering HIF-1α inhibitor augment transarterial chemoembolization by reversing tumor hypoxia and immunosuppression 1.00
Bioorthogonal and Synthetic Biology-Engineered Bacterial Outer Membrane Vesicles for Enhanced Photo-Immunotherapy 1.00
Enhanced Immunotherapy Efficacy through Molecularly Imprinted Nanoparticles Co-Targeting Cluster of Differentiation-73 and Programmed Death-Ligand 1 0.88
Matrix-Modulating pH-Gated Hydrogel for Coordinated Regulation of Cancer-Associated Fibroblast Phenotype and Mn²⁺-STING Activation for Enhanced Tumor Immunotherapy 1.00
Restoring Antitumor Immunity by Reprogramming Abnormal Lipid Metabolism in the Tumor Microenvironment Using Irisin-Manganese Co-loaded Nanoparticles 0.92
A Multifunctional PD-L1 Modulator for Metabolic Reprogramming to Induce Pyroptosis and Enhance Glutamine Inhibition-Mediated Antitumor Immunotherapy 1.00
A biodegradable theranostic sonosensitizer for afterglow-guided sonodynamic therapy 0.85
Micellar Co-delivery of KRAS-Mutant Inhibitors and TLR7/8 Agonists Synergizes Targeted Therapy and Immunotherapy in Lung Cancer 1.00
Photosensitive calcium-based nanoinducer for NIR-triggered immunogenic cell death and anti-tumor immunity 1.00
Cascade-amplified iron-doped bismuth sulfide biomimetic nanoplatform for synergistic therapy and multimodal imaging of triple-negative breast cancer 1.00
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial 1.00
Omeprazole-Mediated Nanodelivery of Copper for Synchronous Remodeling of Copper Influx and Efflux in Cuproptotic Glioblastoma Therapy 1.00
Precise diagnosis of pancreatic fibrosis using fluorescent aptamer probes targeting cellular fibronectin 1.00
Supramolecular copolymerized peptide self-assembly enables in situ reprogramming of tumor-associated macrophages to potentiate mild photothermal immunotherapy of cold tumors 1.00
T-cell Hitchhiking Nanodrug Activates the cGAS-STING Signaling Pathway for Enhanced Cancer Immunotherapy 1.00
Biomechanical Profiles and Molecular Regulation of Clinical Cancer Stem Cells and Tumor Cells: Implications for Tumorigenicity and Metastasis of Lung Cancer 1.00
β-Glucan nanotubes loaded with iron diselenide for enhanced photothermal and photodynamic therapy in hepatocellular carcinoma 1.00
Biomineralized PCAL microspheres trigger synergistic calcicoptosis-ferroptosis for enhanced non-small cell lung cancer therapy 1.00
MIL-100(Fe)-based Co-Delivery Platform as Cascade Synergistic Chemotherapy and Immunotherapy Agents for Colorectal Cancer via the cGAS-STING Pathway 1.00
Calcium phosphate-mineralized nanoplatform for enhanced ferroptosis and synergistic anti-PDL1 therapy in triple-negative breast cancer through multi-pathway targeting 1.00
Nanoparticle-induced excessive mitophagy combined with immune checkpoint blockade for enhanced cancer immunotherapy 1.00
Quaternary ammonium salt microspheres loaded with vascular disrupting agents for targeted interventional therapy of hepatocellular carcinoma 1.00
Controlled Delivery of C-C Motif Chemokine Ligand 25 by a Hydrogel for Tumor Microenvironment Remodeling in Triple Negative Breast Cancer 1.00
Mitochondria-targeting pseudo-stealthy nanophotosensitizer as a potent immunogenic cell death inducer to unleash the cancer-immunity cycle for melanoma therapy 1.00
Enhancing inter-system crossing efficiency of NIR-II emitting type-I photosensitizers for tumor ferroptosis induction 0.93
Construction of TiO2@Ag2O p-n junctions for synergistic sonodynamic/sonothermal tumor therapy with enhanced efficacy 0.91
Construction of Z-Scheme MOF-on-MOF heterostructures for mitochondria-targeted sonodynamic therapy 1.00
Vincristine/Volasertib polymersome injection enables high-efficiency synergistic treatment of acute lymphoblastic leukemia 1.00
Janus hydrogels delivering low-density lipoprotein receptor-related protein 6 inhibitor enhance myocardial repair via m6A-dependent cuproptosis in bama pigs 1.00
Self-propelled smart nanomotors for enhanced mild photothermal therapy of tumors through autophagy modulation 0.89
Targeted nanosensitizer-augmented sono-immunotherapy with STING agonist to remodel the immune microenvironment in hepatocellular carcinoma 1.00
Endogenous nanoplatforms for tumor photoimmunotherapy: Hypoxia modulation and STING pathway activation 0.90
Immune-activated microspheres for enhanced chemoembolization of hepatocellular carcinoma by blocking the adenosine A2A receptor 1.00
101 98.11
Targeting Energy-Metabolism-Imbalance Nanoagonist for High-Resolution NIR-II Imaging and Potentiated Photoimmunotherapy 1.00
Single‐Atom Magnesium Nanozymes Orchestrate Redox Homeostasis and Controlled Autophagy for Glioblastoma Therapy 1.00
One-Step Synthesis of Hemin@Au Nanoparticles for Inducing Ferroptosis in Photothermal-Immunotherapy Against Cancer 1.00
Global Cold Local Photothermal‐Mediated Synergistic Metabolic Antitumor Immunity 0.90
“AND” Logic‐Gated MRI Nanoswitch in Response to Copper and Glutathione for Precise Diagnosis of Microtumors 1.00
Biomimetic Nanoreactor-Driven Synergistic Anti-Glioblastoma Therapy Through Integrated Bioorthogonal Catalysis and Sonodynamic Activation 1.00
MoB MBene Based Nanoplatform for Enhanced Cancer Immunotherapy via cGAS Demethylation and Hypoxia Reversion 1.00
Nano‐Biohybrid‐Induced Inflammatory Cancer Cell Death Reprograms Anti‐Tumor Immunity to Suppress Tumor Progression and Metastasis 1.00
High-Cubic Bornite Nanoparticle-Enabled Photothermoelectric Catalysis Induces Dual Cuproptosis and Ferroptosis in Hepatocellular Carcinoma 1.00
A Self-Reinforcing Photonanocatalytic Platform Remodels Tumor Microenvironment for Synergistic Apoptosis/Ferroptosis Therapy in Liver Cancer 1.00
Alkyl Chain Regulation-Based Biomimetic Nanoparticles: Excellent Stability and Photothermal Efficiency for Personalized Tumor Targeted Therapy 1.00
Ultrasound-Responsive Bimetallic Hydroxide for Inducing Pyroptosis and Reversal of Immunosuppressive Microenvironment 1.00
Manganese-Doped Piezoelectric Layered Double Hydroxides Induce Catalytic Therapy and Ferroptosis 1.00
Tripartite Cascading Functions of Ultrathin RhMo Nanozymes in Tumor Catalytic Therapy 1.00
Enhanced Catalytic Therapy by Modulating Substrate Adsorption and Local Electron Density through Coordinatively Unsaturated Cu-N2 Single-Atom Sites on Carbon Dots 1.00
Photo/Sono/Magneto-Responsive Ternary Heteronanocrystals with S-Scheme Heterojunction for Penetrative and ROS-Amplified Tumor Ablation 1.00
Immune-Engineered Hydrogels Combat Orthotopic and Metastatic Cancer via Hypoxia-Relieved Photodynamic Therapy and Ferroptotic Cell Death 0.74
Hypoxia-Responsive Nanosystem for Synergistic Cancer Therapy: Enhancing Ferroptosis via a Novel GPX4 Inhibitor and Facilitating Precise Photodynamic Therapy 1.00
Coordination of Mechanodynamic Structure and Biochemical Signaling Restores ECM Soft‐Stiff Homeostasis for Anti‐Metastasis Tumor Therapy 0.98
Dual-Functional Sonodynamic Therapeutic Platform for Complete Osteosarcoma Elimination With Synchronized Bone Defect Regeneration 1.00
SR-B1-Targeted Cholesterol Depletion Nanosystem Synergizes Cholesterol Metabolic Reprogramming and Immunotherapy for Clear Cell Renal Cell Carcinoma 1.00
Biomimetic Exosome‐Camouflaged pH‐Responsive Dendrimer Nanogels as a Therapeutic Vaccine Against Pancreatic Cancer Through Reprogramming of Multiple Cell Types 1.00
Pyroptosis‐Activating Nanoplatform Unleashes Metabolic‐Directed Neutrophil Reprogramming to Boost Cancer Immunotherapy 1.00
Biomimetic SIRPα–CAR Engineering for In Situ Macrophage Reprogramming and Potent Solid Tumor Immunotherapy 1.00
Stimuli‐Responsive Heterobimetallic Prodrug Platform Enables In Situ Copper Complex Synthesis and Photosensitizer Activation for Targeted Chemo‐Photodynamic‐Immunotherapy 1.00
An All-in-One DNA Nanodevice as a Programmed Theranostic Platform for Intelligent Cancer Cell Identification and On-Site Drug Release 1.00
Supramolecular DNA Di-Tetrahedral Neoadjuvants Dynamically Prime Melanoma Microenvironment for Enhancing Radio-Immunotherapy Responses 1.00
Biodegradable Nanomissile Targeting the NKG2D/NKG2DL Axis Boosts Photo-Immunotherapy by T Cell plus NK Cell Attack 0.91
Electronic Structure Modulation of Zn–Y Dual Single-Atom Sites for Synergistic Sonodynamic/Catalytic Cancer Therapy: “One Heart (Zn) and One Mind (Y)” 0.91
Sequential Magneto‐Activation Platforms Break Multiple Cellular Defenses to Potentiate Mildthermal‐Oxidative‐Immunotherapeutics 1.00
Chiral Au@Ag Nanoparticles Regulate Macrophage Reprogramming for Enhanced Anti-Tumor Efficacy 1.00
Dual‐Pathway Pyroptosis Synergistically Triggered by ZIF‐90 and Photothermal Boosting of Multienzyme Activity for Enhanced Breast Cancer Immunotherapy and Lung Metastasis Suppression 1.00
Electrostatic Reinforcement of NIR-II Charge-Transfer Complexes for Durable Phototheranostics 0.83
Allosteric DNA Nanorobots for Targeted Glioma Therapy: Acid‐Triggered Doxorubicin Delivery 0.81
Persistent and Potent Anticancer Immunity Empowered by Manganese‐Coordinated STING‐Activating Microgels 1.00
A Modular DNA Hydrogel Vaccine with Optimized Nanoadjuvants and Tumor Targeting Capacity 1.00
Quantity‐Quality Dual‐Regulation Strategy: Enzyme‐Like Nanoclusters for Improved Cancer Immunotherapy 1.00
Molecular Scaffolding Engineering Generates High‐Efficiency Anti‐Quenching Small Molecules for NIR‐IIb Fluorescence Imaging and Phototheranostic Applications 1.00
Near‐Infrared Boron Difluoride‐Based Photosensitizers Targeting Endoplasmic Reticulum Stress for Antitumor Immunotherapy 1.00
Lycium Barbarum Polysaccharide-based Hydrogel as a Novel Oral Colon-Targeted Drug Delivery System for Enhanced MSS-CRC Treatment by Macrophage Lipid Reprogramming 1.00
Hyaluronic Acid-Coated DNA Nanoflowers as Smart Nanocarriers for Deep Tumor Penetration and Enhanced Gene Therapy in Pancreatic Cancer 1.00
Engineering of 2D Ultrathin CuS-PMA Heterostructures for Enhanced NIR-II Photothermal Therapy Facilitating Oxidative Stress and Immunotherapy 1.00
Multi-Stage Regulated Peptide Microneedle for Enhancing Ferroptosis in Melanoma Therapy 1.00
Cage-Like Nanodrug Potentiates Tumor Immunotherapy by Orchestrating Endoplasmic Reticulum–Mitochondrial Crosstalk 1.00
Liquid Metal Gallium Drives Glycosidic Bonding of Glucose 0.06
Microglial Membrane Camouflaged Nano‐AUTAC to Promote Autophagy‐Mediated β‐Catenin Degradation for Reducing TMZ Resistance in Glioblastoma 1.00
Ambient Laser Writing of Strongly Coupled High-Entropy Alloy Nanohybrids for Peroxide Electrocatalysis and On-Chip Dual-Mode Sensing 1.00
Activated Fluorescent Probe for Long‐Term Imaging and Surgical Navigation via Enzyme‐Mediated Fluorogenic Reaction and Self‐Assembly 1.00
Closed-Loop Brain–Immune–Tumor Modulation via Magnetoelectric Nanocatalysis for Synergistic Cancer Immunotherapy 1.00
Engineered Ginseng‐Derived Nanovesicles with MCSP Targeting and Mitochondria‐Directed Prodrug Delivery for Synergistic Immunotherapy of Metastatic Melanoma 1.00
Synergistic S···O and S···H Conformational Locks for Planarity-Enhanced NIR-II Phototheranostics 1.00
Heteronuclear Single‐Atom Nanozymes Overcome Radiotherapy Resistance via Synergistic Multi‐Enzyme Activities 1.00
Enhanced Diradical Feature of Quinoid-Donor–Acceptor Semiconducting Polymers by Strong Pro-Quinoidal Acceptor Engineering for Efficient NIR-II Photothermal Theranostics 1.00
Dye Sensitized Lanthanide‐Triplet Cascade Energy Transfer for Near‐Infrared Therapy 1.00
High-Concentrated Reactive Oxygen Species from Chiral Thyroxine for Piezocatalytic Antitumor Therapy 1.00
GSH-Triggered Self-Cascading Nanoreactor Integrates Efficient ICD Induction and Immune Checkpoint Blockade for Pancreatic Cancer Therapy 1.00
Coordination Polyphenol and Hydrogenation Coarmed Ce−Mo Bimetal Nanozymes for Robust Anticancer Therapy 1.00
Bioactivated Nanoionizers: Calcium Storm-Triggered Pyroptotic Cascade Activation Empowering Boron Neutron Capture Therapy 1.00
Zr-Based Metal–Organic Framework Dual-Sensitized by Carbon Dot Sonosensitizers and MnO2−x Nanozymes for cGAS-STING Activation Enhanced Sonocatalytic-Immunotherapy 1.00
A Single-Metal-Doped Nanoplatform for Ferroptosis-Driven cGAS-STING Pathway Activation in Hepatocellular Carcinoma Immunotherapy 0.71
A Microalgae-Based Dual-Pathway Therapy for Simultaneous Ammonia Detoxification and Colorectal Cancer Suppression 1.00
An Integrated Engineered Bacterial Nanocomposite System for Targeted Prodrug Delivery and Enhanced Antitumor Efficacy 1.00
Subcellular Targeting and Pyroptosis Activation of Aggregation-Induced Emission Photosensitizers for Enhancing Photodynamic Therapy of Oral Cancers 1.00
Molecular Engineering of AIE‐Active Ionic Photosensitizer for Dual‐Organelle Targeted NIR‐II Phototheranostics 1.00
Sequentially Responsive Framework-Reconstituted Highly-Active Selenium Nanoparticles Potentiate NK Cell Surveillance against Hepatocellular Carcinoma through Mitochondrial Dysregulation and NKG2DLs-Upregulation 1.00
Inhibiting NFS1 by Targeting Liposomes for Combating Cisplatin‐Resistant Colorectal Cancer 1.00
Valence‐State Transitive Selenium Nano‐Reservoir for Immuno‐Activated Cancer Phototherapy 1.00
Dual-Functional Iridium Complex for Tumor Treatment via Ultrasound Driven Water-Splitting Oxygen Evolution Cascade Sonodynamic Therapy 1.00
X‐Ray‐Activated Self‐Calibrating Second Near‐Infrared Fluorescent Probes for Precision Radiosensitization Therapy in Esophageal Cancer 1.00
Antigen‐Enriched Hydrogel Platform Coordinates Hydrogen Sulfide and Bacterial Adjuvants for Augmenting the Photothermal Immunotherapy of Breast Cancer 1.00
Molecular Dipole Moment Regulation of NIR-Ir(III) Complex for Boosting Tumor Phototheranostics 1.00
Dual Metabolic Rewiring Amplifies Cellular Oxidation and Reverses Immunosuppression for Combating Orthotopic Triple-Negative Breast Cancer 1.00
Deciphering the Intrinsic Chemistry of Protein‐Enhanced Type I Photodynamic Processes 1.00
Molecular‐Twist‐Engineered Non‐Fullerene Acceptor Type Organic Sonosensitizers with Enhanced Intersystem Crossing for Highly Effective Sonodynamic Therapy of Large Solid Tumors 1.00
Supramolecular‐Engineered Immune Modulator Orchestrates Tumor Microenvironment Reprogramming for Antibody‐Independent Radio‐Immunotherapy 1.00
Self‐Immolative Activatable Nanoassembly toward Immuno‐Photodynamic Therapy in TME 0.55
Quinoid-Engineered Small-Molecule Photothermal Agents Ignite Deep-Tissue Tumor Photothermal-Immunotherapy Driven by 1064 nm Light 1.00
Amplifying ER Stress via Biodegradable Pseudo-Conjugated Polymer Nanoparticles for Enhanced Sonodynamic Immunotherapy 1.00
Inflammation-Driven Doxycycline-Glucose Oxidase Nanoparticle Induce Starvation-/Chemodynamic-/Immunotherapy against Intratumoral Bacteria-Assisted Tumor Development 1.00
Microenvironmental Self‐Optimizing HOFs Biocatalysts for Boosting Disulfidptosis‐Mediated Antitumor Immunotherapy 1.00
Electric‐Field‐Mediated In Situ Electrocatalysis for Enhanced Chemodynamic Therapy and Immunotherapy via 3D Electrode Arrays 1.00
Dynamic Redox‐Switchable Nanotransducer Enabling Spatiotemporal cGAS‐STING Remodeling and Immunogenic Cell Death Induction for Cancer Immunotherapy 1.00
Intracellular Delivery of CRISPR/Cas9 via Living Bacteria to Block Arginine Metabolic Reprogramming and Enhance Tumor Chemotherapy Sensitivity 1.00
Urchin-Like Sulfate Radical Nano-Generator Based on MoS2/Bi2S3 Heterostructure for Enhanced Anticancer Therapy 1.00
Dual‐Targeted Biomimetic Hybrid Nanovesicles for Tumor Microenvironment Reprogramming and Intratumoral Bacteria Eradication in Triple‐Negative Breast Cancer 1.00
Sono‐Responsive Hydrogel for Fractionated PROTAC Release to Alleviate Resistance and Immunosuppression Induced by Multi‐Course Postoperative Radiotherapy 1.00
DNA Programed Controllable Photodynamic Therapy with Positive‐Feedback Effect 1.00
Synergizing Ferroptosis and Immunotherapy via a PROTAC/PDT/HPK1 Inhibitor-Loaded Nanoplatform for Enhanced Antitumor Efficacy 1.00
A Responsive Hydrogel Containing Bimetallic MOF Enabling Amplified Ferroptosis for Cancer Therapy via Dual Cellular Homeostasis Disruption 1.00
Coordination‐Guided Therapeutic‐Coating Oncolytic Bacteria Enabling Pyroptosis Amplification and Synergistic Breast Tumor Suppression 1.00
Targeted Inhibition of Tumor Extracellular Vesicle Secretion Improving the Anti‐Tumor Immunity of Lymph Node‐Targeted Vaccines 1.00
From Exciton Dynamics to Cell Fate: A Carbon Dot Based NIR Photocatalytic Platform for Pyroptosis via Self‐Trapped Excitons 1.00
An ‘AND’ Logic Gate Nanoreactor for Metabolic Remodeling in Starvation-Ferroptosis-Immunotherapy of Pancreatic Cancer 1.00
Therapeutic Adoptive Cell Transfer (ACT) Vaccine Patch: Bioengineered Tumor Cells Prime Macrophage Immunoregulation to Prevent Postsurgical Tumor Recurrence and Metastasis 0.71
Genetically Engineered Bacteria‐Derived Hydrogel Orchestrates T Cell Spatial Dynamics for Triple‐Negative Breast Cancer Immunotherapy 1.00
Ultrasound‐ and Magnet‐Enhanced Blood‐Brain Barrier Transport for Self‐Augmented Piezo‐Fenton Glioblastoma Therapy 1.00
Antibody‐Programmable Bimetallic Nanozymes for Transcriptional Blockade Therapy in HER2/ER‐Positive Breast Cancer 1.00
Boosting Immune Checkpoint Therapy Efficacy of Pancreatic Cancer by Cell‐Anchoring Probiotic 1.00
Mitochondria‐Targeted Energy Disruptor for Augmented Mild Hyperthermia Therapy of Orthotopic Lung Cancer 1.00
NIR‐II Imaging‐Guided Self‐Enhanced Nanomedicine With Reactive Oxygen Species Amplification for Type I Photodynamic Therapy of Prostate Cancer 1.00
Enhancing PD‐1 Inhibitor Efficacy in Cholangiocarcinoma by Reprogramming Tumor‐Associated Neutrophils With CAF‐Derived Extracellular Vesicles Loaded with Ruxolitinib 1.00
95 92.22
Photothermal Sensitive Nano Heterojunction Triggering Ferroptosis and PANoptosis for Improving Tumor Immunotherapy 1.00
Microbial‐Semiconductor Hybrids Enable Near Infrared‐Driven Photosynthetic Hydrogen Production for Tumor‐Targeted Immunotherapy 1.00
A Morphology‐Driven Cascade Delivery of Antigens for Potent T Cell Immunity 1.00
Oxygen Vacancy-Engineered CaCu3Ti4O12 Nanocatalyst for Piezoelectrically Driven Cascade Apoptosis/Cuproptosis/Ferroptosis Therapy 1.00
Bone-Targeted Nanoparticles Enable Metabolic Reprogramming via cGAS Lactylation Suppression to Restore Chemosensitivity and Antitumor Immunity in Osteosarcoma 0.94
Reprogramming Disulfide Reduction in Endoplasmic Reticulum Uncouples Immune Evasion of Pancreatic Cancer 1.00
Wireless Electro-Fenton Overcomes Tumor Electric Field Treatment Resistance 1.00
Ratio-Tunable Dual-Peptide and Ultrasound-Assisted Nanoplatform for Enhancing Personalized Antitumor Immunotherapy 1.00
Reprogramming Tumor-Associated Neutrophils to Enhance Radio-Immunotherapy 1.00
Sono-Activated Artificial Vanadium Enzyme System for Efficient and Renewable Reactive Oxygen Nanobiocatalytic Therapies 1.00
Lemon‐Derived Extracellular Vesicles Engineered Oral Capsules for Enhanced Colorectal Cancer Chemotherapy by Mechanical Stress‐Induced Intestinal Epithelial Barrier Opening 1.00
High-Entropy Alloy Synergized with Gene Editing for Cocktail-Sensitized Radioimmunotherapy of Lung Metastases 1.00
A Tumor-Targeted tRF Therapeutics Triggers Ovarian Cancer Ferroptosis via Dual Inhibition of System Xc− 0.80
Thymidine‐Auxotrophic Salmonella Enables Selective Tumor Colonization and Adenosine Depletion for Cancer Immunotherapy 1.00
G-Quadruplex-Modular CpG Nanoplatform Drives Multi-Pathway Immunity for Abscopal Chemoimmunotherapy 1.00
Bi‐Target Nanomodulator for Glioma‐Associated Myeloid Cells Polarization by Inducing Pyroptosis and Regulating Tryptophan Metabolism to Reshape Immunosuppressive Microenvironment of IDH‐Mutant Gliomas 1.00
Lipid Droplet-Targeted Biomimetic Liposomes Potentiate Chemo-Ferroptosis Therapy in Leukemia 0.93
On-Demand Operando Embolization by Rapid Sonodynamic Gelation of Liquid Metal-Embedded Hydrogels for Effective and Durable Tumor Treatment 1.00
Nanoadjuvant-Mediated Electro-Immunotherapy Enhances Irreversible Electroporation for Pancreatic Cancer Treatment 1.00
A Stepwise‐Enhanced Schottky Heterojunction Enables Ultra‐Low‐Dose Radiodynamic Therapy via Matrix Remodeling and Electron–Hole Separation 1.00
Close and Enhance the Cancer-Immunity Cycle by Engineered Dual-Targeted Nano-Adaptors 1.00
Coupling Pt Single-Atoms with Amorphous LDH Nanosheets as a High-Efficiency Sonosensitizer for Sonodynamic Immunotherapy 1.00
Self‐Amplified Nanomedicine Enables Lysosomal Blockade to Potentiate Starvation Therapy of Pancreatic Ductal Adenocarcinoma 1.00
Potentiating Chemo-Immunotherapy via a Programmable Nanocapsule-Hydrogel Platform for Sequential Tumor Microenvironment Remodeling 0.72
An Antigen-Capturing Nanoparticle Harnesses the Protein Corona to Enhance Antigenic Immunogenicity and Clonal Diversity against Cancer 1.00
Layered Double Hydroxide‐Based Sonosensitizer Triggers “Paraptosis+” Multidimensional Cell Death Network for Augmented Sonodynamic Immunotherapy 1.00
Chemiluminescence‐Powered Immunotherapy for Deep Tumors: Promoting PD‐L1 Degradation and Igniting Pyroptosis Through Subcellular Trafficking and Targeting 1.00
Self-Assembled Two-Dimensional Chiral Meso-Topography Determines the Balance of Cellular and Humoral Immunity Against Tumors 1.00
NIR‐II‐Excited Type‐I Conjugated Polymer Photosensitizer for Cancer Photodynamic Therapy 0.25
Thread‐Designed Vascular Scaffold with Magneto‐Optical Probes Capture and Elimination of Circulating Tumor Cells In Vivo 1.00
Optimized Lipid Nanoparticles for Co‐Delivery of mRNA and siRNA Therapeutics in Refractory Liver Cancer 1.00
In Vivo Generation and Manipulation of CAR-T-mimicking Cells via Magnetic Bispecific Nano-antibody for Solid Tumor Therapy 1.00
De Novo Construction of Glutathione Activatable Photosensitizers Boosts Sequential Photoacoustic and Fluorescence Imaging and Precise Photodynamic Therapy 1.00
Liquid Metal Nanoparticles-Mediated Mitochondrial Damage Enhances Immunogenic Cell Death for Cancer Vaccine Therapy 0.96
pH-Responsive Biomineralized Probiotic for Self-Amplifying Mucosal Vaccination: Gut-Engineered Antigen Factories Drive Targeted Cervical Tumor Regression 1.00
Redirecting Tryptophan Metabolism Through Host‐Microbial Crosstalk to Enhance Precise Bioorthogonal Chemoimmunotherapy 1.00
An Immune Nanoenhancer Revitalizes Chemotherapeutics to Tailor Tumor-Derived dsDNA for Anticancer Immunoengineering 1.00
Antagonistic Iron Competition Induced by Iron Chelators Heightens Cuproptosis in Both Tumors and Intratumoral Bacteria 1.00
Triple‐Kill Nano‐Disruptor Integrating Ion Interference, Metabolic Inhibition, and Immune Activation for Augmented Apoptosis and Pyroptosis‐Mediated Immunotherapy 1.00
Suppressing Reverse Intersystem Crossing by Confining Organic Molecules within LDH Interlayers for Near-Infrared-II Photodynamic Immunotherapy 1.00
NIR-II Photoactivatable Cobalt(III) Nanoparticles for Photoactivated Metal Chemo-Immunotherapy 0.71
A New Strategy for Controlled In Situ Release of IL-2 from Tumor Spheroids Using a NIR-II Light-Mediated Optogenetic Manipulation System 1.00
A Radiotherapy‐Responsive Peptide Hydrogel for Pulsatile Release of mRNA‐LNPs Synergizes with Immune Activation to Prevent Breast Cancer Recurrence 1.00
Dual‐Enhanced Sonodynamic Therapy: Synergizing Cavitation Amplification and Efficient Sonoluminescence‐to‐ROS Conversion for Orthotopic Breast Cancer Treatment 1.00
Senescence Reprogramming Unleashes Tumor Immune Surveillance via Coordinated Gene Modulation 1.00
Harnessing Targeted Photodynamic Therapy to Synergistically Activate T Cell and NK Cell Responses in Multiple Myeloma 1.00
Microwave-Actuated Hot-Carrier/Polarization Triggers Catalysis to Coordinate Staphylococcus aureus Ribosome Stalling and Treat Deep-Seated Infections 1.00
A Sono-Responsive Nanoplatform Integrating STING Activation and CXCR4 Blockade for Synergistic Immunotherapy of Glioblastoma 1.00
Tumor-Targeting Co-Delivery of T-Cell Antigen and Camptothecin Guided by Cascade-Responsive Peptide Self-Assembly to Reshape Tumor Antigenicity for Cancer Immunotherapy 1.00
Neutrophil/Leukemia‐Tropic Dual‐Drug Nanomedicine Potentiates the Treatment of Acute Myeloid Leukemia 1.00
Proton‐Driven Deformability Enables Nanozyme‐Integrated Vaccine for Enhanced Tumor Immunotherapy 1.00
An Activable Photosensitizer for Sunshine-Driven Photodynamic Therapy Against Multiple-Antibiotic-Resistant Bacteria by Exploiting Macrophage Chemotaxis 1.00
Dual-Heterojunctions with Reversibly Photoactivated Structure Shift Alternately Decode Photocatalytic H2 Burst and Cascade Catalytic ROS Birth to Repress Cancer 1.00
Ultrasound‐Activated Sonophage Synergizes Sonodynamic Therapy and Saltoptosis for Solid Tumor Eradication 1.00
Dual Targeting of m7G tRNA Modification and Histone Acetylation using Carrier-Free Nano-Epidrugs to Evoke Osteosarcoma Chemosensitization 0.56
Immuno-Packed T-Cell-Fusogenic Liposome Empowers Adoptive T Cell Therapy for Solid Tumor Treatment 0.92
Self-Assembled Protonated Porphyrin Dimer Nanoparticles with an 83.7% Near-Infrared Photothermal Conversion Efficiency for Antitumor Therapy 1.00
Personalized Vaccination of Tumor‐Derived Antigens and STING Agonists for Specific Cancer Immunotherapy 1.00
Multichannel Immune Nanoregulators Suppress Lactic Acid Metabolism and Lactic Acid‐Shaped Acidic Microenvironment to Uproot Anti‐Tumor Immunosuppression 1.00
Polymer‐PARPi Conjugates Delivering USP1i for Maximizing Synthetic Lethality to Stimulate STING Pathway in High‐Grade Serous Ovarian Cancer 1.00
Molecularly Engineered Nanoagents with Efficient Free Radicals Generation and Photothermal Conversion Performance for Enhanced Tumor Photoimmunotherapy via Targeting Lactate Metabolism-Immune Circuit Rewiring 0.90
An Intracellular Magnetic Micromotor Drives Spatiotemporal Mechano‐Immunotherapy 0.92
Defect Engineering‐Driven Electron Spin Polarization and Charge Transfer in MOFs for Enhanced Sonocatalytic Therapy 1.00
Preventing Glioblastoma Relapse by Igniting Innate Immunity through Mitochondrial Stress in the Surgical Cavity 0.90
Sn4+-Mediated Trap Engineering in Cr3+-Activated Titanate Nanophosphors Enables Self-Sustained Multimodal Imaging and Combinatorial Oncotherapy 1.00
Inhalable Nanovaccine Based on Bioengineered Bacteria‐Derived Membrane Vesicles Against Lung Metastasis 1.00
Peptide Coacervates with Metal–Phenolic Membranes Modulate Glucose Metabolism and Enhance Cancer Immunotherapy 0.78
A Synergistic 3D-Printed Collar Transforms Radiofrequency Ablation Into Potent Thermal Immunotherapy for Lung Cancer 0.93
An Epigenetic Nanoagonist Facilitates T Cell Priming, Recruitment, and Reinvigoration in Tumors Resistant to PD-L1 Therapy 1.00
Synergistic Copper‐Coordination/Glutathione Reduction Drives an In Situ Type II‐to‐Type I Photodynamic Switch in Iridium‐Based Photosensitizer Nanocomposites for Potentiated Cancer Immunotherapy 1.00
Nanozyme‐Based Biomimetic Intelligent Immune Organelles for the Treatment of Bladder‐Metastasized Tumors 1.00
Proteolysis‐triggered RNA Interference for Mitochondrial Iron Dyshomeostasis to Activate Antitumor Immunity in Hepatic Carcinoma 1.00
A Noninvasive and Highly Effective Inhaled Nanovaccine Based on Natural Polysaccharide for Lung Cancer Treatment 1.00
Self‐Assembled Ruthenium–Amino Acid Conjugates Enable Endoplasmic Reticulum–Nucleus Cascade Targeting for Cell Pyroptosis and DNA Destruction 1.00
On‐Demand ER Stress Modulation in Tumor Cells and TAMs via an Adaptively Transformable Nanoplatform Enhances Photodynamic Immunotherapy 1.00
Personalized 3D Vaccine Integrates Immunotherapy and Antiangiogenic Therapy to Prevent Oral Squamous Cell Carcinoma Recurrence 1.00
Biohybrid Microrobot Enteric‐Coated Microcapsule for Oral Treatment of Colorectal Cancer 1.00
A Gas Nanobomb to Promote Drug Penetration and Amplify TACE Therapy for Orthotopic Liver Tumor 1.00
Dynamic Size‐Change Nanovaccine for Enhancing Lymph Node Deep Penetration and Eliciting Robust Antitumor Immune Responses 1.00
A Dendritic Cell‐Nanogel Conjugate for Tumor‐Draining Lymph Node‐Specific PD‐L1 Blockade 1.00
Engineering a Lipid Nanoparticle with Atypical Calcium Crystal Structure for Enhanced IFNβ‐Mediated Immunotherapy 1.00
Self‐Powered α Radionuclide Nanomedicine: Mitochondria‐Targeted Multimodal Energy Recycling for Amplified Radioimmunotherapy 1.00
Engineered Nanozymes with Asymmetric Mn─O─Ce Sites for Intratumorally Leveraged Multimode Therapy 1.00
A Smart DNA Nanoframework Enables Synergistic Photodynamic Therapy of Pancreatic Cancer 1.00
Driving Multifunctional Nanomedicine Design for Non‐Inflammatory Tumor Therapy with Integrated Machine Learning and Density Functional Theory 1.00
Organic AIE Nanoradiosensitizer Potentiates X-Ray Triggered Continuous Reactive Oxygen Species Generation for Potent Cancer Radioimmunotherapy 1.00
Biomimetic Engineering of Hybrid Radiosensitizers to Boost Radiotherapy against Cancer Metastasis 1.00
Breaking Apoptosis‐Induced Immune Silence: Ultrasound‐Activated Nano‐Oncolytic Therapy Reinvigorates Antitumor Immunity 1.00
Engineering CRISPR System‐Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer Immunotherapy 1.00
A PROTAC‐Based Cuproptosis Sensitizer in Lung Cancer Therapy 1.00
De Novo Design of Efficient NIR‐II‐Activated Heavy‐Atom‐Free Type‐I Photosensitizer for Anti‐Tumor Photoimmunotherapy 1.00
Engineering Red Blood Cells for Amplified Tumor Dual‐Gas Transfusion Therapy 1.00
Dual‐Defect Nitrogen‐Rich Carbon Nitride‐Based Heterostructural Nanocatalyst for Improving the Therapeutic Efficacy of iα/iPD‐1 via Tumor Immune Microenvironment Remodelling 1.00
Cu2O/CuVO3 Nano-Heterojunction as a Highly Active Therapeutic Catalyst for Aggravating Redox Dyshomeostasis of Neoplastic Cells 1.00
Efficient Artificial T Cell Therapy for Bacterial‐Colonized Tumors 1.00
1 0.35
Pre-diagnostic Body Mass Index Trajectories and Associations with Lung Cancer Risk 0.35
1 1.00
Extremely early genomic events and temporal order of esophageal squamous cell carcinogenesis: Longitudinal self-comparison of progressors and non-progressors 1.00
9 8.09
The nucleoporin NUP188 Enhances Liver Cancer Stemness via POU5F1 Import and SOX2 Stabilization 1.00
Single-Cell Sequencing Plus Spatial Transcriptomics: Dissecting Tumor Heterogeneity, Immunosuppression, and Potential Targets for ASPSCR1::TFE3 Renal Cell Carcinoma 1.00
SYT8 Drives Colorectal Cancer Progression and Immune Evasion via the SETD1A-H3K4me3 Axis 1.00
Ras Homolog Family Member V Promotes Pancreatic Ductal Adenocarcinoma Progression 0.09
Deciphering the cellular and metabolic landscape of lymph node metastasis in breast cancer using single-cell and spatial multi-omics 1.00
Targeting CDH2 and TUBA1A in Neuroblastoma Bone Marrow Metastasis: Insights from Single-Cell Analysis and Drug Screening 1.00
OPA1-mediated mitochondrial hyperfusion orchestrates YAP1 nuclear-translocation to sustain ameloblastoma stemness 1.00
Single-cell and spatial transcriptomics-based research reveals association between M2a macrophages and tumor spread through air spaces in lung adenocarcinoma 1.00
NSUN5 Mediates Resistance to Doxorubicin via Upregulation of DNA Damage Repair Proteins BRCA2 and BRIP1 in Colorectal Cancer 1.00
3 2.74
Hypoxic niche drives lineage imbalance and early tumorigenesis in EGFR-mutant lung cancer 1.00
A trans-omics gene-smoking interaction study of lung cancer based on consortium data 0.74
Accurate and Early Diagnosis of NSCLC Using Aberrant Fragmentomic Features of Circulating Cell-Free Mitochondrial DNA. 1.00
88 87.12
Detection of Ultralow-Frequency ctDNA Mutations Using a Dual Hairpin-Competition CRISPR/Cas14a System 1.00
Selection and Optimization of a High-Affinity FGFR4 Aptamer that Blocks FGF19–FGFR4 Signaling 1.00
Identification of a Novel AT1R-Targeted Near-Infrared Fluorescent Probe for Visualization and Imaging-Guided Surgery in Pancreatic Cancer 1.00
A Proximity-Driven, Spatially Matched 3D Aptasensor for Precise HER2 Diagnostics in Living Cells and Clinical Specimens 1.00
Cascade Cell-Assisted Enhanced Fluorescence Strategy for Highly Sensitive Detection of Lung Adenocarcinoma Cells in Whole Blood 1.00
Profiling of Single Cells on a Droplet Microfluidics–SERS Platform for Multiplexed Analysis of Oxidative and Inflammatory Stress 1.00
Novel IDH1-Targeting Fluorescent Probe Enables Intraoperative Visualization and Resection of Glioblastoma 1.00
Spatially Resolved Laser Tweezers Raman Spectral Snapshots Reveal Single-Cell Molecular Heterogeneity 1.00
A Single lncRNA-Initiated Multiple Rolling Circle Amplification Based on Proximity Hybridization for One-Step Ratiometric Fluorescence Detection of lncRNAs in Breast Cancer 1.00
Multiselective Recognition of Metal Ion–Nucleic Acid Complexes by CRISPR/Cas12a and Quantum Dots Enables the Profiling of Circulating Tumor DNA in Breast Cancer 1.00
DNA Logic Circuit-Equipped Redox Imbalance Amplifier for Precise Mitochondrial Disruption and Efficient Cancer Therapy 1.00
Compatible Fluorescent-Afterglow Luminescent Probe Enables Quantification of Photochemical Reaction-Driven Tumor Theranostics 1.00
Integrating Mass Spectrometry Imaging with Tumor Organoid-Immunity Platform to Identify Metabolic Adaptations in Tumor Immune Resistance 1.00
Aptamer-Based Discovery of Neuropilin-2 as a Potential Biomarker and Therapeutic Target in Bladder Cancer 1.00
Point-of-Care Detection of Dual Methylation Genes for Rapid Bladder Cancer Diagnosis and Prognosis 1.00
Integrated and Ultrafast Multiomics Sample Preparation Workflow for Screening Biomarker Panel of Platelet Biomolecules for Early Diagnosis of HCC 1.00
A Spatially Ordered Three-Input Logic Gate for Highly Specific and Sensitive Breast Tumor Imaging 1.00
Evaluating Therapeutic Efficacy of SCL7A11 and GLUT1 Inhibition in Triple-Negative Breast Cancer via a GSH/ATP Dual-NIR-Responsive Fluorogenic Sensor 1.00
NIR-II Fluorescent Timer-Embedded Drug for Real-Time Tracing of Immunogenic Cell Death and Guiding Chemo-immunotherapy 1.00
Quantitative Analysis of Binding Kinetics Behavior of CD47 by Atomic Force Microscopy 1.00
Phosphoproteins Identification on Stretchable Photonic Crystal for Cervical Cancer Assessment 1.00
CRISPR/Cas13a-Engineered RNA-Based Fluorogenic Biosensor for Label-Free Quantification of RNA in Colorectal Tissues 1.00
Ultrasensitive and Rapid Screening of Tumor-Associated Extrachromosomal Circular DNA by Selective Real-Time Rolling Circle Amplification 1.00
Deep-Red Multiple-Resonance B,N-Heteroarenes as Type I Photosensitizers for Fluorescence Imaging-Guided Photodynamic Therapy 1.00
Single-Nucleotide Variation Analysis in Oral Squamous Cell Carcinoma-Related ctDNA by dCas9/sgRNA Recognition-Mediated Proximity Ligation-Triggered Terminal Hairpin Formation and Self-Priming Amplification 1.00
An Electrochemical Biosensor for Detecting Calreticulin In Situ to Assess Immunogenic Cell Death in Tumor Cells 1.00
From Tissue Archives to Liquid Biopsy: Transfer Learning for MicroRNA-Based Lung Cancer Diagnosis 1.00
Plant-Derived Polysaccharide Ultrafast Purification Reinvented: A Green Aqueous Two-Phase System with Deep Eutectic Solvents for Simultaneous Decolorization and Deproteinization 0.93
In Situ Monitoring of Cathepsin B-Induced Mitochondrial Permeabilization by Raman Spectroscopy 1.00
Super-Resolution Fluorescence Imaging Reveals the Role of CD24 Clusters in NSCLC Proliferation 1.00
TROP2 Promotes Tumor Cell Migration through Downregulation of DSG2 Revealed by Super-Resolution Fluorescence Imaging 1.00
Nanoflower-Shaped Peptide Assemblies Driven by Serrated β-Sheets and Hydrophobic Interactions for High-Affinity MUC1 Recognition 1.00
Protonic Acid/Viscosity-Activatable Type-I Photosensitizer via Donor and π-Bridge Modulation for Second Near-Infrared Imaging-Guided Photodynamic and Photothermal Therapy 1.00
Fluorescent Affinity Probe for mTOR Protein Synthesized via Click Chemistry and Its Applications 1.00
MED: Multiplexed, Entropy-Driven Catalysis, Single-Nucleotide-Resolved ctDNA Detection 1.00
Bottom–Up Protein Analysis Workflow for Simultaneous Characterization of Payloads, Disulfide Bonds, and Free Thiols in Antibody–Drug Conjugates 1.00
Integrated Biomimetic Platform for Enhancing the Efficient Capture and Visual Identification of Circulating Tumor Cells 1.00
Facile Dual Asymmetric Contraction–Expansion Array Integrated Chip Online Coupled with ICP-MS for High-throughput Counting of Circulating Tumor Cells 1.00
Molecularly Engineered Dual-Lock Activatable NIR-II Fluorogenic Probe for Precision Tumor Resection and Real-Time Chemotherapy Response Monitoring 1.00
A Covalent Click Chemistry Chip for Highly Efficient Capture and Brightfield Identification of Circulating Tumor Cells 1.00
Allele-Specific CRISPR-Cas9-Based Ratiometric Fluorescence Platform for Portable EGFR L858R Mutation Detection 1.00
Precise Tumor Delineation via Dual Fluorescence Lifetime Imaging 1.00
Sensitive Imaging of Intracellular Long Noncoding RNAs In Situ in Living Cells Based on Synergistic Dual Hybridization Chain Reaction 1.00
Entropy-Driven Nucleic Acid Amplifier Based on Spatial Confinement as a “Booster” for Detection of Extracellular Vesicle MicroRNAs to Diagnose Gastric Cancer and Monitor Therapeutic Response 1.00
Dual-Targeting Near-Infrared Fluorescent Probe for Simultaneous Mitochondrial Injury Assessment and Fibrosis Monitoring in Pulmonary Fibrosis 1.00
Multiplex Aptamer-Guided DNA Nanosuppressors for Quantitative Modulation of Autophagy–Survivin Crosstalk and Imaging-Guided Apoptosis Induction 1.00
Ag+/Hg2+-Controlled Programmable DNA Nanostructures Enable Tumor Liquid Biopsy by Mass Spectrometry Simultaneous Sensing of Multiple Circulating Tumor DNAs 1.00
Preclinical Evaluation of a Trop2-Targeted Peptide Probe for PET Imaging of Triple-Negative Breast Cancer 1.00
Triple-Synergistic Mitochondria-Targeted NIR Fluorescent Probe for Mitochondrial Hydrogen Sulfide: Precision Monitoring and Image-Guided Resection of Metastatic Breast Cancer 1.00
Development of an Aptamer/CRISPR-Cas12a-Based Dual-Modal Biosensor for Fusobacterium nucleatum Detection in Non-Invasive Colorectal Cancer Screening 1.00
Dual-Pathway Enhanced Single-Molecule Electrochemiluminescence Imaging of T Cell Early Activation Biomarkers 1.00
H2S-Activatable Nanoagent for NIR-II Fluorescence Imaging and Photodynamic Therapy of Colon Cancer 1.00
Highly Sensitive and Multiplexed Detection of Low-Frequency Mutation in Fragmented ctDNA by a Dual-Role Mediator Blocker Amplification Strategy 1.00
Single-Cell Raman Spectroscopy Combined with Metabolomics Reveals Distinct Metabolic Profiles in Medulloblastoma Subtypes 1.00
Efficient and Sensitive Bisulfite-Free Methylation Detection Approach for Low-Abundance and Highly Fragmented cfDNA 1.00
Deep Raman Quantitative Profiling and Augmented Features for Biologically Interpretable GI Cancer Detection 1.00
Ultrasensitive Electrochemiluminescence Multiplex Immunoassays of Circulating Tumor Cells via Cerasomes within MXene-Modified Single-Electrode Electrochemical Systems 0.19
Deciphering the Mechanism of Interactions between Polyubiquitin Chains and Caspase Activation and Recruitment Domains Using Protein–Polymer-Engineering-Assisted Native Mass Spectrometry 1.00
Serum SERS Analysis Reveals Amino Acid- and Protein-Associated Vibrational Features for Subtype Identification in Acute Lymphoblastic Leukemia 1.00
Discovery of Novel Multifunctional Paramagnetic Platforms: Cell Sorting and Theranostics Based on Active Molecules of Vascular Normalization 1.00
A New Biomarker for Predicting the Abscopal Effect: Quantifying Polyclonal Effector Tumor Antigen-Specific T Cells by Using Nanoparticles Loading Whole Tumor Antigens 1.00
Dual Organelle-Targeted Near-Infrared Fluorescent Probe for Exploring Dynamic Nuclear Changes during Photodynamic Therapy 1.00
An LF-NMR Biosensor for the Detection of Circulating Tumor Cells Based on Target-Triggered Bioorthogonal Chemistry and Click Chemistry 1.00
De Novo Design of Photosensitizers Activated by Tumor Microenvironments for NIR Imaging and Photodynamic Therapy of Tumor 1.00
DNA Tetrahedral Sensors for Visualizing miR-21-Mediated Angiogenesis 1.00
Fast Screening of Circulating Tumor Cells in Blood Samples by Sialic Acid Recognition and Microfluidic Chip-Single-Cell ICP-MS: A Breakthrough in Non-invasive Cancer Diagnosis 1.00
Dual-Functional g-C3N4@AgNPs Nanosheets-Based Chemiluminescence Immunosensor for PD-L1-Expressing Exosomes and Classification of Lung Adenocarcinoma Subtypes 1.00
A Sensor Array Composed of Organelle-Targeting Fluorescent Probes and Polydopamine Particles for Deep Learning-Assisted Identification and Ablation of Drug-Resistant Lung Tumors 1.00
Reactive Oxygen and Nitrogen Species Release of Single Pancreatic Cancer Cells Subjected to Pulsed Electric Field Ablation: Concentration and Dynamics 1.00
Precision Visualization of Surgical Margins and Depth Imaging Performance in Orthotopic Hepatocellular Carcinoma Using Galactose-Targeted NIR-II Fluorescence Nanoprobe 1.00
Ultrasensitive eccDNA Detection for Tumor Diagnostics by Using CRISPR/Cas12a-Coupled Nested PCR 1.00
Comparative SERS Analysis of Passive and Active Tumor Targeting in Single Cells, Spheroids, and Tissues 1.00
Visualization of Hypoxic Tumors: Stimulated by NIR-IIb Emissive Erbium(III)-Phthalocyaninate Nanoagent 1.00
Vesicular Stomatitis Virus Glycoprotein- and Lentiviral RNA-Based Robust Approach for Rapid and Accurate Quantification of Viable Lentiviral Vectors 1.00
Dynamic Monitoring of Chelatable Zinc on Endoplasmic Reticulum During Immunogenic Cell Death by TPPLIM Using a Theranostic Ir(III) Complex 1.00
Hypersensitive Multiparametric MRA for Mild Traumatic Brain Injury: Simultaneous Imaging of Hemorrhagic Foci, Vascular Integrity, and Collaterals 1.00
First Fluorescent Probe for TREX1 Enables Real-Time Tracking of DNA Repair and Immune Regulation in Cancer Cells 1.00
Development of 68Ga-NOTA-cRGD Probe Mediated by Sulfenic Acid for Prolonging Tumor Imaging 1.00
Time-Gated Raman Spectroscopy Combined with Deep Learning for Rapid, Label-Free Histopathological Discrimination of Gastric Cancer 1.00
Antifouling Capture and Dual-Targeting Recognition-Induced Signal Amplification for Triple-Mode Detection and Identification of Circulating Tumor Cells 1.00
Dual-Modulation Design to Develop ER-Targeting NIR Pyroptosis Inducers with Type I PDT Efficacy and Amplified Antitumor Immunity 1.00
Light-Addressable Regenerative Photoelectrochemical Biosensor Array with Self-Calibration for High-Throughput and Accurate Detection of Circulating Tumor Cells 1.00
Discovery of Environment-Sensitive Near Infrared SHP2-Targeting Fluorescent Ligands for Living Cells and Tissue Section Imaging 1.00
Aminopeptidase N-Triggered Electron Rearrangement of Fluorescein for Covalent Fluorescent Labeling and Image-Guided Orthotopic Bladder Cancer Resection 1.00
Fusion of Molecular and Mechanical Phenotypes Enables High-Purity and Low-Loss Reacquisition of Viable CTCs for Transcriptome Analysis 1.00
Multiplexed lncRNA Analysis in Breast Cancer via Cascade Amplification Reaction through Fluorescent and Electrochemical Dual-Signal Output Modalities 1.00
Microfluidics-Based High-Throughput Single-Cell Analysis of Reactive Oxygen Species and T Cell Exhaustion 1.00
Sequential Labeling-Assisted Precise and Multitarget Analysis of Surface Proteins on Extracellular Vesicles 1.00
56 52.46
Mitochondria‐Targeted Photodynamic Agents Drive Robust Pyroptosis by Caspase‐3/GSDME Activation and Cardiolipin Externalization 1.00
Mitochondria-Targeting Iridium(III) Complexes Induce PANoptosis and Ferroptosis for Boosting Chemoimmunotherapy Against Immune-Desert Colorectal Cancer 1.00
Hydrophobic Tag Degraders Overcome Endocrine-Resistant Breast Cancer by Recruiting HSP27-Mediated E3 Ligase Complex for ERα Proteasomal Degradation 1.00
Long-Acting Dynamic Therapy Using X-Ray Activated Organic Nanoparticles for Afterglow Imaging Guided Deep Tumor Treatment 0.92
Dual-Interface Nanopore Array Sensor Revealing the Synergistic Oscillations of Lactate Efflux in Cancer Cells 1.00
Enzyme‐Guided Assembly Enables Precision Delivery of a Singlet Oxygen Battery for Membrane Lipid Peroxidation Therapy 1.00
Piezoelectric Nanozymes With Acoustically Rejuvenated Catalytic Activities Rewire Lipid Metabolism for Two-Pronged Ferroptotic Therapy 1.00
Smart Sonoafterglow Nanobombs for High‐Contrast Imaging and Synergistic Gas‐Sonodynamic Therapy of Hypoxic Tumors 0.90
Programmable Chimeric Antigen Receptor T Cell Circuits With DNA Computing for Precision Tumor Therapy 1.00
Anthraquinone‐Based Electron Reservoir‐Pump Photosensitizer Generating Radical Ion Pairs for Metabolism‐Targeted Photodynamic Therapy 1.00
Oxygen Vacancy-Driven Dual-Site Pd-TiO2 Sonocatalyst for Amplified Reactive Oxygen Species Generation and Sonocatalytic Therapy 1.00
Precise Modulation of Excited-State Energy Flow via Consecutive Twisted Intramolecular Charge Transfer (ConTICT) for Autophagy-Blocking Photothermal Therapy 1.00
A Cell‐Resolved Ultrastable Biosensor Enables One‐Step Detection of Gene‐Fusion Transcripts in Unprocessed Whole Blood 0.90
Charge‐Tunable Dense Dual‐Atom Nanozymes Reprogram Biothiol Metabolism Through Multi‐Enzyme‐Mimetic Catalysis to Synergistically Induce Ferroptosis and Disulfidptosis 1.00
Axial Sulfur-Bridged Mo-S-Cu Nanozymes With an Asymmetric Local Electric Field Boosting Multi-Enzymatic Activities for Ferroptosis-Pyroptosis Therapy 1.00
Nanozyme-Mediated PROTACs Delivery for Targeted Protein Degradation and Ferroptosis Sensitization in Prostate Cancer 1.00
A Biomimetic Nanovesicle‐Based Synthetic Vaccine Platform Through Co‐Anchoring Oxidized Phospholipid and CpG for Rejuvenating Antitumor Immunity in Aged Mice 1.00
Zinc‐Complex Orchestrating Pyroptosis for Hypoxia‐Tolerant Photoimmunotherapy 1.00
Atomic‐Precision Triple‐Enzyme Nanozyme Synchronizes Mitochondrial Dual‐Pathway Disruption for Precision Oncology 1.00
Sono-Flexocatalytic Tumor Suppression Enabled by SrTiO3 Nanoflexocatalysts 1.00
Organoplatinum(II) J‐Aggregates with Prolonged Triplet Lifetimes for Enhanced Photodynamic and Photocatalytic Therapy 0.75
Boosting Cancer Chemoimmunotherapy with Mitochondria-Targeting Iridium(III)-Based Immunogenic Oncosis Inducers 0.75
NIR‐II‐Photopyroelectric Catalysis for Immunoactivation/Ferroptosis Combined Therapy of Tumor 1.00
Screening Metal Ions to Tailor Carrier Dynamics in Porphyrin‐Based Covalent Organic Polymers for Enhanced Sonocatalytic Pyroptosis and Immunotherapy 1.00
Rhodium(III)-Nitroxyl Radical Complex Triggers Dual-Pronged Disulfidptosis-Apoptosis in Hepatocellular Carcinoma via Metabolic Sabotage and Redox Catalysis 1.00
Biodegradable Nano‐Regulator Reprograms Glioblastoma Immunosuppression: Pyroptosis‐Metabolism‐Immunity Crosstalk for Cascading Immune Activation 1.00
Construction of Small-Molecule Deubiquitinase-Targeting Chimeras to Reactivate and Stabilize Mutant p53 Y220C in Vitro and in Vivo 1.00
Simultaneously Enhancing NIR‐II Emission, Type‐I, and Type‐II Photosensitization Through Acceleration of Charge‐Separated‐State Formation for Tumor Phototheranostics 1.00
Phase‐Transition Nanoparticles Enable Fluorescence Self‐Reporting for Close‐Loop Photodynamic Therapy 1.00
Reactive Oxygen Species-Responsive Biomimetic Nanoplatelets for Thrombus-Mediated Photothermal Immunotherapy of Tumor 0.44
Photooxidation‐Induced Ultrabright and Ultraphotostable NIR‐II Emissive Water‐Soluble Gold Nanoclusters 1.00
Superhydrophilic FeIV2MnII Nanocluster: A Combined Diagnostic and Therapeutic Agent 0.90
Naphthalimide-Based Type-I Nano-Photosensitizers for Enhanced Antitumor Photodynamic Therapy: H2S Synergistically Regulates PeT and Self-Assembly 0.73
Self‐Assembled Nanoconjugates with Aggregation‐Induced Emission for Near‐Infrared II Imaging and Transcytosis‐Driven Cancer Therapy 1.00
Cell Membrane‐Targeted J‐Aggregation Strategy for Synergistic Immune Checkpoint Degradation and Immunogenic Pyroptosis to Augment Tumor Immunotherapy 1.00
Concurrent Ferroptosis and Pyroptosis Induced by a Dual‐Organelle‐Targeted Type I/II AIE Photosensitizer for Bladder Cancer Immunotherapy 1.00
Fe−O−Mo Site‐Activated Nanozymes for Bienzymatic/Upconversion Synergistic Catalytic Anticancer Therapy 1.00
MitoSiege‐Driven Catalase Collapse: A GSH‐Responsive, Mitochondria‐Targeted COF Prodrug for Amplified Chemodynamic Therapy 0.55
Atorvastatin‐Loaded Mineralized Vaccine Reprograms Endosomal Trafficking to Amplify STING‐Driven Cancer Immunotherapy 1.00
Dual‐Locked Polymeric STING Nano‐Agonist/Sonosensitizer Augments Spatiotemporally Controlled Cancer Sono‐Immunotherapy 1.00
Cyclometalating Ligand Affords NIR Absorption in Ruthenium Complexes for Type‐I Photodynamic Therapy 0.93
EDTA‐Mg Nano‐Chelators Amplify Ferroptosis by Artificially Simulating the Epithelial‐Mesenchymal Transition Process and Endogenous Iron Deprivation 1.00
Unveiling the Power of Dark State Photocages: An Efficient Pathway to Triplet State Under Near‐Infrared Light Irradiation 0.75
A Photon‐Driven Unimolecular Immunostimulant for Self‐Amplified Pyroptosis and cGAS‐STING Pathway by Destroying the Pyroptosis Checkpoint 0.88
HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking 1.00
Engineering a Multifunctional Nanozyme Platform for Synergistic Melanoma Therapy: Integrating Enzyme Activity, Immune Activation, and Low‐Temperature Photothermal Effects 0.79
Au6Cu2 Clusters with High Electron Affinity and Oxygen-Mimetic Properties for Hypoxic Tumor Radiosensitization 0.83
Harnessing Porous Coordination Cages for Sonodynamic Therapy: Enhanced Efficacy Through Atomic Precision and Immune Activation 1.00
Aptamer as a Molecular Tethering Agent Induces PrPC Aggregation and Degradation to Inhibit Melanoma Proliferation 1.00
Lysine‐Targeting, Covalent Inhibitors of Bromodomain BD1 of BET Proteins in Live Cells and Animals 0.79
Resiquimod‐Induced Nanovaccine (RINV) for Personalized Cancer Immunotherapy 1.00
Circular RNA-Based Molecular Computation Enhances Plasma Biomarker Detection in Biliary Tract Cancer 1.00
NO‐Enhanced Sonodynamic Nanovesicles with Co‐Stimulatory Molecule Self‐Presentation for Multidimensional Tumor Immunotherapy 1.00
ATP‐Inducible Receptor Oligomerization Enables Fine‐Tuning of T Cell Immunity 1.00
Multipath ROS Storm and Immune Activation via Sulfur Vacancy-Optimized ZnIn2S4 Nanosheets for Piezocatalytic Tumor Therapy 1.00
A Hypoxia‐Triggered Bioreduction of Hydrophilic Type I Photosensitizer for Switchable In Vivo Photoacoustic Imaging and High‐Specificity Cancer Phototherapy 0.64
2 2.00
Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain : A Prospective, Randomized, Phase 3 Trial. 1.00
Palliative Care Educational App for Family Caregivers of Homebound Patients With Incurable Cancer : A Single-Center Randomized Trial. 1.00
5 1.46
The International Study Group for Pancreatic Surgery (ISGPS) Definition and Classification of Postpancreatectomy Mortality. 0.02
Setting the Standard in Robotic Whipple Surgery: International Multicenter Benchmark Analysis. 0.03
Impact of Celiac Axis Stenosis in Patients Undergoing Pancreatoduodenectomy and Total Pancreatectomy: International Multicenter Study. 0.31
Association of Recurrence with a Tumor-informed Personalized ctDNA Detection Approach in Resectable Colorectal Cancer: Results of a Prospective Observational Study. 1.00
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials. 0.10
2 2.00
Heterogeneous responses of IM19 anti-CD19 CAR T-cell therapy in refractory systemic lupus erythematosus: an open-label pilot study and a mini-review 1.00
BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis 1.00
2 2.00
Unveiling the interface effects of plasma-activated micro-nano bubbles water: An emerging avenue for cancer therapy 1.00
Cancer metastasis: How blood flow affects platelet–cancer cell interactions 1.00
1 1.00
Dual-Targeting BCMA–CD19 CAR-T Cell Therapy in Systemic Lupus Erythematosus: Single-Cell and Immune Repertoire Analysis Reveals Mechanisms of Immune Reconstitution 1.00
7 1.99
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies 0.01
Magrolimab plus azacitidine vs physician’s choice for untreated iTP53/i-mutated acute myeloid leukemia: the ENHANCE-2 study 0.05
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia 0.02
CircFUT8 promotes proplatelet formation by interacting with IGF2BP2 and stabilizing TNS1 mRNA in megakaryocytes 0.85
Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin 0.02
Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1 1.00
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of iJAK2/i-mutated post-MPN AML 0.04
2 1.13
De novo and inherited variants in DDX39B cause a novel neurodevelopmental syndrome 0.31
Deep learning analyses of splicing variants identify the link of PCP4 with amyotrophic lateral sclerosis 0.82
2 0.15
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements 0.05
Survival After Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma 0.10
24 22.43
Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration 0.93
Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer 1.00
Cancer stem cells orchestrate immune evasion through extracellular vesicle-mediated non-canonical signaling pathways 1.00
JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial 1.00
Molecular insights into early malignant transition of hepatocellular carcinoma 0.86
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial 1.00
Candida albicans synergizes with Fusobacterium nucleatum in colorectal cancer progression via the Flo9-RadD interaction 0.98
Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer 1.00
Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases 1.00
Lipid oxidation reprogramming in cancer-associated fibroblasts enhances CD8+ T cell cytotoxicity and therapeutic response 1.00
Single-cell screens identify ADAM12 as a fibroblast checkpoint impeding anti-tumor immunity 1.00
Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer 0.80
Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer 0.93
Remodeling of T and endothelial cells during total neoadjuvant therapy in rectal cancer 1.00
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study 1.00
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial 1.00
Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study 1.00
Ketogenic diet inhibits glioma progression by promoting gut microbiota-derived butyrate production 1.00
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers 1.00
CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases 0.89
Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer 1.00
Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps 1.00
Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma 1.00
Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling 0.05
70 64.66
Serglycin Drives LAG3+ Treg Differentiation and Immunosuppression in Gastric Cancer 1.00
Spatial Multiomics Analyses Reveal That Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation 1.00
ARID1A Mediates SWI/SNF-Independent Maintenance of Heterochromatin Architecture to Restrain Viral Mimicry and Immunogenicity in Colon Cancer 0.87
Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression 1.00
Intratumoral Prevotella copri Reprograms MARCO+ Tumor-Associated Macrophages by Depleting Glycerophosphocholine to Drive Colorectal Cancer Progression 1.00
GAL3ST1-Mediated Histone Tyrosine Sulfation Induced by Cancer-Associated Fibroblasts Promotes Gastric Cancer Metastasis 1.00
AKT3-Driven Epithelial–Mesenchymal Plasticity Governs Ovarian Metastasis in Colorectal Cancer via Tumor Microenvironment Remodeling 1.00
CCL5hiCD4+ T Cells Regulate Macrophage Polarization and Promote Immunotherapy Response in Bladder Cancer 1.00
Androgen Receptor Signaling Induces CD8+ T-cell Dysfunction That Is Reversed by Androgen Deprivation Therapy in Male Head and Neck Squamous Cell Carcinoma 1.00
Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma 1.00
FOSL1 Orchestrates Epigenetic Reprogramming of Anaplastic Thyroid Cancer and Suppresses NK Cell–Mediated Antitumor Immunity 1.00
VGF-Mediated Mitochondrial Remodeling Fuels Lung Adenocarcinoma Brain Metastasis 1.00
Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression 0.91
Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy 1.00
NRF1 Induces ApoEhigh Cancer-Associated Fibroblasts to Promote Stemness of Renal Cell Carcinoma 1.00
KLF5 Activation Promotes Malignant Transformation to Drive Development of Lung Squamous Cell Carcinoma 1.00
Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Antitumor Immune Evasion 1.00
PAK5-Mediated Suppression of β-Hydroxybutyrate Production Promotes Breast Cancer Metastasis and Can Be Overcome with Ketogenic Diet 1.00
Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells 0.95
Extracellular Vesicle-Mediated O-GlcNAcase Transfer Drives Neuronal Necroptosis to Facilitate Gallbladder Cancer Perineural Invasion 1.00
Comprehensive Multi-Omic Characterization of Perineural Invasion in Cervical Cancer Reveals Diagnostic Markers, Molecular Drivers, and Therapeutic Strategies 0.85
Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer 1.00
Fusion of Tumor Cells with Lipid-Associated Macrophages Drives Metastatic Progression of Breast Cancer 1.00
Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma 0.31
LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in Prostate Cancer 1.00
CDK12 Deficiency Induces BRD4S to Promote Cancer Metastasis by Enhancing Phase Separation and Chromatin Engagement. 0.91
Cancer-Associated Fibroblasts Promote Imatinib Resistance in Gastrointestinal Stromal Tumors through PGK1-Mediated Metabolic Reprogramming. 1.00
Tetraspanin 13 Enhances Immune Evasion in Breast Cancer by Promoting MHC-I Degradation. 1.00
RORγ Hijacks HIF-1α to Promote Peritoneal Metastasis of Gastric Cancer. 1.00
FNDC4 Drives Metastasis and Immune Evasion in Pancreatic Cancer. 0.61
SPP1 Drives Colorectal Cancer Liver Metastasis and Immunotherapy Resistance by Stimulating CXCL12 Production in Cancer-Associated Fibroblasts. 1.00
Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma 1.00
Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer 0.91
TERC Stimulates Fatty Acid Metabolism to Promote Bladder Cancer Progression 1.00
TRIM49 Deficiency Stabilizes a Galectin-3/EGR1 Transcriptional Complex that Drives Invasiveness of Gastric Adenocarcinoma. 1.00
Integrating Circulating Tumor DNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy. 1.00
CRB2 Activates an Epigenetic Axis to Promote Ferroptosis in Head and Neck Squamous Cell Carcinoma. 0.94
Stress Promotes Lung Metastasis in Breast Cancer by Altering Neutrophil Differentiation. 1.00
MEN1 Promotes Ferroptosis by Disrupting CD44 Alternative Splicing to Suppress Lung Cancer. 1.00
Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion 1.00
A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition 1.00
FADD Activation in Hepatocellular Carcinoma Potentiates CD8+ T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors 1.00
Mitochondrial Calcium Uniporter Links Acetyl-CoA Metabolism and H3K27 Acetylation to Maintain Glioblastoma Stem Cells 1.00
CLK2 Regulates the KEAP1/NRF2 and p53 Pathways to Suppress Ferroptosis in Colorectal Cancer 1.00
Neuropeptide Precursor VGF Promotes Neuroendocrine Differentiation and Cancer-Associated Fibroblast Activation in Small Cell Lung Cancer. 0.94
Intracellular Interleukin-1α in Peritumoral Monocytes Induces IL8 Production and Inhibits Mitophagy to Promote Stemness and Metastasis of Hepatocellular Carcinoma. 1.00
The Acetyltransferase ARD1 Induces Glutathione Synthesis to Facilitate Ferroptosis Evasion in Hepatocellular Carcinoma. 0.85
Targeting ATP7A-Dependent Copper Metabolic Homeostasis Induces Cuproptosis and Suppresses the Progression of Mutant KRAS-Driven Lung Cancer. 1.00
Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2- Breast Cancer. 1.00
Genome-Wide CRISPR Screening Reveals that mTOR Inhibition Initiates Ferritinophagy and Ferroptosis in Head and Neck Cancer 0.08
PCBP2 Mediates Olaparib Resistance in Breast Cancer by Inhibiting m6A Methylation to Stabilize PARP1 mRNA. 0.83
SRSF9 Forms Phase-separated Condensates to Promote Ovarian Cancer Progression by Inducing RNA Alternative Splicing that is Inhibited by m6A Modification. 1.00
Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer 0.09
Comprehensive Characterization of Somatic Mutation Timing Reveals the Evolutionary Trajectory of Lung Adenocarcinoma in Chinese Patients 1.00
Pancreatic Neuroendocrine Tumors Secrete Apolipoprotein E to Induce Tip Endothelial Cells That Remodel the Tumor–Stroma Ratio and Promote Cancer Progression 0.94
Exon Skipping of Ste20-Like Kinase Enhances Glycolysis and Tumor Progression by Activating Enolase 1-Mediated Phosphoenolpyruvate Production. 1.00
Oxytocin Receptor Regulates the Hippo/YAP Axis to Drive Hepatocarcinogenesis 1.00
Aberrant CircTMEM45A Facilitates Inflammatory Progression of Esophageal Squamous Cell Carcinoma through m5C-Mediated NLRP3 Activation 1.00
Large-scale Characterization of Orthotopic Cell Line–Derived Xenografts Identifies TGFβ Signaling as a Key Regulator of Breast Cancer Morphology and Aggressiveness 0.02
Mannose Enhances Immunotherapy Efficacy in Ovarian Cancer by Modulating Gut Microbial Metabolites 1.00
Chronic Stress Stimulates Protumor Macrophage Polarization to Propel Lung Cancer Progression 0.81
Targeting LTBP2 Derived from Cancer-Associated Fibroblasts Sensitizes Esophageal Squamous Cell Carcinoma to Chemotherapy 1.00
TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis. 1.00
Tumor-Specific MHC-II Activates CD4+ and CD8+ T cells in Head and Neck Squamous Cell Carcinoma to Boost Immunotherapy Efficacy. 1.00
A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer 1.00
Cancer-Associated Fibroblasts Foster a High-Lactate Microenvironment to Drive Perineural Invasion in Pancreatic Cancer 1.00
Perivascular Niche–Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment 0.96
SMYD3 Activates Fatty Acid β-Oxidation to Promote Self-Renewal of Leukemia Stem Cells 1.00
Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy 0.93
Targeting the SP/KLF Transcriptional Regulatory Network Synergizes with HDAC Inhibition to Impede Progression of H3K27M Diffuse Intrinsic Pontine Glioma 0.95
14 11.47
Farnesylation-driven KRAS phase separation promotes colon tumor growth 1.00
A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers 0.97
Stabilizing MARCH7 as a ferro-guardian against ferroptosis 1.00
Rational discovery of therapeutic PAK1 allosteric activators 0.09
Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias 0.91
Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment 1.00
Divergent tumor immunity determined by bacteria-cancer cell engagement 1.00
Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors 0.56
Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy 0.95
Inhibition of oligomeric BAX by an anti-apoptotic dimer 0.10
Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance 1.00
Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis 0.94
Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy 0.99
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis 0.97
4 3.88
Engineered probiotics recruit CAR macrophages and establish immune memory to eradicate heterogeneous glioblastoma in mice 0.88
UBE2O-mediated monoubiquitination licenses NLRP6 inflammasome activation in the intestine 1.00
Bacterial effector OspB hijacks apoptosis through peptide-bond recombination of BH3 domain proteins 1.00
Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity 1.00
8 6.91
Iron-addicted colorectal cancers exploit heme-complex II axis to resist oxidative cell death 0.01
The S100A8/A9 complex promotes food intake and prevents adipose tissue loss during cancer cachexia in mice 0.99
Compartmentalized branched-chain amino acid metabolism orchestrates colorectal cancer dissemination via an UMP-vimentin axis 0.95
Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML 0.95
Serotonin-licensed macrophages potentiate chemoresistance via inositol metabolic crosstalk in ovarian cancer 1.00
Extracellular vesicles from obese visceral adipose promote pancreatic cancer development and resistance to immune checkpoint blockade therapy 1.00
Quercetin-derived microbial metabolite DOPAC potentiates CD8+ T cell anti-tumor immunity via NRF2-mediated mitophagy 1.00
Arachidonic acid triggers spermidine synthase secretion from primary tumor to induce skeletal muscle weakness upon irradiation 1.00
6 6.00
MMRN1-EGFR drives sialylglycan-Siglec immune evasion in AML leukemia stem cells 1.00
Engineered MSCs enable bone marrow-targeted immunomodulation 1.00
Paired patient-derived organoids reveal transcription factor-driven epigenetic remodeling in breast cancer metastasis 1.00
Pluripotent stem cell-derived CAR-NK progenitor therapy targets minimal residual disease and prevents relapse in leukemia models 1.00
A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy 1.00
An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer 1.00
29 29.00
Copper-coordinated dendritic photosensitizer for spatiotemporally synergistic PDT-CDT cascade antitumor therapy 1.00
Lighting up the linear ubiquitin code: a bioluminescent sensor for M1-specific deubiquitinase activity and drug discovery 1.00
Beyond apoptosis: platinum phototherapeutics overcome resistance by triggering diverse cell death pathways 1.00
A lipid droplet-targeted Pt(ii) complex enables photoinduced ferroptosis and apoptosis against cisplatin-resistant cells 1.00
Dual inhibition of ERα/NF-κB pathways coupled with sonodynamic therapy via a multifunctional AIEgen 1.00
Imaging of viscosity in ferroptosis-mediated acute alcoholic gastric injury and tumor models using an endoplasmic reticulum fluorescent probe 1.00
A dual-strike strategy against glycolytic and mitochondrial metabolism for potentiated mild photothermal therapy 1.00
Sulfur- or selenium-substituted Nile blue-based superoxide radical generators for precise photodynamic therapy and immunotherapy 1.00
Novel radiation-activated N-oxide prodrugs for highly selective and synergistic tumor therapy to promote DNA damage and the ATM/ATR pathway 1.00
Engineering principles of nanomedicine in gas-mediated enhanced anti-tumor photodynamic therapy 1.00
A matrix metalloproteinase-responsive iridium(iii)-based hydrogel for cancer cell-specific imaging and lysosome-targeted photodynamic therapy 1.00
NIR-II photozymes with stoichiometric chemistry-regulated enzyocatalytic activities for multi-modal nanocatalytic therapy 1.00
A thiazolo[5,4-d]thiazole-bridged dinuclear iridium(iii) photosensitizer induces ferroptosis for boosting photoimmunotherapy against hypoxic melanoma 1.00
Near-infrared-activated Ru(ii)-nile blue conjugates as type-I photosensitizers for efficient hypoxia tumor therapy 1.00
Activatable and multifunctional supramolecular photosensitizers via macrocycle-based host–guest interactions: enabling safe and efficient photodynamic therapy 1.00
A new perspective on intracellular redox environment-mediated innovative photodynamic therapy 1.00
A membrane camouflaged copper single-atom nanozyme for combined mild photothermal and chemodynamic therapy 1.00
Aggregation-induced emission sonosensitizers: molecular engineering and biomedical applications 1.00
A PET-activated photosensitizer based on ROS-sensitive Trolox for tumor microenvironment-responsive imaging and therapy 1.00
Repurposing vaccine-induced anti-HBV antibodies for endogenous immunotherapy against EGFR-positive tumors 1.00
A TLR7/8 agonist–chitosan conjugate as an adjuvant for carbohydrate-based anticancer vaccine development 1.00
Spatiotemporal Flt3L delivery via photoactivation enhances tumor-selective immunotherapy 1.00
Balancing UV-to-blue light conversion by membrane-embedded AIE antennas for enhanced photosynthesis 1.00
Thioguanine-coordinated assembly for synthetic lethality of colorectal cancer with defective mismatch repair 1.00
Design of TNFR peptide agonists for inducing receptor oligomerization and cell apoptosis 1.00
Chemical proteomics reveals hesperidin and hesperetin as AKR1C1/2 inhibitors with chemosensitization effect 1.00
A near-infrared light-triggered covalent nanodrug for combined singlet oxygen therapy and photothermal therapy 1.00
A pyrene-based HDAC inhibitor for dual-action therapy of breast cancer 1.00
Construction of balanced-transition AIE phototherapeutic agents based on a fluorination strategy for prolonged triplet excited state lifetime 1.00
21 20.92
Core–wing modulated squaraines with enhanced two-photon absorption and efficient photothermal eradication of bacteria 1.00
Zero-trigger ultrafast charge-transfer J-aggregates via Se/π-directed assembly enable synchronous ROS/heat amplification for NIR-II photoimmunotherapy 0.92
A highly effective self-supplying photosensitizer drug for the treatment of deep-tissue metastatic tumors 1.00
A unimolecular near-infrared fluorescent probe for in vivo imaging of enzymes with minimized false-negative signals 1.00
Rhodamine-functionalised rhodium(iii) complexes: dual role as bioimaging agents and controllable reactive oxygen species photosensitisers for photocytotoxicity applications 1.00
Phosphorescent iridium complexes activated by endogenous zinc as a mitochondrial DNA nuclease for stimulation of the cGAS-STING pathway 1.00
A bioorthogonal-catalytic artificial antigen-presenting cell for chemo- and immuno-therapy 1.00
Shortwave infrared absorbing and fluorescent BODIPY J-aggregates for high-contrast in vivo imaging 1.00
Discovery of an allosteric 14-3-3 inhibitor for suppressing NRF2-driven cancer via phenotypic screening and chemoproteomic-based target deconvolution 1.00
An acceptor motor-driven electronic donor–acceptor supramolecular scaffold towards imaging-guided tumor therapy 1.00
Rationally designed sonocatalyst-enhanced supramolecular ferroptosis inducers for effective cancer therapy 1.00
Single-walled carbon nanotubes hitchhike on Ly-6Chi monocytes for photoacoustic image-guided photothermal shock therapy of metabolic inflammation 1.00
Mimicking NADPH oxidase and lipoxygenase by using a biodegradable single-site catalyst via a cascade reaction to trigger tumor-specific ferroptosis 1.00
All-component-active metal–organic frameworks for tailored chemoradiotherapy of self-defensive tumors 1.00
Novel tryptophan 2,3-dioxygenase-targeted ruthenium(ii)-indole complex activates immunotherapy in vitro and in vivo 1.00
A nuclear targeted type-I photosensitizer for anti-tumor therapy 1.00
“Dual lock-and-key” triggered and endoplasmic reticulum targeting nanophotosensitizers for activatable Type-I photodynamic and photothermal therapies 1.00
An activatable unimolecular phototheranostic agent for synergistic chemo-photodynamic therapy 1.00
Photo-uncaging of a ferrocene-bridged dinuclear iridium(scpiii/scp) complex for three-photon photoimmunotherapy against hypoxic melanoma 1.00
Endoplasmic reticulum-targeting activatable nanophotosensitizers for hypoxia relief and enhanced photodynamic therapy 1.00
Detecting microsatellite instability in cancer via multiplexed orthogonal gap-enhanced Raman tags 1.00
1 0.86
Timing of screening benefit for lung cancer with low-dose computed tomography 0.86
1 0.06
miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction. 0.06
10 7.93
A machine learning-based megakaryocyte identification system uncovers resident organs, markers, and functional diversity 1.00
Unleashing T cell surveillance for the eradication of quiescent persister tumor cells resistant to neoadjuvant chemotherapy 1.00
CircRNA-encoded RIPK1-98 protein drives lung adenocarcinoma progression 0.79
Multiscale mechanisms driving tissue rupture by invading cells 0.11
Long-range deployment of tumor-antigen-specific cytotoxic T lymphocytes inhibits lung metastasis of breast cancer 1.00
Dapk2 dysfunction leads to Mic60 lactylation and mitochondrial metabolic reprogramming, promoting lung cancer EGFR-TKI resistance and metastasis 1.00
The extracellular-matrix-remodeling capability exposes therapeutic vulnerability in a subset of renal cell carcinomas with tumor thrombi 1.00
Cloche/Npas4l is a pro-regenerative platelet factor during zebrafish heart regeneration 1.00
Rbpms2 prevents major cardiac defects in cardiomyocyte-specific Rbpms-deficient mice 0.04
RIPK4 promotes epidermal differentiation through phase separation and activation of LATS1/2 1.00
1 1.00
Macrophages-derived exosomal non-coding RNA circ_0055194 regulating miR-665/YAP1/Twist axis is involved in pulmonary fibrosis induced by Nd2O3 1.00
2 1.14
Sustainable remediation of tetracycline-contaminated soil: A Fe-g-C3N4 nanozyme driven abiotic-biotic strategy 1.00
Effects of Residual PAH Exposure from Firefighters’ Skin and Turnout Gear on Biospecimen microRNA Expression 0.14
7 7.00
Environmental PFOS and 6:2 Cl-PFESA Reshape Ferroptosis Vulnerability in Liver Cancer 1.00
Integrated Evidence for Lysosomal Dysfunction-Mediated Iron Dysregulation induced by PM2.5 Exposure 1.00
Identification of Halophenol-Deoxyguanosine Adducts in SV-HUC-1 Cells Exposed to Halobenzoquinones via the Neutral Loss and Information-Dependent Acquisition Strategy 1.00
Mitochondrial Metabolomics Reveals the Mechanism of SCCP Induced Energy Metabolism Inhibition 1.00
Establishing a Genetically Stable COS7-RXRα Cell Model for Screening Emerging Contaminants with RXRα Modulatory Effects 1.00
Underestimated Toxicity: UV Amplifies Low-Dose Cr(VI) Damage to Skin at Molecular and Tissue Levels 1.00
Profiling the Chemical Exposomic Landscape of Esophageal Squamous Cell Carcinoma 1.00
2 2.00
Breast tumour-secreted ADAM10 mediates atrial fibrogenesis and fibrillation 1.00
Deficiency of the RNA-binding protein RBMS1 improves myocardial fibrosis and heart failure 1.00
1 1.00
Single-Cell Analysis of Chemotherapy-induced Remodeling Reveals CD276-driven Basal-like Chemoresistance in Pancreatic Cancer 1.00
1 0.30
ERRγ impedes neuroendocrine prostate cancer development 0.30
4 3.89
Nanopore sequencing identifies high-frequency somatic structural variations in laryngeal squamous cell carcinoma genomes 1.00
Adaptation of centromeres to breakage through local genomic and epigenomic remodeling in wheat 1.00
Cancer driver topologically associated domains identify oncogenic and tumor-suppressive lncRNAs 1.00
Multi-tissue single-nucleus RNA-seq reveals cell type-specific regulatory patterns of alternative polyadenylation in pigs 0.89
36 30.73
PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer 1.00
Hepatocellular carcinoma attributable to hepatitis B, hepatitis C and other risk factors at global, regional and national levels: an updated systematic review and meta-analysis 0.17
Norepinephrine promotes tumour cell aggressiveness and NK cell ferroptosis via ADRB2 in intrahepatic cholangiocarcinoma with perineural invasion 1.00
<atl>iTff2/i marks gastric corpus progenitors that give rise to pyloric metaplasia/SPEM following injury</atl> 0.37
Hypoxia-related and immune phenotype-related fusion model for non-invasive prognostication of hepatocellular carcinoma treated by TACE: a multicentre study 1.00
<atl>SLC6A14-mediated carnitine transmembrane uptake from PPARγ sup+/sup cancer-associated fibroblasts promotes recurrence of pancreatic cancer</atl> 0.85
SDC1+ CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancers 0.99
<atl>Trogocytosis-orchestrated CLDN18.2-“dressed” CD8 sup+/sup T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade</atl> 1.00
KRAS-driven protein disulfide isomerase family A member 6 expression suppresses PRKR-like endoplasmic reticulum kinase-mediated immunogenic cell death to desensitise pancreatic ductal adenocarcinoma to immune checkpoint blockers 1.00
<atl>iAcinetobacter baumannii/i promotes gastric cancer metastasis via NA-mediated NAD metabolism reprogramming and glycolytic activation</atl> 1.00
Prospective evaluation of radical surgery for adenocarcinoma of oesophagogastric junction: real-world insights from the CLAEG study 1.00
LY6D identifies persistent stem-like cells driving pancreatic tumourigenesis 1.00
Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics 0.46
KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy 1.00
Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition 0.90
<atl>iStreptococcus anginosus/i -derived methionine promotes gastric cancer progression</atl> 1.00
Targeting cancer stem cells enhances multikinase inhibitor therapy in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma 1.00
Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study 0.84
Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer 1.00
PDE5Asup+/sup cancer-associated fibroblasts enhance immune suppression in gastric cancer 1.00
SMYD2-mediated methylation of STAT1 protects against hepatic ischaemia/reperfusion injury by blocking JAK-STAT1 signalling pathways 1.00
KIF1Bβ suppresses hepatocellular carcinoma by transporting and secreting FBLN5 to attenuate the integrin pathway 1.00
Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies 1.00
Gastrin-dependent expansion of Cck2r+ corpus progenitors accelerates ulcer healing and inhibits gastric dysplasia 0.27
Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma 1.00
Glycaemic control is a modifiable risk factor for pancreatic cancer development in patients with diabetes: a population-based cohort study 1.00
Fructose drives colorectal cancer progression by regulating crosstalk between cancer-associated fibroblasts and tumour cells 1.00
Bacteroides intestinalis mediates the sensitivity to irinotecan toxicity via tryptophan catabolites 1.00
Comparative risk of high-risk neoplasia after polypectomy among individuals aged below 50 years versus 50 years and older 0.07
Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial 0.75
Targeting Aurora kinase B regulates cholesterol metabolism and enhances chemoimmunotherapy in cholangiocarcinoma 1.00
Pericyte drives the formation of circulating tumour cell-neutrophil clusters to promote colorectal cancer metastasis 0.97
Extracellular vesicle-induced lipid dysregulation drives liver premetastatic niche formation in colorectal cancer 1.00
A fusion-based deep-learning algorithm predicts PDAC metastasis based on primary tumour CT images: a multinational study 0.15
NLRP6 deficiency enhances macrophage-mediated phagocytosis via E-Syt1 to inhibit hepatocellular carcinoma progression 0.93
Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer 1.00
16 12.84
Low-dose chemotherapy remodels hepatic immune landscape and potentiates anti-tumor response to immune checkpoint blockade in cholangiocarcinoma. 1.00
Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy. 1.00
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses. 0.01
An α-specific PI3K inhibitor improves chemotherapy efficacy by inhibiting hepatic stellate cell activation in liver cancer. 0.13
Spatiotemporal landscape of intrahepatic cholangiocarcinoma liver metastasis at the single-cell level. 1.00
Targeting mTORC2-Dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET-activated and β-catenin-mutated hepatocellular carcinoma. 0.43
Satellite lesions versus intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling. 0.33
MSR1+ macrophages passivate antitumor immunity by inducing ITM2A+ CD4T exhaustion differentiation. 1.00
Targeting sterol O-acyltransferase 1 rewires fatty acid metabolism and uncovers immune vulnerability in hepatocellular carcinoma. 1.00
FXR splicing by SF3B3 promotes MYC-driven hepatocarcinogenesis. 0.95
RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1-mutated hepatocellular carcinoma. 1.00
NEK7 induced phosphorylation of EGFR on serine 1070 drive the acquired lenvatinib resistance in hepatocellular carcinoma. 1.00
Antiangiogenic therapy combined with immune checkpoint blockade mediates CCR7+CD8+ T-cell entry into HCC through high endothelial venules. 1.00
Tumor microenvironment heterogeneity and progression mechanisms in intrahepatic cholangiocarcinoma: A study based on single-cell and spatial transcriptomic sequencing. 1.00
Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice. 1.00
The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in hepatocellular carcinoma. 1.00
1 0.89
On-Chip Dynamic Mechanical Characterization: from Cells to Nucleus* 0.89
6 4.02
Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome 0.01
Mechanical signaling via β2 integrin decouples T cell proliferation and differentiation for generating stem cell-like CAR T cells 1.00
Innate immune sensing of Z-nucleic acids by ZBP1-RIPK1 axis drives neuroinflammation in Alzheimer’s disease 1.00
Succinate preserves CD8+ T cell fitness to augment antitumor immunity 0.92
Gasdermin C cleavage by Cathepsin S modulates Rab7 vesicles in intestinal epithelial cells to amplify anti-helminth immunity 0.09
Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy 1.00
8 7.55
Application of PARP1-Specific Pt(II)-Based Targeted Drug Conjugate in the Treatment of Ovarian Cancer by Inhibiting PARP1 and Suppressing DNA Damage Repair 1.00
A Heterometallic Decanuclear CeIII–WVI Cluster Incorporated Antimonotungstate for Sensitive Electrochemical Detection of Multidrug Resistance Genes 1.00
Type I Rhodamine-Sensitized Iridium(III) Complex Photosensitizers Activate Pyroptosis for Hypoxic Photodynamic Immunotherapy 1.00
Cyclometalated Iridium(III) Complexes with Optimally Allocated Excited-State Energy for Near-Infrared Photodynamic and Photothermal Therapy 1.00
A Highly Stable Photoactivatable Pt(IV) Prodrug with Lower Dark Cytotoxicity for Photochemotherapy 1.00
Coordination Confinement on the Decay Chains of Typical Medical α-Radionuclides 1.00
Mitochondria-Localized and Aggregation-Induced Near-Infrared Emission Iridium(III) Complexes for Photodynamic Therapy 1.00
Fluorescein-Functionalized Iridium(III) Complexes as Dual-Mode Type I Photosensitizers for Hypoxia-Tolerant Photodynamic and X-ray-Induced Therapy 0.55
1 0.23
Exosomal Liquid Biopsy for the Early Detection of Gastric Cancer 0.23
75 72.98
Low-dose EGFR inhibition unlocks ferroptosis susceptibility to sensitize chemotherapy in EGFR-high triple-negative breast cancer 1.00
GALNT7-induced O-glycosylation of NUP50 activates fatty acid β-oxidation to promote lung adenocarcinoma metastasis 1.00
LATS kinase activity and tumor suppressor function are regulated by a second autophosphorylation site 1.00
HPV16 E2 protein possesses intrinsic helicase activity and sterically hinders E1 function through direct interaction 1.00
HuR-HuB Autoregulatory Network Governs Inflammatory Factors Expression 1.00
Isolinderalactone Suppresses the Progression of Cholangiocarcinoma by Modulating the CARMA1-BCL10-MALT1 Signalosome 1.00
The retinol-metabolizing enzyme DHRS3 coordinates antigen presentation, endothelial stability, and cholesterol metabolism to suppress hepatocellular carcinoma progression 1.00
TRIM25 enhances hypoxia signaling by catalyzing K11-linked polyubiquitination and stabilization of HIF-α 1.00
PPIL2 suppression induces cellular senescence and inhibits proliferation in hepatocellular carcinoma via c-Myc/p21 axis 1.00
A tri-specific EGFR/cMet/VEGF antibody demonstrates potent multi-mechanistic activity in preclinical triple-negative breast cancer models 0.93
Ubiquitin E3 Ligase MYCBP2 Targets KIF14 and Contributes to Acute Myeloid Leukemia Progression 1.00
Phosphorylation of RBM39 by CDK13 stabilizes RAD50 mRNA to drive cisplatin resistance in endometrial cancer 1.00
CircNOLC1/KRT16 Promotes Colorectal Cancer Invasion and Migration via c-Met Nuclear Translocation and Reprogramming of the Oxidative Pentose Phosphate Pathway 0.95
D-lactate Drives Lysine D-lactylation to Regulate Metabolism in Escherichia coli 1.00
G6PD facilitates axon regeneration via clathrin-mediated endocytosis 1.00
PLLP inhibits the progression of WT p53 gastric cancer by reducing p53 protein ubiquitination by binding to TRIM59 1.00
E3 ligase LMO7 enhances temozolomide sensitivity by promoting MGMT degradation in lung cancer 1.00
Mitotic spindle–organizing protein 2A (MZT2A) promotes cisplatin resistance through NEMO ubiquitination and NF-κB activation in lung adenocarcinoma 1.00
Optimization of protein UFMylation modification method and its application in substrate identification in human cells 1.00
Single-Cell Insights into Cisplatin Resistance Mechanisms in Bladder Cancer Tumor Microenvironment 1.00
Landscape of splicing factors in early-onset gastric cancer reveals SRSF1 as a key driver of oxaliplatin resistance 1.00
CEP55 promotes prostate cancer progression via TPX2-dependent activation of AURKA–PI3K–AKT signaling and inhibition of ferroptosis 1.00
The RNA-Binding Protein MSI2 Controls Blood-Tumor Barrier Permeability via LINC00667-Mediated IRF6 mRNA Decay 1.00
Engineering an orthogonal ubiquitin transfer cascade with Ring E3 RNF38 by phage display to reveal its regulation of nuclear transport 0.11
Photodynamic activation of a KRAS RNA G-quadruplex–targeted photosensitizer induces ferroptosis in cisplatin-resistant non–small cell lung cancer 1.00
The KANSL1-ARL17A Fusion Gene Generates Oncogenic chKANSARL and F-circKA RNAs that Synergistically Drive Lung Cancer Progression via a Novel F-circKA/miR-6860/chKANSARL Axis 1.00
Metformin suppresses PPARδ-driven CD47 transcription to enhance macrophage phagocytosis in lung cancer 1.00
Allosteric zinc inhibition and interdomain regulation govern the catalytic mechanism of the E3-independent ubiquitin-conjugating enzyme hUBE2O 1.00
ANP32A-mediated histone 3 K27 acetylation is essential for sotorasib activity in KRAS-mutant non–small cell lung cancer 1.00
AGEs promote the metastasis of colorectal cancer cells via centrosome amplification by KLF5–CEP57L1 axis 1.00
UBE2I promotes immune infiltration and tumor progression in thyroid cancer and modulates hnRNPA2B1 SUMOylation 1.00
A cell-specific computational framework reveals a pan-cancer hypoxia signature predicting overall survival and ICI response 1.00
A bispecific antibody designed to act as a NRP2/PLXNA1 agonist mimics anticancer activity of SEMA3F 0.67
KRASG12D mutation promotes pancreatic tumorigenesis by suppressing sirtuin three via the guanine nucleotide exchange factor RCC1 0.88
E3 Ubiquitin Ligase TRIM47 Promotes Intrahepatic Cholangiocarcinoma Progression by Ubiquitinating Fumarate Hydratase and Modulating Macrophage Polarization 1.00
The cyclin-dependent kinase inhibitor p27 facilitates chemosensitivity by promoting ferroptosis in epithelial ovarian cancer 1.00
Telomere-protecting protein 1 promotes gastric cancer cell metastasis via enhancing endoplasmic reticulum stress 1.00
ZNF280A and ACRV1 Enhance Aerobic Glycolysis and Drive Ovarian Cancer Progression via the PI3K/AKT Signaling Pathway 1.00
O-GlcNAcylation of the tumor suppressor LATS1 drives mitotic progression via PLK1 1.00
Polarity protein Par3L deletion causes chromosomal segregation defects and tumorigenesis 1.00
Integrin β4 Drives Immune Evasion and Therapeutic Resistance to PD-1 blockade in Bladder Cancer via MEK/ERK Signaling 1.00
RhoE down-regulation leads to enhanced cholesterol biosynthesis and sorafenib resistance in hepatocellular carcinoma 1.00
Transmembrane BAX inhibitor motif containing 1 Inhibition of lysosomal degradation of TGF-β receptor 1 suppresses cellular senescence and hepatocarcinogenesis 1.00
Mutational Landscape of the G-Quadruplex DNA in cMyc proto-oncogene promoter: Insights into the Structural Polymorphism and Transcriptional Regulation 1.00
Mechanism of NUMBL Enhancing Axitinib Resistance in Clear Cell Renal Cell Carcinoma by UCHL1-Mediated Deubiquitination of MMP9 1.00
Structural basis of nectin-4 recognition by the antibody–drug conjugate 9MW2821 1.00
The deubiquitinase OTUD4 suppresses TAK1 kinase–dependent NF-κB signaling and inflammation 1.00
NITAC-mediated ISGylation of eIF4E2 attenuates GSK3β proline-directed kinase activity, conferring cytoprotection 1.00
SLC39A5 promotes the malignant progression of gastric cancer by activating BATF phosphorylation 1.00
Loss of TRIM44 promotes renal cell carcinoma progression by regulating K48-linked ubiquitination of vimentin 1.00
USP52 inhibits cell ferroptosis via Hippo–YAP pathway and blocks immunotherapy in colorectal cancer 1.00
The long noncoding RNA SNHG12 defines KEAP1 stability and ferroptosis susceptibility by targeting E3 ligase TRIM25 0.86
Dephosphorylation of astrocyte elevated gene-1 protein upregulates eIF4E expression to promote gastric cancer progression 1.00
FOXO1-mediated argininosuccinate lyase transcription inhibits ammonia metabolism and breast cancer cell metastasis 1.00
FBXO9 mediated the ubiquitination and degradation of YAP in a GSK-3β-dependent manner 1.00
Ciprofloxacin enhances RSL3-induced ferroptosis by promoting mitochondrial Zn2+ accumulation via the STING1–CAV2 pathway 0.78
A small-sized imidazole-derived ligand binds to the KRAS promoter G-quadruplex and inhibits cancer growth with enhanced immunomodulation 1.00
Mapping cellular cytosolic pH in vivo under physiological and pathophysiological conditions 1.00
The chromatin remodeling factor BAP18 promotes non–small cell lung cancer progression via the recruitment of β-catenin with the transcriptional coactivator complex ACTL6A–PAF1 0.89
The pyruvate dehydrogenase complex in concert with the DNA/RNA-binding protein YBX1 regulates cell senescence and tumorigenesis 1.00
A non-coding RNA circGNAI2 suppresses triple-negative breast cancer progression by sponging miR-454-3p to inhibit the VGLL4-STAT3 signaling 1.00
Structural insights into the substrate transport mechanism of the amino acid transporter complex 1.00
BCI inhibits MKP3 by targeting the kinase-binding domain and disrupting ERK2 interaction 1.00
TORC2 and MAPK signaling pathways regulate mitochondrial degradation induced by iron starvation in Schizosaccharomyces pombe 1.00
Ubiquitin-specific protease 7-mediated stabilization of discoidin domain receptor 1 drives progression of TP53-Mutant cancers 1.00
The splicing factor SRSF6 mediates ferroptosis resistance in head and neck squamous cell carcinoma through induction of stearoyl-CoA desaturase 1.00
A novel protein encoded by circTUBGCP3 blocks ferroptosis and promotes gastric cancer progression 0.92
N4BP1 is a nucleocytoplasmic shuttling protein and recognizes aggregates of the ubiquitin-like protein NEDD8 to protect cells under heat shock 1.00
CK1ε/SRSF10 axis regulates the alternative splicing of Bcl-x in lung cancer cells 1.00
Vacuole protein sorting 18 (Vps18) suppresses epithelial growth factor receptor (EGFR) expression and lung tumorigenesis 1.00
TFAP2C Drives Cisplatin Resistance in Bladder Cancer by Upregulating YAP and Activating β-Catenin Signaling 1.00
The stage-specific roles of HIF-1α in regulating mESC pluripotency during oxygen transition 1.00
FHL2 Facilitates LUSC Growth and Therapy Resistance through PI3K/AKT/mTOR Activation 1.00
USP25 maintains KRAS expression and inhibiting the deubiquitinase suppresses KRAS signaling in human cancer 1.00
The transcriptional regulator Sin3a activates CD44 and promotes collective luminal breast cancer cell migration 1.00
3 2.94
lncRNA EGFR-AS1 promotes DNA damage repair by enhancing PARP1-mediated PARylation 1.00
SCFFBXO21-mediated ubiquitination and degradation of NMNAT2 regulates axon survival in nerve injury 1.00
Plasticity of mitotic cyclins in promoting the G2–M transition 0.94
1 1.00
From molecular ferroptosis to ecosystem recovery: A metal-driven temporal ecological switch as a hidden node of wetland resilience 1.00
3 2.95
US-guided Nanosecond Pulsed Electric Field Ablation of Low-risk PTMC: Interim Results of a Prospective Multicenter Study 1.00
An Interpretable Machine Learning Model for Predicting Occult Central Lymph Node Metastasis in Papillary Thyroid Cancer 0.95
PBK as a potential biomarker and therapeutic target for metastatic pheochromocytomas and paragangliomas 1.00
43 34.71
Targeting RANKL-independent osteoclastogenesis overcomes denosumab resistance in models of ER+ breast cancer bone metastasis 1.00
IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor-induced inflammatory arthritis 0.92
HER2 deficiency causes a developmental disorder with growth retardation and craniofacial malformations 1.00
Therapy-induced cholesterol biosynthesis drives lung cancer dormancy and drug resistance 1.00
EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates anti-tumor activity in metastatic castration-resistant prostate cancer 1.00
Tescalcin is a phagocytic checkpoint driving immune escape and limiting immunotherapeutic efficacy in hepatocellular carcinoma 1.00
Genome-wide CRISPR screen identifies a cytokine–enhancer circuit driving HIF-2α activation in renal cancer 0.06
A HHEX/IKKα positive feedback loop promotes intestinal inflammation 1.00
The allosteric IDH1 inhibitor ivosidenib overcomes chemoresistance in intrahepatic cholangiocarcinoma models expressing wild-type IDH1 1.00
Tumor cell–derived IFN spatially reprograms osteopontin-enriched macrophage niches to promote PARP inhibitor resistance 1.00
Macrophage-rich niches regulate T cell dynamics at the liver invasive margin during gallbladder cancer progression 1.00
Comprehensive genomic profiling of triple-negative breast cancer metastases identifies role of PKD1 in immunotherapy resistance 1.00
Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models 0.31
Proteogenomic characterization of cervical cancer identifies molecular subtypes predictive of clinical outcomes and subtype-specific targets 1.00
Posttranscriptional regulation of PD-1 by PRMT5/WDR77 complex shapes T cell effector function and antitumor immunity 1.00
Oligodendrocyte transcription factor 2 orchestrates glioblastoma immune evasion by suppressing CXCL10 and CD8+ T cell activation 0.95
Reversing enhancer RNA–mediated IKBKE gene repression enables synthetic anticancer immunity in prostate cancer models 0.51
FBXO11 suppression rewires an NPM1-centered interactome influencing the progression of myelodysplastic syndrome 0.03
Targeting the N-acetyltransferase 10/DKK2 axis enhances CD8+ T cell antitumor activity in colorectal cancer models 1.00
EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-γ 1.00
Vessels encapsulating tumor clusters promote non-invasive metastasis of hepatocellular carcinoma by shaping an immunosuppressive microenvironment 1.00
FBXO2-mediated KPTN ubiquitination promotes amino acid-dependent mTORC1 signaling and tumor growth 1.00
Auranofin attenuates TOPBP1-mediated ATR replication stress response and improves chemotherapeutic response in breast tumor models 1.00
Leukemia-expanded splenic CD81+ erythroblasts potentiate disease progression in mice by reshaping leukemic cell metabolism 1.00
Targeting kinesin family member 20A sensitizes stem-like triple-negative breast cancer cells to standard chemotherapy 0.02
HDAC5 deficiency induces intrinsic resistance to KRAS inhibition by disrupting c-Myc acetylation-ubiquitination homeostasis 1.00
A fungal-derived cyclic peptide enhances Th9-mediated antitumor immunity by targeting ZAP70 and SREBP1 1.00
Non-canonical functions of UGT2B17 promote castrate-resistant prostate cancer progression 0.28
Chronic stress-induced ANPEP drives liver cancer progression by increasing glutathione synthesis and inhibiting ferroptosis 1.00
LC3-dependent intercellular transfer of phosphorylated STAT1/2 elicits CXCL9+ macrophages and enhances radiation-induced antitumor immunity 1.00
USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I 0.11
PIM3-mediated phosphorylation stabilizes myeloid leukemia factor 2 to promote metastasis in osteosarcoma 1.00
C6orf223 promotes colorectal cancer growth and metastasis by facilitating PRMT5-MEP50 multiprotein complex assembling 1.00
S100a9 lactylation triggers neutrophil trafficking and cardiac inflammation in myocardial ischemia/reperfusion injury 1.00
IL-17-producing γδ T cells in the tumor microenvironment promote radioresistance in mice 1.00
ZEB1 promotes chemo-immune resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16 0.85
A smooth muscle cell lncRNA controls angiogenesis in chronic limb-threatening ischemia through miR-143-3p/HHIP signaling 0.13
Jab1 promotes immune evasion and progression in acute myeloid leukemia models under oxidative stress 1.00
A CD4+ T lymphocyte–specific TCR/GSDMD/IL-2 axis facilitates antitumor immunity 1.00
Mutations in spliceosomal gene SNW1 cause neurodevelopment disorders with microcephaly 0.55
Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop 0.53
Disruption of the KLHL37–N-Myc complex restores N-Myc degradation and arrests neuroblastoma growth in mouse models 1.00
CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors 0.46
31 16.22
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort 0.05
Multicenter Cohort Study of Original or Substitute Systemic Therapy With or Without Brain Radiotherapy for Extensive-Stage Small Cell Lung Cancer With Brain-Only Progression After First-Line Treatment 1.00
Efficacy and Safety of Camrelizumab Plus Apatinib in Patients With Refractory Chordoma: A Phase II Clinical Trial 1.00
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study. 0.04
Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002). 0.95
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study. 0.01
Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study. 0.94
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. 1.00
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001). 1.00
Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005/CARES-005): A Randomized Phase II Trial. 1.00
Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial. 1.00
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. 1.00
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer. 0.04
Randomized Parallel-Group Phase II Study (NEOTERIC) of Atezolizumab With or Without Tiragolumab After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. 1.00
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial. 0.96
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. 0.04
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer. 0.05
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 0.19
Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial. 1.00
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial. 1.00
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). 0.21
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas 0.07
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. 0.03
Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma. 1.00
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study. 1.00
Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer. 0.06
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. 0.09
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. 0.19
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab. 0.04
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study. 0.19
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. 0.09
10 5.27
Defects in intron recycling suppress the antiviral response via a mechanism of intronic endogenous dsRNA 0.04
HIF-1–mediated ISG20 expression promotes breast cancer stemness and immune evasion 0.04
Adenosine metabolic clearance maintains liver homeostasis by licensing arginine methylation of RIPK1 1.00
Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function 0.06
RIPK1 S161 phosphorylation promotes further autophosphorylation and cecal necroptosis in TNF-treated mice 1.00
Specific loading of oncolytic VSV on CAR enhances CAR-T cell signaling and antitumor activity 1.00
Integrated screens identify AURKB dependency in advanced gastrointestinal stromal tumors 1.00
Tumor-instructed glutamine synthesis in cancer-associated fibroblasts promotes pro-tumor macrophages 0.05
Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control 1.00
Sympathetic axonogenesis promotes adenoid cystic carcinoma progression 0.08
10 8.63
Tim-3 facilitates dendritic cell ferroptosis and impairs anti-tumor immunity in steatohepatitis-related HCC 1.00
Distinct molecular pathways regulated by activated AKT and YAP signaling during intrahepatic cholangiocarcinoma progression 0.46
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma 0.23
MARCO+ macrophages drive immunosuppressive remodeling and metastasis in chemotherapy-associated steatohepatitis 0.93
An etiology-stratified single-cell atlas identifies FABP4 as a prognostic marker for MASLD-related HCC 1.00
Targeting cell-state plasticity driven by FOXM1/CEBPB axis disrupts developmental heterogeneity and therapeutic resistance in hepatocellular carcinoma 1.00
PARG inhibition halts cholangiocarcinoma progression via the Hippo pathway and enhances response to chemotherapy and immunotherapy 1.00
Targeting xanthine oxidoreductase reverses resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma 1.00
Restoration of N-glycosylation via leucine-activated leucyl-tRNA synthetase 1 overcomes chemoresistance in intrahepatic cholangiocarcinoma 1.00
Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification 1.00
2 2.00
Immune checkpoint inhibitor-induced rapid decline in HBV markers improves the prognosis of HBV-related hepatocellular carcinoma patients 1.00
Risk and response adapted treatment in pediatric Epstein-Barr virus associated hemophagocytic lymphohistiocytosis 1.00
4 3.20
Histone Lactylation Contributes to Neuropathic Pain by Facilitating m6A Reader Protein IGF2BP2 Expression in DRG Sensory Neurons 1.00
The Role of Chaf1b in Maintaining Glioma Stem Cells Stemness and Regulating Microglial Polarization 1.00
Smg5 Enhances Oligodendrocyte Differentiation via Nonsense-Mediated mRNA Decay of Hnrnpl Variant Transcripts 1.00
Neddylation E1 obligatory subunit Nae1 is critical to neuromuscular junction development and maintenance 0.20
11 10.04
Postoperative MRD status Refines Recurrence Risk Stratification Beyond Pathologic Response After Neoadjuvant Chemoradiotherapy for ESCC 0.88
Surgery versus definitive radiotherapy after induction immunochemotherapy for stage II and III non–small cell lung cancer: A multicenter, pragmatic analysis 1.00
Pathologic response and nodal status guide adjuvant immunotherapy in non–small cell lung cancer after neoadjuvant chemoimmunotherapy: An eastern Asian cohort study 1.00
Pathologic complete response after neoadjuvant immunochemotherapy: Persistent recurrence risk highlights the need for stratified management 1.00
Validation and refinement of the ninth edition ypN descriptor in patients with non−small cell lung cancer receiving neoadjuvant therapy 1.00
Lymph node dissection in neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter real-world study 1.00
Spatial metrics of lymph node metastasis refine prognostic stratification of t1–t2 esophageal squamous cell carcinoma 1.00
The clinicopathological characteristics and prognosis of mucin-laden nonmucinous lung adenocarcinoma 1.00
Clinic-Radiologic Predictors of Pathological Characteristics in Pure Ground-Glass Nodules: Development and Validation of a Predictive Nomogram 1.00
Incidental use of angiotensin system inhibitors during neoadjuvant therapy for esophageal adenocarcinoma: An analysis of survival 0.17
A Pathologic Classification Approach in Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy: Distinguishing Postoperative Outcomes and Exploring the Potential Benefit of Adjuvant Therapy 1.00
1 1.00
Association of Primary Tumor Location with All-cause and Cancer-specific Mortality in Cutaneous Malignant Melanoma patients 1.00
57 50.63
“Zero-On” NIR-II Photoacoustic Organic Nanoprobes for Ultra-Accurate Companion Diagnostics of Cancer Immunotherapy Response 1.00
Chirality-Driven Immune Checkpoint Modulation by Chiral Iridium(III) Nanoparticles 1.00
A Cascade-Responsive AND-Logic-Activatable Nanoprobe for Intraoperative Fluorescence Imaging of Colorectal Cancer 0.75
Dual-Targeting Multivalent Aptamer-Drug Hybrids for Synergistic Cancer Immunotherapy 0.88
Light-Mediated In Situ Synchronous Capture of Antigens and Nucleic Acids as Nanovaccines to Boost Tumor Radioimmunotherapy 1.00
Enzyme-Triggered Self-Immobilization of an NIR Prodrug for Tumor-Selective Cancer Vaccination 1.00
Photocatalytic Atomization of the Elemental Species in Solution for Atomic Fluorescence Spectrometry 1.00
In Vivo Spatiotemporal Protection and Recognition of Circulating Tumor DNA for Early Cancer Diagnosis and Monitoring 1.00
Translating a miRNA Signal into Physical Immunomodulation via Programmed DNA Network Assembly on Mitochondria 0.83
Discovering Targetable Conformation of RhoA Mutant by Integrating Native Mass Spectrometry, Ultraviolet Photodissociation, and X-ray Diffraction 0.97
Divergent Syntheses of the Euphorbia Diterpenoids Pepluanol A and Pepluacetal 1.00
Immune-Evasive NIR-II Nanoplatforms for Repeatable Photodynamic Therapy 0.71
Sprayable Lactococcus lactis-Nanocatalyst Gel for Postsurgical Immunomodulation in Preclinical Oral Squamous Cell Carcinoma 0.17
NIR-II Nanomedicine Engineered CAR-NK Cells for Precision Navigation and Potentiating Lung Cancer Immunotherapy by Remodeling Tumor Microenvironment 0.92
Long-Acting Fractionated Sonodynamic Therapy Enabled by Fused-Trianthracene Nanoparticles with Ultra-Bright Ultrasound-Induced Afterglow Luminescence 1.00
Conformation-Transformable, Spiked Polypeptide Enables In Situ Cancer Vaccination via Conditional Antigen Capture and STING Activation 1.00
Defective Single-Site Nanozymes with Exposed Unsaturated Cu–N2 Sites for Antitumor Immunotherapy via Innate Immune-Checkpoint Blockade 0.56
Succinylated D-Type Neuropeptide Integrated with Iron-Based Probes for Regulating Mitochondrial Function and Homeostasis in Breast Cancer 1.00
Two-Dimensional Iridium(III)–Carbon Nitride Nanocomplexes Induce Simultaneous Oncosis and Necroptosis for Synergistic Chemo- and Sono-Immunotherapy in Hypoxic Melanoma 1.00
MSA-2 Loaded Three-Dimensional Metal Covalent Organic Framework for Synergistic Radiosensitization and Innate Immune Activation 0.41
Dibenzocyclooctyne Conjugation Enhances Antigen Cross-Presentation and T-Cell Killing for Potent Cancer Vaccines 1.00
Electroacupuncture-Activated Mitochondria-Targeted Polymeric Radicals for cGAS-STING-Activated Immunotherapy 1.00
Highly Expressive Bienzyme and Photothermal Effect Co-Enabled by the Co–O–Mn Bridge for Potentiating 1550 nm Light-Triggered Photodynamic Therapy 1.00
Radio-Activable Gold-Single-Atom-Based Artificial Enzymes with Cascade Biocatalysis and Enhanced Radiosensitization to Prevent Metastasis and Recurrence in Malignancies 1.00
Development of Substrate-Directed Activity-Based Probes via Disulfide-Trapping for Site-Specific Interrogation of Nucleosomal Deubiquitination 1.00
Spatial Confinement of Platinum Nanoclusters in a Photoactive Metal–Organic Framework for Radiotherapy Enhancement and Redox-Mediated Immune Activation 0.06
Caged Ligand-Decorated Near-Infrared Photosensitizer with In Vivo Albumin-Hijacking Capacity for Tumor-Targeted Hypoxia-Tolerant Photoimmunotherapy of Cancer 0.80
Ultrasound-Triggered Type I Supramolecular Photosensitizer for Precise In Situ Chemiluminescence-Based Photodynamic Cyclic Therapy 1.00
NIR-Actuated Morphodynamic 2D Nanopatches for Interface-Programmed Immunoactivation and Tumor Regression 0.86
A Spatially Controllable DNA Origami-Based T-Cell Cluster Engager for Precise Tumor Elimination 1.00
Encapsulation of 211At(Ø)+ into a Nanoscale Covalent Organic Framework Prevents Deastatination In Vivo 1.00
Disulfide-Directed Multicyclic Peptides for Chimeric Antigen Receptors Targeting Solid Tumors 1.00
Organoplatinum(II) Type II Immunogenic Cell Death Inducers Target Protein Tyrosine Phosphatase 1B to Drive Immunogenicity 0.60
pH-Isomerizable Acylhydrazone-Based Ionizable Lipids for Spleen-Targeted mRNA Vaccines 1.00
Metabolic Hijacking by Engineered Probiotics Reprograms Tumor Metabolism and Immune Microenvironment for Self-Reinforcing Photodynamic Immunotherapy 1.00
Sensitive and Accurate Detection of Low-frequency Mutations via Pyrophosphorolysis-Activated Selective Amplification and MALDI-TOF-MS Single-Nucleotide Resolution Identification 1.00
Marine Natural Product Chagosendine C Induces Cuproptosis in Colorectal Cancer Cells by Targeting FDX1 1.00
Controlled Electron Transfer: Implementing a Reservoir-Pump-Integrated Strategy to Develop a Type I Photosensitizer for Evoking Long-Term Tumor Immunological Memory 1.00
Multicyclic Peptides Targeting PD-L1 for Radiotheranostics: From Discovery to Clinical Proof-of-Concept 1.00
Type-I Supramolecular Photosensitizer Enables GSH Depletion by Hydrogen Atom Transfer 1.00
An Activatable and Covalent Tumor-Associated Antigen Capturer Enabling Systemic Injection In Vivo for Promoted Antitumor Immunity 1.00
Self-Immolative Cationic Iridium(III) Complex-Encapsulated Nanoprodrug for Enhanced Chemo-Photodynamic Synergistic Therapy of Melanomas 0.63
Autonomous Activation of a Gated Chemiluminescent Photosensitizer Enables Targeted Photodynamic Therapy in Tumor Cells 0.06
Metal-Phenolic Outer Membrane Vesicles for Cancer Radioimmunotherapy 0.79
Regioisomeric Engineering of Sterically Hindered Bright Near-Infrared Paraptosis Agents for Chemo-Photodynamic Therapy 0.80
Ferrous Iron Metabolism Modulator for Immune Stress Regulation and Its Application in Skin Allograft Models 1.00
Sono-Destructive Polymeric Nanocapsules Enable Spatiotemporal Orchestration of DC-T Cell Crosstalk in Combined In Situ Vaccination and Cytokine Therapy 1.00
Biomineralized Engineered Bacterial Outer Membrane Vesicles as cGAS-STING Nanoagonists Synergize with Lactate Metabolism Modulation to Potentiate Immunotherapy 1.00
Delivery of Peptide-LYTAC via Polyporus Polysaccharide Microneedles for Targeted CD47 Degradation and Enhanced Tumor Immunotherapy 1.00
Cathepsin B-Ignited Nanorocket To Blast Tumor Lysosomes for TLR-Fortified Lysosomal Immunotherapy with Dual-Switchable Fluorescence/Magnetic Resonance Imaging 1.00
Self-Propulsion of Biomimetic Nanomotors Promotes Diffusion and Convection Transport for Enhanced Radiotherapy in Solid Glioblastoma 1.00
A Heteroleptic/Trimetallic OsII–RuII–ZnII Sierpiński Triangle for Efficient Photodynamic Therapy of Hypoxic Tumors Mainly through Type I Mechanism 1.00
Engineering of Sono-Activatable Immunogels for Immunometabolism Disorder Normalization Therapy of Breast Cancer 0.86
Nanoparticles Selectively Regulate the Generation and Scavenging of Multiple Reactive Oxygen Species at Designated Locations and States 1.00
Smart Energy-Storing DNA Hydrogel for On-Demand Laser-Free Photoimmunotherapy of Melanoma 1.00
Self-Generative Singlet Oxygen (1O2)-Initiated Chemical Modification of Nuclear DNAs Combats Tumor Drug Resistance 1.00
Sterically Controlled Cyclobutane-Dioxetane Ultrabright Afterglow Nanosystem for Cyclic Therapy of Choroidal Neovascularization in Mice 1.00
1 0.09
Association of Palliative Care Initiation With Acute Healthcare Utilization Among Community‐Dwelling Adults Living With Dementia 0.09
10 2.75
Identifying expression and DNA methylation biomarkers for lung adenocarcinoma risk in East Asia 0.02
Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials 0.10
Sex steroid hormones, gonadotropins, and risk of testicular germ cell tumors: results from the STEED study 0.06
Time-dependent relationship between urinary biomarkers of nucleic acid oxidation and colorectal cancer risk 0.08
Electro-acupuncture for quality of life during adjuvant chemotherapy in gastric cancer: a randomized trial 0.85
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.21
Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant 0.05
Prospective associations of diabetes with 15 cancers in 2.2 million UK and Chinese adults 0.35
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 0.02
Accelerometer-derived concentrated physical activity pattern and mortality in cancer survivors: the UK Biobank accelerometry study 1.00
1 1.00
Aggregation-Induced Emission-Enhanced Conjugated Polymer Supramolecular Network: An Efficient Light-Harvesting System with Ultrahigh Reactive Oxygen Species Generation Efficiency 1.00
18 14.31
Acyltransferase ZDHHC22 promotes N-Myc transcriptional activation to drive neuroblastoma progression and chemoresistance 1.00
Alu repeat-containing RNAs spatially organize actively transcribed genomic regions around nuclear speckles 1.00
RNF25 confers mRNA damage tolerance by curbing activation of the integrated stress response 0.01
ER-tethering directs TREX1 penetration of a BAF-dependent barrier at micronuclei 0.15
HSPA1A and DNAJB1 regulate NELF condensate dynamics to safeguard transcriptional recovery under heat stress 1.00
ICAM1 mRNA entraps ILF2/ILF3 to inhibit transcription of EIF4E and global protein synthesis 1.00
CASTOR1 and CASTOR2 respond to different arginine levels to regulate mTORC1 activity 1.00
Debranching enzyme DBR1-mediated lariat RNA turnover requires ALBA proteins in Arabidopsis 1.00
UMP functions as an endogenous regulator of NR4A1 to control gastric cancer progression 0.95
Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response 1.00
Endocytosis is essential for cysteine-deprivation-induced ferroptosis 0.10
Extrachromosomal DNA biogenesis is dependent on DNA looping and religation by YY1-Lig3-PARylation complex 1.00
HIF-independent oxygen sensing via KDM6A regulates ferroptosis 0.10
YTHDC1 lactylation regulates its phase separation to enhance target mRNA stability and promote RCC progression 1.00
BAG2 releases SAMD4B upon sensing of arginine deficiency to promote tumor cell survival 1.00
Non-canonical PRC1.1 licenses transcriptional response to enable Treg plasticity in immune adaptation 1.00
Glucose-1-phosphate promotes compartmentalization of glycogen with the pentose phosphate pathway in CD8+ memory T cells 1.00
Mediator regulates transcriptional termination through crosstalk with pre-mRNA 3′ end processing factors 1.00
1 1.00
TRAF6 regulates ubiquitination-independent TDP-43 condensation and related neurodegeneration 1.00
38 36.41
In Situ Electroactive Bacteria-Activated Nanozyme for Amplifying Chemodynamic Therapy of Solid Tumors 1.00
Activatable Polymeric STING Agonist–Gold Nanorod Conjugate Driving STING Signaling and Immunogenic Activation in Colorectal Cancer Immunotherapy 1.00
Photothermally Triggered Bacterial–Manganese Immune Amplifier Enables Spatiotemporal STING Hyper-Activation against Cold Tumors 1.00
Magnetically Actuated Iron Oxide Nanoparticles Sensitize Acute T-Lymphocyte Leukemia Cells to Vincristine via Reprogramming Cellular Homeostasis 1.00
Programmable Assembly of Artificial Antigen-Presenting Cells with Framework Nucleic Acids 1.00
Rewiring Metal-Dependent Cell Death to Unlock Immunotherapy in Colorectal Cancer 1.00
Assembly Module-Empowering Lipid-Prodrug Nanoamplifier for Enhancing Ferroptosis-Driven Cancer Treatment 1.00
Bismuthene-Based Nanoplatform for Synergistic Thermogenetic CRISPR and Photothermal Cancer Therapy 0.64
A Mutually Reinforcing Nanoplatform Orchestrates Immunogenic Ferroptosis and Reprogramming of Tumor-Associated Macrophages for Potent Immunotherapy 1.00
An Integrated NIR-II Fluorescence-Free Reporter for Multimodal Imaging-Guided Breast-Conserving Surgery 1.00
HepatoAILFA: Machine-Learning-Assisted Nano-enhanced Point-of-Care System for Personalized Precise Diagnosis of Hepatocellular Carcinoma 1.00
Amifostine–Iron Nanoparacrystalline for Tumor-Selective Immunogenic Ferroptosis 1.00
DNA Nanoflowers Efficiently Encapsulate Photodynamic Agents and CRISPR/Cas9 for Synergistic Pancreatic Cancer Therapy 1.00
Achieving Efficient Sonopiezoelectric Therapy for Tumor through Electron Spin Modulation via the Chiral-Induced Spin Selectivity Effect 1.00
Insights into the Molecular Mechanism Underlying tBID-Triggered Cell Death Probed by In Situ Raman Spectroscopy 1.00
Near-Infrared Photothermal-Pyroelectric Coupling (PTPC)-Activated Trace Element Prodrug Nanoplatform for Tumor-Specific Immune Modulation and Therapy 1.00
Tumor-Targeted Bacterial Vaccine Induces In Situ Immunogenic Cell Death for Cancer Immunotherapy 1.00
Bubble Multimer-Enhanced Fluorescence Enables Self-Contained Profiling of Colorectal Cancer Extracellular Vesicles 1.00
Synergistic Nucleus-Targeting Photodynamic Therapy and DNA Repair Inhibition to Activate Innate and Adaptive Antitumor Immunity for Amplifying Photoimmunotherapy 1.00
A Tailor-Made Biaryl-Stapled Peptide Nanoprodrug with Esterase-Triggered Dual Immunomodulation for Amplified Cancer Therapy 1.00
Nanospiky Copper Peroxide as Lactate-Modulating Nanoadjuvant To Induce Cuproptosis and Pyroptosis for Enhanced Tumor Immunotherapy 1.00
Multiplexed Aptamer-Lattice Nanodevice for One-Step Phenotyping and Functional Quality Control of CAR-T Cells 1.00
Multivalent Metal–Nucleotide Nanoagonists Amplify Innate Immune Activation for Cancer Metalloimmunotherapy 0.90
Spatiotemporally Ultrasound-Activatable Self-Amplifying Biomimetic Liposomes for Imaging-Guided Synergistic Cancer Sonodynamic Chemotherapy 1.00
Neutrophil-Mediated Delivery Platforms for Synergistic Chemo-Immunotherapy of Non-Small-Cell Lung Cancer Therapy 1.00
Systemic Delivery of an mRNA-Encoding, Tumor-Activated Interleukin-12 Lock to Eliminate Tumors and Avoid Immune-Related Adverse Events 1.00
Nanoshield Architecture Harnessing Neoantigen-Targeting Peptides Enables Durable Post-surgical Glioma Immunotherapy 0.92
Metabolic Hijacking: An MOF-Based Nanoprogrammer Overcomes Drug Resistance in Glioblastoma 1.00
Carrier-Free Nanoadjuvant-Loaded Bilayer Microneedles for Programmed and Individualized Cancer Chemo-Immunotherapy 1.00
Artificial Cytotoxic T Lymphocytes Selectively Eliminate Tumor Cells for Effective Cancer Therapy 1.00
Defining the Critical Valency of Peptide-MHC on Nanoscale Artificial Antigen Presenting Cells for Expanding Endogenous Tumor-Specific T-cells iIn Vivo/i 0.09
Overcoming Epithelial–Mesenchymal Transition Challenges in Cancer Detection through a Dual-Targeting Strategy 1.00
Nanohydroxyapatite-Stabilized Pickering-Emulsion-Incorporated Hydrogel Prevents Postoperative Osteosarcoma Recurrence and Promotes Bone Repair 1.00
Synergistic Defect-Driven Chemocatalysis and Ultrasound-Activated Piezocatalysis by Two-Dimensional SnSe Nanosheets 0.95
Oxamate Nanoparticles for Enhanced Tumor Immunotherapy through Blocking Glycolysis Metabolism and Inducing Pyroptosis 1.00
A Metal–Phenolic Network Nanoresensitizer Overcoming Glioblastoma Drug Resistance through the Metabolic Adaptive Strategy and Targeting Drug-Tolerant Cells 1.00
Intracellular Bacteria-Mimicking Whole-Cell Cancer Vaccine Potentiates Immune Responses via Concurrent Activation of NLRP3 Inflammasome and STING Pathway 0.91
Environmental Charge-Mediated Nanopiezocatalysis for Sonodynamic Therapy 1.00
12 5.22
Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma 0.09
Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma 0.95
Cell-free chromatin state tracing reveals disease origin and therapy responses 1.00
Ancient co-option of LTR retrotransposons as yeast centromeres 0.10
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance 0.07
The ubiquitin ligase KLHL6 drives resistance to CD8 T cell dysfunction 0.64
Intratumoural vaccination via checkpoint degradation-coupled antigen presentation 1.00
Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma 0.03
Polyclonal origins of human premalignant colorectal lesions 0.08
SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer 0.33
Human gastroids to model regional patterning in early stomach development 0.90
The mutagenic forces shaping the genomes of lung cancer in never smokers 0.03
2 1.11
A logic-gated trispecific engager enhances macrophage killing of cancer cells in solid tumors 1.00
Modifications of microbiome-derived cell-free RNA in plasma discriminates colorectal cancer samples 0.11
10 9.22
Aberrant amino acid-sensing promotes immunotherapy resistance via the inflammatory cytokine–ZBTB5–mTORC1 axis 0.87
Peritumoural adipose tissue promotes ferroptosis resistance by 3-hydroxykynurenine-mediated suppression of ferritinophagy 1.00
The lncRNA DAMER selectively guides mA-dependent regulation of ATF4 and asparagine metabolism under nutrient stress in cancer 1.00
Peritumoural adipose tissue drives immune evasion in colorectal cancer via adipose–mesenchymal transformation 1.00
THY1 cancer stem cells drive metastasis through a pseudohypoxic state shaped by neutrophil-derived mitochondria 1.00
SLC2A1+ tumour-associated macrophages spatially control CD8+ T cell function and drive resistance to immunotherapy in non-small-cell lung cancer 1.00
Defining heterogeneity in core regulatory circuitry reveals HOXB3 condensation as a potential target in glioblastoma 1.00
Diet-derived galactose reprograms hepatocytes to prevent T cell exhaustion and elicit antitumour immunity 1.00
A ROS-mediated oxidation-O-GlcNAcylation cascade governs ferroptosis 0.35
YAP maintains the dynamics of TDP-43 condensates and antagonizes TDP-43 pathological aggregates 1.00
7 6.83
Nuclear OXCT1 attenuates histone β-hydroxybutyrylation-mediated MHC-I transcription 1.00
IDO1 regulating ROS rhythm reveals glycogenolysis/PPP as a cancer treatment target 1.00
Targeting thymine DNA glycosylase induces synthetic lethality in p53-deficient cancers 1.00
Unique gluing effect of ASXL1 K351 monoubiquitination stimulates the PR-DUB activity 1.00
Deacetylase-independent HDAC1 condensation defines temozolomide response in glioblastoma 1.00
Structural basis for E4 enzyme Ufd2-catalyzed K48/K29 branched ubiquitin chains 1.00
In situ proximity labeling of proteins associated with circRNA and RNA G-quadruplexes 0.83
283 249.21
Caspase-4 transgenic mice exhibit cytoplasmic TDP-43 accumulation and age-dependent neuropathology 1.00
Recurrence in the chemotherapy regimen of bladder carcinoma originates from quiescent epidermoid-like cells 0.97
Diffusion attention expert model for predicting and semi-automatic localizing STAS in lung cancer histopathological images 1.00
Targeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in -deficient triple negative breast cancer 1.00
Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis 1.00
Iron overload in the tumor microenvironment induces CD8+ T cell ferroptosis and dysfunction 1.00
Acetylated mitochondrial MDH2 regulates CTR2 transcription to induce cuproptosis during Escherichia coli infection 1.00
Distinct phosphorylation mechanisms as dynamic switches for Hsp90 regulation 1.00
Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study 1.00
A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma 1.00
Arid3b suppresses CD8 + T cell infiltration and function in microsatellite-stable colorectal cancer via Runx3 1.00
The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial 0.94
BCAT1 inhibits crotonate-related epigenetic modulation of metabolic genes in tumor-associated macrophages to counter immunosuppression 1.00
ACAD8 deficiency promotes pathological cardiac hypertrophy in response to pressure overload by regulating histone isobutyrylation 1.00
Complex I protein NDUFB9 is a metabolic vulnerability in triple negative breast cancer brain metastases 1.00
Oral delivery of enterocyte-mimetic butyrate-loaded nanoparticles repairs the gut barrier and inhibits growth of digestive system tumors 1.00
Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial 1.00
Disrupting sympathetic nerve-tumor crosstalk via biomimetic nanovesicles to augment chemotherapy efficacy under chronic stress 1.00
GLUT6-facilitated noncanonical glucose metabolic rewiring enables resistance to targeted cancer therapy 1.00
HuR coordinates systemic aging through platelet infiltration 1.00
A context-aware artificial metabzyme in intervertebral disc degeneration metabolic convergence therapy 1.00
Mild-Sunlight-Activated Safe Photodynamic Therapy Using On-Off Polymer Photosensitizers in Wearable Microneedle Patch 0.40
Small heat shock and J-domain proteins direct defense against areca palm velarivirus 1 by degrading coat protein via autophagy 1.00
Augmented prediction of multi-species protein–RNA interactions using evolutionary conservation of RNA-binding proteins 1.00
Neoadjuvant toripalimab plus CapeOX in locally advanced Epstein-Barr virus-associated gastric or gastroesophageal junction adenocarcinoma: a phase Ⅱ trial 1.00
T-cell mesenchymal transition represents a potential pathogenic mechanism of female cancer-related lymphedema 1.00
Engineered BCG selectively triggers trained immunity in tumor-associated macrophages and sensitizes glioblastoma to radiotherapy in mice 1.00
Genetic landscape and functional exploration of kidney cancer predisposition in cross-ancestral populations 0.87
Hijacking innate immunity to enhance mRNA therapeutics by blocking IFN-P-body-XRN1 axis-mediated degradation 1.00
ELMO2 is a therapeutic vulnerability in mesenchymal-like and drug-resistant non-small cell lung cancer 1.00
Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial 1.00
Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer 0.18
Chemical anchoring of immunotherapeutic drugs within senescent tumor cells overcomes senescence-driven immunotherapy resistance 1.00
Dissecting origin factors of lymph node metastasis in non-small cell lung cancer via multimodal omics 1.00
VGLL4-driven TEAD4 multimerization orchestrates DNA binding and YAP recruitment 1.00
NLRP14 modulates the activity of E3 ubiquitin ligases during the oocyte-to-embryo transition 1.00
A live biohybrid bacterial therapy based on engineered Serratia marcescens 1.00
Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial 1.00
MYC-induced USP10 stabilizes SOX4 to promote thymocyte proliferation and leukemia onset in mice 0.83
D-π-A sensitized carbon dots as long-lived type-I/Ⅱ photosensitizers for NIR-excited hypoxia-regulated photodynamic therapy 1.00
FSHR and LHR functional compensation reveals the mechanism and treatment of Ovarian Hyperstimulation Syndrome 0.93
PD-1 blockade plus tyrosine kinase inhibitor remodels the tumor microenvironment in advanced renal cell carcinoma 1.00
Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs 1.00
Structures of ZYG11B-EloB-EloC-substrate complex reveal mechanisms of CRL2ZYG11B assembly and function 1.00
Epitranscriptomic RNA editing resolves Mus81 DNA repair tradeoffs in heat tolerance and meiosis 0.89
NEK8 kinase-mediated lactate increase impairs antitumor immunity decreasing radiotherapy sensitivity in colorectal cancer 1.00
Iminium-linked hyperporphyrin covalent organic framework mediates type I photodynamic therapy via a photoredox process 0.09
Structural basis for the carboxylation and epoxidation of human gamma-glutamyl carboxylase 1.00
Targeting a super-enhancer induced aldehyde dehydrogenase metabolic loop mitigates CDK4/6 inhibitor resistance in estrogen receptor-positive cancers 1.00
Structural and evolutionary insights into the eukaryotic RNase MRP ribonucleoprotein complex 1.00
Small-molecule degraders for oncogenic KRAS and pan-KRAS mutations 1.00
Spatiotemporally engineered tumor-derived extracellular vesicle-based scaffold vaccine for personalized cancer immunotherapy 1.00
X-ray preactivated reversible persistent luminescence enables photodynamic immunotherapy of deep tumors 1.00
Dalpiciclib plus chidamide in HR + /HER2−advanced breast cancer after CDK4/6 inhibitor failure: a phase Ib trial 1.00
A cell cycle-dependent transition of acetylation to phosphorylation regulates timely centrosome maturation 1.00
IVNS1ABP mutation drives cellular senescence in newly identified progeroid neuropathy 0.08
CXCR5+ monocyte emigration impairs the radiation-induced antitumor immune response 1.00
Engineering programmable CAR and antigen pairing via drug-gated light activation 0.08
The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study 0.01
Programmable nanomicelles rewire myeloid immunity for durable control of primary and metastatic breast cancer 1.00
Inhibition of the cancer stem cell immune checkpoint SOAT1 suppresses regulatory T cell functions through a trans-cellular 20(S)-Hydroxycholesterol-GPR132 pathway in mice 1.00
Stepwise transcription stalling by the anti-cancer drug Actinomycin D and insights into short tandem repeat transcription inhibition 1.00
Multitrait GWAS and functional validation reveal genetic loci for gastric cancer 0.85
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial 1.00
Targeting Prolyl 3-hydroxylase 1 inhibits pancreatic cancer progression and macrophage immunity 0.95
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer 0.07
Protection of telomeres 1b safeguards the Arabidopsis genome by regulating ROS homeostasis 0.03
Sororin locks the DNA-exit gate of cohesin to preserve sister-chromatid cohesion 1.00
An ultraconserved pseudo 5’ splice site fine-tunes development by regulating alternative splicing within TOR-related pathways 1.00
A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance 0.07
Targeting leucine-rich repeat kinase 2 overcomes resistance to oncolytic herpes simplex virus-based therapies in glioblastoma 1.00
Prussian blue nanoparticles targeting multiple PANoptosome-mediated PANoptosis for myocardial ischemia-reperfusion injury therapy 1.00
Molecular insights into mRNA export regulation by the human TREX-2 complex 1.00
Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer 0.82
Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis 0.94
Cryo-EM structures of light chain fibrils from abdominal fat biopsies of multiple myeloma patients 1.00
B7-H3-mediated cis-inhibition of EGFR by a tumor-selective bispecific antibody enhances anti-tumor efficacy and minimizes toxicities 1.00
Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC 0.70
A neurotoxic cryptic peptide arising from TDP-43-dependent cryptic splicing of 1.00
R-loop editing by DNA cytosine deaminase APOBEC3B modulates the activity of oestrogen receptor enhancers 0.36
Recruitment of BRD4 to the ASXL1 genomic targets depends on the extra-terminal domain of BRD4 0.11
cfGWAS reveal genetic basis of cell-free DNA end motifs 1.00
Amelioration of colorectal cancer-associated fibroblasts in immunosuppressive microenvironment by ferroptosis-based nanotherapy 1.00
Lactate derived from macrophages drives skin dermal fibroblasts phenotypic remodeling via MCT1-primed histone H3 lysine 23 lactylation in hypertrophic scar 1.00
STING synergizes with TOX suppressing HO-1 expression to trigger ferroptosis in tumor-infiltrating CD8+ T cell and immunotherapy resistance 1.00
Histone lactylation increases CXCL1 expression for neutrophil infiltration and immune escape in pancreatic cancer 1.00
Hepatocytes functionally reprogrammed by KIAA1199-high colorectal cancer cells favour the accumulation of pro-metastatic Egr1+ neutrophils 1.00
Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma 0.01
Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial 0.83
Paclitaxel drives TREM2 macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel 1.00
An interpretable AI system reduces false-positive MRI diagnoses by stratifying high-risk breast lesions 1.00
Dalpicilib combined with cetuximab in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma: A phase II trial 1.00
Endothelial PDLIM5 promotes tip cell filopodia formation and tumor angiogenesis by regulating ACTN1/ACTN4-dependent actin bundling 1.00
The functional landscape of alternative splicing in hematopoietic lineage commitment 0.90
Stenotrophomonas promotes gastrointestinal tumor progression via STING degradation in tumour cells and mitigated immune response 1.00
De novo variants in the splicing factor gene are associated with neurodevelopmental disorders 0.04
CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction 0.02
negatively regulates self-renewal of liver cancer stem cells and hepatocarcinogenesis via suppressing transcription 1.00
INCENP and CDCA8 predict neoadjuvant chemotherapy response and outcomes in esophageal squamous cell carcinoma 1.00
In situ self-assembled cell reservoir hydrogel for maneuvering multistage radioimmunotherapy 1.00
ZNF683 NK cells govern chemotherapy sensitivity in advanced HPSCC via reshaping immune microenvironment 0.92
An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression 1.00
Neoadjuvant chemoradiotherapy plus sintilimab in proficient mismatch repair locally advanced rectal cancer with intermediate/high-immunoscore (SILAR): a single-arm phase II trial 1.00
TET1 as a master regulator controlling GPX4-dependent and -independent ferroptosis surveillance in acute myeloid leukemia 1.00
Targeting the UFL1-AKT cascade suppresses triple-negative breast cancer progression 0.90
Disruption of iron homeostasis sensitizes pancreatic cancer to irreversible electroporation 1.00
Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM) 1.00
Multiscale imaging on proton pump-driven acidity for assessing tumor progression and metastasis 1.00
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial 1.00
Cryo-EM structure of the human COP1-DET1 ubiquitin ligase complex 1.00
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma 1.00
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS) 0.94
Hypoxia-driven remodeling of SELENOP macrophages shapes T cell dynamics and promotes ovarian cancer metastasis 1.00
Targeting SPAK suppresses progression and averts an immune exhaustive microenvironment in hepatocellular carcinoma 1.00
USP10 promotes glioma stem cell maintenance and glioblastoma growth by antagonizing DTX3L-mediated SATB2 ubiquitination 1.00
A Mechanophenotyping chip for high-throughput detection of metastatic bacteria-infected circulating tumor cells 1.00
Perioperative tislelizumab plus lenvatinib treatment for resectable hepatocellular carcinoma at high risk of recurrence: single-arm phase II trial 1.00
Boron neutron capture therapy preserves immune cells and induces robust anti-tumour immunity in preclinical mouse model 1.00
Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial 1.00
Peptide-functionalized membrane camouflage for endogenous HS-induced photothermal immunotherapy of orthotopic colorectal cancer 1.00
Design of precision therapeutics for a CKD risk allele by targeting Shroom3-Rock interaction 0.05
Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy 1.00
GPR4 promotes immune exclusion in colon cancer through LOXL2-mediated extracellular matrix remodeling 1.00
Decoding necrosome assembly: harmonizing signal amplification and attenuation through optimal RIP3 stoichiometry 1.00
Structural insights into toxicant export mediated by ABCC2 in 1.00
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial 1.00
Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial 1.00
SPLiCR-seq: A CRISPR-Based Screening Platform for RNA splicing Identifies Novel Regulators of IRE1α-XBP1 Signaling Under ER Stress 1.00
Structural insights into cationic amino acid transport and viral receptor engagement by CAT1 0.90
Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment 1.00
Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial 1.00
AAK1 activation-mediated iron trafficking drives ferroptotic cell death 1.00
Metabolic syndrome promotes endometrial cancer by Oleic acid-mediated polyamine accumulation 1.00
Concurrent PIK3CA mutant promotes cachexia through inflammatory signaling in EGFR mutant lung cancer 1.00
Polypeptide sono-adjuvant for ultrasound-activatable regulation of innate immunity and cancer vaccination therapy 1.00
Structural basis for genome-wide site-specific DNA recognition by Nuclear Factor IA 0.92
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial 1.00
Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma 0.99
αPD-1-conjugated acid-cleavable nanodrugs overcomes cellular immunotherapy barriers in pancreatic tumors 0.94
Targeting LRBA triggers CTLA4 degradation and antitumor immunity for cancer immunotherapy 0.95
Targeting of the m6A eraser ALKBH5 suppresses stemness and chemoresistance of colorectal cancer 1.00
Prodrug nanoplatform for triggering ferroptosis to eliminate senescent cells in age-associated pathologies 1.00
Histone acetylation homeodynamics navigates cell survival and apoptosis 0.92
Motorized chromosome models of mitotic chromosome folding 0.50
USP29 and SMURF1 orchestrate FSP1-mediated ferroptosis suppression to facilitate chemoresistance in gastric cancer 0.39
Lypd6b depletion promotes CD8+ T cell-mediated anti-tumor immunity via metabolic reprogramming in colorectal cancer 0.93
BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interaction 0.08
Phosphorylation of PA28γ by CK2 kinase facilitates HNSCC tumor formation and progression 1.00
Ubiquitination by HRD1 is essential for TLR3 trafficking and its innate immune signaling 0.90
Inhibiting the formation of neutrophil extracellular traps to prevent the recurrence of post-operative glioblastoma 1.00
Metabolic support protects mucosa from ferroptosis in radiation-induced mucositis 0.87
Inhibiting B cells enhances the efficacy of STING agonism or immune checkpoint blockade in hepatocellular carcinoma 0.05
Precise diagnosis of small invasive pulmonary nodules driven by single-cell immune signatures in peripheral blood 0.94
ANKLE1 processes chromatin bridges by cleaving mechanically stressed DNA 0.82
Adjuvant benmelstobart plus anlotinib in patients with high-risk recurrence after resection of hepatocellular carcinoma: a phase II study (ALTER-H006) 1.00
Tissue-resident microbiota impacts colorectal cancer progression and prognosis 0.60
Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer 0.93
KY216-tubulin complex captures VASH2 to inhibit NSCLC metastasis 1.00
CAV2-expressing nerves induce metabolic switch toward mitochondrial oxidative phosphorylation to promote cancer stemness 1.00
DDX6 undergoes phase separation to modulate metabolic plasticity and chemoresistance 0.08
Residual tumor cells after insufficient radiofrequency ablation promote lung metastasis by educating CD177PAD4 neutrophils 1.00
THRAP3 promotes ferroptosis resistance in acute myelocytic leukemia through SLU7-mediated alternative splicing of GIT2 1.00
Molecular mechanism of PINK1 regulation by the Hsp90 machinery 1.00
MYC drives left-handed Z-DNA formation to shape gene expression 1.00
Targeting leukemic stem cell biomechanics suppresses stemness and enhances NK cell-mediated immunotherapy 1.00
IFN-γ-driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer 1.00
NEK7 couples SDHB to orchestrate respiratory chain electron transport homeostasis that impedes liver fibrosis 1.00
Targeting hepatocytic TβRI ameliorates liver metastatic outcomes by revitalizing stem-like CD8+ Tex subsets 1.00
Gut microbial β-glucuronidases and their role in the microbiome-metabolite axis in colorectal cancer 1.00
Aurora kinase B phosphorylates ZBP1 to drive PANoptosis following treatment with PARP and ATR inhibitors combination 0.89
N-terminal α-amino SUMOylation promotes phosphorylation-independent cofilin-1 translocation to the mitochondrial matrix and induces apoptosis 0.90
Enhancer regulator MLL4 controls skeletal muscle metabolic efficiency by limiting AMPK-mediated fuel catabolism 0.88
Uncovering the immune mechanisms underlying the emergence of immunotherapy-induced pneumonitis in lung cancer patients 1.00
Non-canonical roles of Keap1/Nrf2 in regulating quiescence and early activation in adult muscle stem cells 0.91
Substrate recognition diversity and transport dynamics of ABCC1 1.00
Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study 1.00
Bioorthogonal optimized virus immuno-nanomedicine (BOVIN) 0.75
Automated MRI system for clinically significant prostate cancer detection development validation and real-world implementation 1.00
Alternating current pre-treatment enhances multi-enzymatic activity of high-entropy alloy nanozymes that regulate metabolism for effective tumor immunotherapy 1.00
A hindrance-plane-hindrance molecular engineering strategy towards self-assembled nanorods for enhanced photodynamic therapy 1.00
Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial 1.00
A moonlighting function of tumoral interleukin-1β precursor promotes metastasis via RACK1-mediated actin remodeling 1.00
A multiplexed assay by self-assembled dual-target responsive DNA hydrogels for efficacy evaluation of immunotherapy 1.00
Hexokinase 2-mediated histone H3K18la promotes PAI-1-dependent thrombosis in acute myeloid leukemia via tumor-endothelial crosstalk 1.00
Self-driven electrical triggering system activates tunneling nanotube highways to enhance drug delivery in bladder cancer therapy 0.77
Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma 1.00
TBC1D1 functions as a negative regulator of satellite cells for muscle regeneration 1.00
Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation 0.95
Human iPSCs-based modeling unveils SETBP1 as a driver of chromatin rewiring in GATA2 deficiency 0.06
A glucose kinase-independent HK2 activity prevents TNF-induced cell death by phosphorylating RIPK1 1.00
Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma 1.00
Targeting polyamine metabolism and ferroptosis enhances the efficacy of KRAS-targeted therapy depending on KEAP1 status 1.00
Systematic characterization of the composition and dynamics of processing body-associated mRNAs 1.00
Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO) 1.00
Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs 1.00
Modeling and addressing on-target/off-tumor toxicity of claudin 18.2 targeted immunotherapies 0.27
Steering H2O2 lysis pathway for ROS generation in Prussian blue nanozymes via alkali cation doping 1.00
Structural basis for transport and inhibition of the human glucose-6-phosphate transporter G6PT 1.00
FAP+ fibroblasts orchestrate tumor microenvironment remodeling in renal cell carcinoma with tumor thrombus 1.00
Targeted degradation of endogenous YAP by nanobody bioPROTAC inhibits tumor progression 1.00
Chromatin looping-based CRISPR screen identifies TLK2 as chromatin loop formation regulator in cancer stemness plasticity 1.00
Astrocytic-OTUD7B ameliorates murine experimental autoimmune encephalomyelitis by stabilizing glial fibrillary acidic protein and preventing inflammation 0.04
αTIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility in mouse models 1.00
Loss of BPTF restores estrogen response and suppresses metastasis of mammary tumors 0.05
A next-generation anti-CTLA-4 probody mitigates toxicity and enhances anti-tumor immunity in mice 1.00
Histone lactylation promotes rheumatoid arthritis progression by increasing NFATc2 expression and the production of anti-lactylated histone autoantibodies 1.00
VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization 1.00
Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial 1.00
A long-term self-driven metronomic photodynamic system for cancer therapy 1.00
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy 0.09
Diabetes reshapes pancreatic cancer-associated endothelial niche by accelerating senescence 1.00
Inhibition of ICAM1 diminishes stemness and enhances antitumor immunity in glioblastoma via β-catenin/PD-L1 signaling 0.76
CXCR4 mediated recognition of HIV envelope spike and inhibition by CXCL12 0.43
Cytoplasmic TRIM24 promotes colorectal cancer cell proliferation by activating Wnt/β-catenin signaling 0.92
Direct - mRNA interaction regulates cell proliferation and cancer progression 1.00
CD137L promotes immune surveillance in melanoma via HLTF regulation 0.92
5-ALA photodynamic metabolite-powered zero-waste ferroptosis amplifier for enhanced hypertrophic scar therapy 1.00
Stabilizing a mammalian RNA thermometer confers neuroprotection in subarachnoid hemorrhage 0.64
Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC 0.92
Structure and transport mechanism of the human prostaglandin transporter SLCO2A1 1.00
Whole-genome methylation profiling of extracellular vesicle DNA in gastric cancer identifies intercellular communication features 1.00
GD2T cells as a platform for single-dose and long-term delivery of biologics 1.00
A strategy for challenging tumorous bone regeneration by borosilicate bioactive glass boosting moderate magnetic hyperthermia 1.00
A -natural antisense RNA regulates alternative polyadenylation of under Pi starvation in tomato 0.79
Molecular landscape, subtypes, and therapeutic vulnerabilities of central nervous system solitary fibrous tumors 1.00
Mesothelin-directed protein-drug conjugates for mesothelin-low solid tumor therapy 1.00
Targeting spermine metabolism to overcome immunotherapy resistance in pancreatic cancer 0.99
Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma 0.01
STN1 facilitates metastasis by promoting transcription of EMT-activator ZEB1 in pancreatic cancer 1.00
Tumor cell-adipocyte gap junctions activate lipolysis and contribute to breast tumorigenesis 0.01
Integrative proteogenomic characterization of Wilms tumor 1.00
Bioengineered hybrid dual-targeting nanoparticles reprogram the tumour microenvironment for deep glioblastoma photodynamic therapy 1.00
Bioinspired ruthenium-manganese-oxygen complex for biocatalytic and radiosensitization therapies to eradicate primary and metastatic tumors 0.92
Structural basis for substrate recognition mechanism of human SLC26A7 1.00
A hollow-tube-like hydrospongel for multimodal therapy of advanced colorectal cancer 1.00
CRISPR screening reveals that RNA helicase DDX41 triggers ribosome biogenesis and cancer progression through R-loop-mediated RPL/RPS transcription 1.00
Nucleophilic addition promoted ring rearrangement-aromatization in aza-/thio-sesquiterpenoid biosynthesis 0.93
OFD1 inhibition induces BRCAness to create a therapeutic vulnerability to PARP inhibition in pancreatic cancer 1.00
Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles 1.00
PROCR diminishes the efficacy of radiation by impairing T-cell-mediated antitumour immunity 1.00
Chimeric exosomes-derived immunomodulator restoring lymph nodes microenvironment for sensitizing TNBC immunotherapy 1.00
Pericytes promote metastasis by regulating tumor local vascular tone and hemodynamics 1.00
Pre-mRNA processing factors differentially impact coordination between co-transcriptional cleavage and transcription termination 0.82
Explainable multimodal deep learning for predicting thyroid cancer lateral lymph node metastasis using ultrasound imaging 1.00
Mogat1 drives metabolic adaptations to evade immune surveillance 1.00
AR+TREM2+ macrophage induced pathogenic immunosuppression promotes prostate cancer progression 1.00
Mitochondrial inflexibility ignites tumor immunogenicity in postoperative glioblastoma 0.73
The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials 0.80
Metabolism archetype cancer cells induce protumor TREM2 macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma 1.00
Structural insights into cholesterol sensing by the LYCHOS-mTORC1 pathway 1.00
DSS1 inhibits autophagy to activate epithelial-mesenchymal transition in a pro-metastatic niche of renal cell carcinoma 1.00
Transdifferentiation of tongue muscle cells into cancer-associated fibroblasts in response to tongue squamous cell carcinoma 1.00
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial 0.01
Determination of trunk neural crest cell fate and susceptibility to splicing perturbation by the DLC1-SF3B1-PHF5A splicing complex 0.92
Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer 1.00
Living therapeutics of nonpathogenic bacteria as biosynthesis factory and active carriers for enhancing tumor-targeted therapy 1.00
Immunodiagnostic plasma amino acid residue biomarkers detect cancer early and predict treatment response 0.02
Androgen receptor promotes arachidonic acid metabolism and angiogenic microenvironment in AFP-negative hepatocellular carcinoma 1.00
Regulation of partial endothelial-to-mesenchymal transition by circATXN1 in ischemic diseases 0.97
Synthetic carbon-based lanthanide upconversion nanoparticles for enhanced photothermal therapy 0.83
Distinct structural mechanisms of LGR4 modulation by Norrin and RSPOs in Wnt/β-catenin signaling 1.00
YY1 enhances HIF-1α stability in tumor-associated macrophages to suppress anti-tumor immunity of prostate cancer in mice 1.00
Tumor vessel-adaptable adhesive and absorbable microspheres for sustainable transarterial chemoembolization therapy 1.00
Adipocyte CLDN5 promotes thermogenesis and energy expenditure through regulation of IL10 expression 1.00
DDX1 methylation mediated MATR3 splicing regulates intervertebral disc degeneration by initiating chromatin reprogramming 1.00
Suppression of multiple mouse models of refractory malignancies by reprogramming IL-18 ligand-receptor interaction 1.00
Glucosamine activates intestinal P-glycoprotein inhibiting drug absorption 1.00
Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial 0.97
Adipocyte-specific Zeb1 downregulation remodels the tumor-associated adipose microenvironment to facilitate female breast cancer progression 0.96
Engineering STING Nanoadjuvants for spatiotemporally-tailored innate immunity stimulation and cancer vaccination therapy 1.00
Cardiomyocyte-derived USP13 protects hearts from hypertrophy via deubiquitinating and stabilizing STAT1 in male mice 1.00
Caffeine enhances antitumor T-cell activity by suppressing kynurenine pathway in colorectal cancer 1.00
Single atom engineering for radiotherapy-activated immune agonist prodrugs 1.00
Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial 0.95
Dual asparagine-depriving nanoparticles against solid tumors 1.00
Orchestrating intratumoral DC-T cell immunity for enhanced tumor control via radiotherapy-activated TLR7/8 prodrugs in mice 1.00
A ferritin-targeted biohybrid triggering ferroptosis immunotherapy via activating endogenous iron and replenishing exogenous iron simultaneously 1.00
EZH2 loss promotes gastric squamous cell carcinoma 1.00
A self-directed Trojanbot-enzymatic nanobot in neutrobot for active target therapy of glioblastoma 1.00
SWI/SNF ATPase silenced HLF potentiates lung metastasis in solid cancers 0.03
Cytoreductive surgery and hyperthermic intrathoracic chemotherapy in thymic epithelial tumors with pleural spread or recurrence: a prospective, single-arm, phase II study 1.00
TIM3-blockade synergizes with IL2 in alleviating intra-tumoral CD8T cell exhaustion 1.00
High mobility group A1 (HMGA1) promotes esophageal squamous cell carcinoma progression by inhibiting STING-mediated anti-tumor immunity 0.88
4 3.01
Global multi-ancestry genome-wide analyses identify genes and biological pathways associated with thyroid cancer and benign thyroid diseases 0.01
Single-cell multi-omic and spatial profiling of esophageal squamous cell carcinoma reveals the immunosuppressive role of GPR116+ pericytes in cancer metastasis 1.00
Single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma 1.00
Multi-omic analysis of gallbladder cancer identifies distinct tumor microenvironments associated with disease progression 1.00
7 3.36
Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer 0.01
Kupffer cell calibration of T cell responses via VSIG4–CD5 interaction promotes tumor evasion 1.00
Tumor-derived branched-chain α-keto acids activate Notch signaling in tumor-associated macrophages to limit immunity 1.00
Purine salvage pathway protects CD8 T cells from metabolic stress 0.02
The transcription complex p52–ETS1 is essential for germinal center formation 0.06
The RNA-binding E3 ligase MKRN2 selectively disrupts Il6 translation to restrain inflammation 1.00
Succinate drives gut inflammation by promoting FOXP3 degradation through a molecular switch 0.26
1 1.00
In situ-generated vaccine-like pyroptosome for personalized cancer immunotherapy 1.00
18 10.21
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial 0.36
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study 0.92
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial 0.04
Global and regional cancer burden attributable to modifiable risk factors to inform prevention 0.07
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial 0.82
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial 0.03
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial 0.04
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial 0.08
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial 0.04
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial 0.98
Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results 0.87
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial 1.00
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial 0.06
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial 0.92
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial 1.00
A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial 1.00
Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial 1.00
AI-based large-scale screening of gastric cancer from noncontrast CT imaging 0.98
1 0.87
An encyclopedic regulatory and functional atlas of RNA interactomes 0.87
9 6.26
Enhancing antitumour nanovaccine efficacy via integrated cholesterol modulation in situ 0.92
Prodrug-tethered lipid nanoparticles for synergistic messenger RNA cancer immunotherapy 0.02
Biomimetic vesicles engineered from modified tumour cells act as personalized vaccines for post-surgical cancer immunotherapy 1.00
A biohybrid chiral hydrogel enhances preclinical postoperative glioblastoma therapy by multi-pronged inhibition of tumour stemness 0.86
Nanorobots hold PD-L1 and break membrane of colorectal cancer cells for immunotherapy 0.97
Prevention of acute thrombosis with vascular endothelium antioxidative nanoscavenger 1.00
Systemic reprogramming of tumour immunity via IL-10-mRNA nanoparticles 0.10
Iron–silver-modified quantum dots act as efficient catalysts in anti-cancer multitherapy through controlled, ultrasound-induced oxidation 0.89
A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy 0.49
3 3.00
Structural basis of G6P/Pi transport and inhibition in SLC37A4 1.00
Architecture of the human KICSTOR and GATOR1–KICSTOR complexes 1.00
TRIM21 and OTUD6A orchestrate AKT K27-linked atypical ubiquitination to modulate cancer chemoresistance 1.00
4 4.00
A peritumoral microenvironment engaged by Reg-EXTL3 axis fosters nerve-cancer interactions in pancreatic ductal adenocarcinoma 1.00
6-Hydroxydopamine promotes antitumor immunity through macrophage remodeling beyond sympathetic ablation 1.00
METTL14 integrates tumor-derived SAM to drive parabrachial epigenetic rewiring in pancreatic cancer 1.00
Social interaction in mice suppresses breast cancer progression via a corticoamygdala neural circuit 1.00
8 7.64
A Bioorthogonal Prodrug–Prodrug Strategy for Dual Activation Via Retro-Cope/Cope Elimination 1.00
Tetrasargltones A and B, Fully Helically Polymerized Lindenane Sesquiterpenoid Tetramers from Sarcandra glabra 1.00
Discovery of seco-(9β-H)-Pimarane Diterpenoids from Icacina oliviformis with Synergistic Anti-Colorectal Cancer Activity 0.64
Asymmetric Total Synthesis of 5,10-seco-Neoansamycin A 1.00
Chizhiaroterpenoids A–C: Benzofused Rearranged Lanostane-Type Triterpenoids from Ganoderma lucidum 1.00
Asymmetric Total Synthesis and NaV1.8 Inhibitory Evaluation of Villosin B, 17-Hydroxymandarone B, and Their Derivatives 1.00
Stelleroids A–C, Three Rearranged Guaiane Sesquiterpenoids with Caged Ring Systems from Stellera chamaejasme 1.00
Scabrosteroids A–D, Four Pyrrolidinone–Ergosterol Heterodimers from Penicillium scabrosum FXI744 1.00
8 8.00
Acoustic delivery of indocyanine green via biosynthetic gas vesicles for tumor photothermal therapy 1.00
Casein kinase 2-mediated phosphorylation of the splicing factor SF3B3 plays a key role in esophageal squamous cell carcinoma progression 1.00
Engineered romidepsin biosynthetic pathways in Escherichia coli Nissle 1917 improve the efficacy of bacteria-mediated cancer therapy 1.00
CUL5 E3 ubiquitin ligase regulates the evasion of bladder cancer cells to CD8+ T cell-mediated killing by inhibiting autophagy 1.00
The lipid-metabolic enzyme HSD17B12 drives lysosomal degradation of PD-L1 potentiating anti-tumor immunity in a mouse model 1.00
Optineurin binding to the novel interacting partner Junction plakoglobin prevents muscle atrophy in mice 1.00
Bi-directional metabolic reprogramming between cancer cells and T cells reshapes the anti-tumor immune response. 1.00
Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes 1.00
6 6.00
ZBP1 Drives CD8+ T cell-mediated anti-tumor immunity in head and neck squamous cell carcinoma 1.00
A novel role of tRNA-derived fragments in porcine granulosa-oocyte cell communication and cuproptosis 1.00
Nebivolol suppresses glioblastoma progression via dual modulation of mitochondrial metabolism and AKT/mTOR/4EBP1 signaling axis 1.00
Genetic dissection of signalling pathways that mediate iron-related tumor growth in a Drosophila model 1.00
Circulating proteins associated with histological subtypes of lung cancer from genetic and population-based perspectives 1.00
Identification of hub gene associated with colorectal cancer: Integrating Mendelian randomization, transcriptome analysis and experimental verification 1.00
8 7.47
Sequential chemo-immunotherapy followed by standard versus reduced thoracic radiotherapy for older and/or frail stage III non-small-cell lung cancer: A randomized open-label cohort trial 1.00
Spatial transcriptomic-metabolic features of tumor foci and tumor capsule in microvascular invasion with hepatocellular carcinoma: A spatial multi-omics study 1.00
Optimal minimal residual disease threshold in pediatric acute myeloid leukemia: A retrospective cohort study based on the TARGET database. 1.00
Metabolomic insights into associations between adiposity markers and liver cancer risk: Results from a prospective cohort study and Mendelian randomization analysis 1.00
Fecal immunochemical test surveillance in colorectal cancer following adenoma resection: A longitudinal, population-based linked cohort study in China 1.00
Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: A single-arm, phase 2 trial from China 1.00
Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial 1.00
Long-term outcomes after unilateral salpingo-oophorectomy: A registry-based retrospective cohort study 0.47
2 2.00
Cell‐Specific Expression and Cellular Compartmental Regulation in Camptothecin Biosynthesis 1.00
Psyllid Cysteine Cathepsins Directly Cleave the Outer Membrane Protein BamD of Citrus Huanglongbing Pathogen 1.00
60 44.19
Lactylation of PD-L1 by a lactyltransferase HAT1 dictates its protein stability and tumor immune evasion 1.00
A BCG hydrogel enables localized NOD2/STING activation to overcome resistance to immune checkpoint blockade 0.90
AR-targeted therapies sensitize prostate cancer to cuproptosis by transcriptionally activating FDX1 1.00
An Octopus probe for high-performance >1,300 nm NIR-II fluorescence molecular imaging of cancer 0.97
Mitochondrial fusion heterogeneity drives bidirectional tumor phenotypic transition in combined hepatocellular–cholangiocarcinoma 1.00
CD28-driven ex vivo generation of stem-like memory CD8+ T cells bypassing CD3/TCR signaling 0.05
Aurora-A drives sorafenib resistance by scaffolding stress granule assembly via phase separation 1.00
Loss of UFL1 drives chromosome instability and tumorigenesis of prostate cancer 1.00
Reciprocal regulation of TNF receptor 1–mediated signaling and inflammatory damages by MARCH2 and USP22 1.00
Structure-guided design of 7-azaindole DNMT1 inhibitors active against hypomethylating agent–resistant acute myeloid leukemia 0.88
Spatial multiomics profiling reveals ZFP36-mediated immunometabolic reprogramming in bladder cancer 0.89
RIPK1 ubiquitination regulates its kinase-independent function in development and inflammation 1.00
Oocyte-inspired universal whole-cell vaccines against tumor heterogeneity 0.75
Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test 0.04
Unveiling the developmental and tumor-suppressive roles of the p53 variant p53psi 0.03
A CHKA–PML autophagy checkpoint enables tumors to evade glutamine starvation 0.97
Synthetic SIGLEC9-based chimeric switch receptor augments the efficacy of CAR macrophages against glioblastoma 0.97
Deubiquitinase OTULIN dampens RIG-I-dependent antiviral signaling by removing linear ubiquitination from TRAF6 1.00
HPV16 E6 oncoprotein promotes microhomology-mediated viral integration by increasing PolΘ protein expression 0.08
Dynamic reprogramming of the tumor immune network via multicycle checkpoint degradation for cancer immunotherapy 1.00
A pharmacovigilance data–driven approach to reveal high fatal adverse events following checkpoint immunotherapy 1.00
Lipid nanoparticle–mediated in vivo generation of panCAR immune cells for solid tumor immunotherapy 1.00
TROP2-targeted NIR-II fluorescence imaging for visualizing surgical margins and metastatic sentinel lymph nodes in breast cancers 1.00
Reversible acetylation of Hpo regulates the Hippo pathway 1.00
ARP2/3 complex mediates the neuropathology of PTEN-deficient human neural cells downstream of mTORC1 and mTORC2 hyperactivation 0.09
Intravenous infusion of engineered megakaryocytes to produce oncolytic platelets in vivo for enhanced cancer immunotherapy 1.00
Metabolic stress conditions dictate MAPKAPK2-dependent efficiency of MEK1/2 inhibition in colorectal carcinoma 0.38
HSCs/MPPs as cells of origin with altered differentiation hierarchy impairing immunomicroenvironment in PML::RARA and CBFα/β fusion AM 1.00
Mitochondrial transfer in the HSC–HCC–macrophage network shapes hepatocellular carcinoma progression 1.00
An interpretable molecular framework for predicting cancer driver missense mutations 1.00
Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug 0.23
Spatially resolved multiomics reveals the self-enforcing property of the leading-edge multicellular ecosystem of head and neck cancer 1.00
Circular RNA–based therapy targeting metabolic vulnerability of fatty acid synthesis overcomes castration-resistant prostate cancer 1.00
Proteasome stress activates YAP/TAZ through the RAP2–MAP4Ks–LATS1/2 pathway and its therapeutic implications in solid tumors 1.00
Occludin acts as a dynein adaptor regulating permeability and collateral angiogenesis 0.04
Potentiation of ryanodine receptor–mediated calcium release by MAPK is responsible for epidermal transformation and carcinogenesis 0.05
Guiding esophagectomy with intraoperative NIR-II fluorescence video imaging and rapid computation 0.97
Immunogenic cell death unlocks the potential for combined radiation and immunotherapy 0.20
USP1–TRAF2 axis–regulated mortalin stability mediates chemoresistance by disrupting calcium transport in peripheral T-cell lymphoma 1.00
Reprogramming tumor microenvironment via systemic delivery of TLR3 agonist and manganese nanoparticle 0.06
ZDHHC11-mediated AXL palmitoylation promotes osimertinib resistance in non-small-cell lung cancer 1.00
CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma 0.79
Genetic dissection of nonconventional introns reveals codominant noncanonical splicing code in Euglena 0.02
Cryo-EM structure of the prohibitin complex in open conformation 1.00
USP14-mediated metabolic competition impairs CD8+ T cell immunosurveillance in hepatocellular carcinoma 1.00
Kupffer cells are essential for platelet-mediated thrombopoietin generation in the liver 0.01
Cellular cartography reveals mouse prostate organization and determinants of castration resistance 0.03
Integrating spatial omics and single-cell mass spectrometry imaging reveals tumor–host metabolic interplay in hepatocellular carcinoma 1.00
Mechanistic insights into the iron–sulfur cluster-dependent interaction of the autophagy receptor NCOA4 with the E3 ligase HERC2 1.00
NEDD4L induces mitochondrial dysfunction and neurodegeneration by promoting LIPT2 degradation in Huntington’s disease 1.00
A versatile immunomodulated nanoCRISPR converter augments the susceptibility and visibility of tumors to the immune system 1.00
The pathogenic factor of ZC4H2-associated rare disorder is a postsynaptic regulator for synaptic activity and cognitive function 1.00
The WWP1–JARID1B axis sustains acute myeloid leukemia chemoresistance 0.15
Controlling T cell–tumor cell interaction with a biomimetic physical barrier for cancer immunotherapy 1.00
A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC 1.00
Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy 1.00
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma 0.13
Acquired resistance to immunotherapy by physical barriers with cancer cell–expressing collagens in non–small cell lung cancer 1.00
Dual-laser “808 and 1,064 nm” strategy that circumvents the Achilles’ heel of photothermal therapy 0.50
PARP12-mediated mono-ADP-ribosylation as a checkpoint for necroptosis and apoptosis 1.00
11 9.47
Survival Outcomes of Microwave Ablation Compared with Repeat Liver Resection in the Treatment of Recurrent Intrahepatic Cholangiocarcinoma. 1.00
CT-based Radiologic Ternary Classification Model in Predicting Pathologic Invasiveness of Pulmonary Nonsolid Nodules. 0.70
Ethiodized Oil-based Transarterial Chemoembolization for Hepatocellular Carcinoma: Randomized Clinical Trial of Anhydrous Cisplatin Suspension versus Cisplatin Emulsion. 1.00
Cross-National Radiomics Validation Using Mammography to Predict Occult Invasion in Ductal Carcinoma in Situ. 0.06
MRI-based Habitat Analysis for the Prediction of Progression-Free Survival in Primary Spinal Tumors. 0.80
Efficacy and Safety of Microwave and Radiofrequency Ablation in the Treatment of Hyperparathyroidism in Older Individuals: A Multicenter Prospective Study. 1.00
Mesorectal Fascia Involvement by Tumor Deposits or Extramural Vascular Invasion at MRI Predicts Prognosis in Rectal Cancer. 0.91
ScreenLungNet: Personalized Long-Term Prediction of Lung Cancer Risk from a Single Low-Dose CT Screening. 1.00
Comparison of 10-year Survival Outcomes between CT Surveillance and Surgery for Ground-Glass Nodules. 1.00
MRI-based Middle Neck Involvement in Stage N1-N2 Nasopharyngeal Carcinoma: A Marker for Risk Stratification. 1.00
Comparing Multi-b-Value Diffusion MRI Models for Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. 1.00
5 2.05
Dynamic U2AF cycling defines two phases of cotranscriptional pre-mRNA splicing 0.94
A hypoxia-responsive tRNA-derived small RNA confers renal protection through RNA autophagy 0.03
Cryo-EM structure of human telomerase dimer reveals H/ACA RNP-mediated dimerization 0.04
Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity 0.04
Structural basis of BAX pore formation 1.00
72 61.51
SRSF3 determines Treg cell fate in antitumor immunity and autoimmunity 0.67
Antigen spreading mediates heterogeneous solid tumor eradication by DNA demethylating agent–programmed CAR T cells 1.00
Chronic stress disrupts hepatic homeostasis and accelerates liver cancer progression through ADRB2 signaling 1.00
In vivo membrane engineering traps Gd-based MRI contrast agents for detecting microhepatocellular carcinoma 1.00
Spliceosomal mutation drives melanoma tumorigenesis via lineage-specific RAS activation 0.90
Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity 0.09
Mucoadhesive tumor-penetrating nanomedicine for intravesical chemo-immunotherapy against bladder cancer 1.00
Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity 1.00
Targeting mitocytosis potentiates mitochondria drug delivery for antimetastasis therapy 1.00
DJ-1 inhibition reshapes tumor microenvironment and potentiates immune checkpoint inhibitors 0.92
Inflammatory arthritis irAE may represent a unique autoimmune disease primarily driven by T cells but likely not autoantibodies 0.03
Tissue-specific inflammation induces cell state plasticity with oncogenic addiction in mucosal melanoma 0.93
Cold atmospheric plasma–engineered nanovaccine with spatiotemporal sequential immunization reprograms antitumor immunity 1.00
TLR9-activating cholesterol azetidine derivative–assisted therapeutic vaccines for cancer immunotherapy 1.00
Disrupting USP14-mediated PARP1 dynamics reinstates MIC-A/B–driven antigen-independent CD8+ T cell killing in glioma 1.00
Deubiquitinase USP8 regulates the spindle assembly checkpoint in oocytes 1.00
Epithelial plasticity shapes intratumoral heterogeneity and cell lineages in early-stage lung cancer 1.00
Aneuploidy of chromosome 8 promotes the mesenchymal lineage during cell fate transitions 1.00
Intratumoral Parvimonas micra promotes esophageal squamous cell carcinoma via p-cresol–induced Treg differentiation 0.99
KRASG12V/HLA-A*02:01–targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors 1.00
Tuning of the RBR1-E2F/DP transcriptional module by the F-box protein FBL17 0.11
<atl>Single-cell epigenetic profiling reveals a tumor-intrinsic interferon response program in ccRCC tied to poor prognosis and iBAP1/i loss</atl> 0.07
Circular RNA circHomer1 mediates hippocampal functions via ribonucleoprotein granule transport and dendritic targeting of synaptic RNAs 0.75
Nanocollision promotes locomotion of dendritic cells for tumor therapy 1.00
A synthetic Antrodia cinnamomea galactomannan library by frameshift unveils a potent immunoregulatory octasaccharide domain 0.62
An electrophilicity-engineered magnetic sensor for MRI detection of dormant tumor cell clusters 1.00
Structural insight into the glucose-6-phosphate transport by G6PT1 and inhibition mechanism of CGA 1.00
Monitoring glioblastoma extracellular vesicle evolution using a nanodiagnostic platform to detect glioma stem cells driving recurrent disease 0.04
Steroid-dependent metabolic rewiring reveals novel therapeutic and imaging approaches for glioblastoma 0.02
On-demand cancer immunotherapy via single-cell encapsulation of synthetic circuit–engineered cells 0.86
Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors 1.00
STING stimulation via supramolecular prodrug hydrogel boosts innate-adaptive immune cross-talk to prevent glioblastoma recurrence 1.00
Impaired nitrogenous waste clearance promotes hepatocellular carcinoma 0.09
Self-transforming hydrogel mimicking tertiary lymph nodes to activate cGAS-STING pathway for enhanced antitumor immunotherapy 1.00
Engineered anchoring aptamers induce relocalization and functional inactivation of transcription factors 1.00
Multicellular force coordination constructs microchannel networks for barrier-free metastasis across extracellular matrix 1.00
Oral delivery of aptamer-decorated SICTERS Raman probes for colonoscopy-guided resection and photothermal immunization of microtumors 1.00
circHERC1—A telomerase activator 1.00
Biohybrid nanorobots induce lactate isomer conversion to reverse the immune environment and promote tumor therapy 1.00
Transcription factor activator protein 4 (AP4)–mediated intrinsic control of axon regeneration 0.83
Targeting RRM2 with dual-modal theranostic smart nanoresponder overcomes osimertinib resistance and triggers immune remodeling in NSCLC 1.00
Enhanced FOS expression improves tumor clearance and resists exhaustion in NR4A3-deficient CAR T cells under chronic antigen exposure 0.94
Genome-wide CRISPR screen identifies splicing factor SF3B4 in driving hepatocellular carcinoma 1.00
Photoactivatable immunostimulatory nanoengineered microalgae for boosting cascade-activated antitumor immunity 1.00
USP13 stabilizes NLRP3 to facilitate inflammasome activation by preventing TRIM31-mediated NLRP3 ubiquitination and degradation 1.00
Glioblastoma exploits ATP from leading-edge astrocytes to fuel its infiltrative growth revealed by spatially resolved chimeric analysis 1.00
RNA binding protein DDX3X drives pancreatic cancer progression via the TLE2-MYL9 axis 1.00
Molecular and neural basis of vomiting behavior in Drosophila melanogaster 1.00
Pulsatile sequential drug release system for cascade tumor deep penetration and differentiation therapy to enhance chemoimmunotherapy 0.97
Engineering noncovalent π-stacked organic framework for intrinsic near-infrared photoactivated drug delivery 0.23
Liver regeneration–associated hepatocellular YAP1 activation prevents colorectal cancer liver metastasis through glutamine competition 0.94
Light-triggered molecular mechanotherapy of tumor using membrane-mimicking conjugated oligoelectrolytes 0.92
Targeting lipid scrambling potentiates ferroptosis and triggers tumor immune rejection 1.00
HLF transactivates TFEB to promote gallbladder cancer stem cells’ self-renewal and determines tumor response to distinct therapies 1.00
In situ–formed immunotherapeutic hydrogel containing sphingosine-1-phosphate for enhanced lung cancer immunotherapy 1.00
Morphology– and adhesion–dual biomimetic nanovaccine boosts antigen cross-presentation through subcellular transport regulation 1.00
Plant defense-directed discovery of a natural anti-psoriasis agent targeting GAPDH 0.90
Targeting tumor-associated CCR2+ macrophages to inhibit pancreatic cancer recurrence following irreversible electroporation 1.00
DNA damage response pathway regulates Nrf2 in response to oxidative stress 0.95
Engineering hybrid nanoparticles for targeted codelivery of triptolide and CYP3A4-siRNA against pulmonary metastatic melanoma 1.00
Human iPSC-based breast cancer model identifies S100P-dependent cancer stemness induced by BRCA1 mutation 0.94
Temporally programmed STING nanoadjuvant delivery unlocks synergistic chemotherapy-induced antitumor immunity 1.00
Transition of cellular senescence to pyroptosis mediates recurrence of small cell lung cancer after chemotherapy 1.00
Src/FN1 pathway activation drives tumor cell cluster formation and metastasis in lung cancer: A promising therapeutic target 0.85
UFMylation maintains tumor suppressor pVHL stability by activating the deubiquitinase BAP1 0.94
Extracellular vesicle–hitchhiking nanoliposomes for cancer-associated fibroblast phenotype modulation impede metastasis progression 1.00
Magnesium microspheres for enhanced transarterial chemoembolization therapy of hepatocellular carcinoma: From animal models to a pilot clinical study 1.00
Tumor-targeting nanocarriers amplified immunotherapy of cold tumors by STING activation and inhibiting immune evasion 1.00
Cardiomyocyte-derived YOD1 promotes pathological cardiac hypertrophy by deubiquitinating and stabilizing STAT3 1.00
FAM50A drives breast cancer brain metastasis through interaction with C9ORF78 to enhance ʟ-asparagine production 1.00
TGFβ-dependent signaling drives tumor growth and aberrant extracellular matrix dynamics in NF1-associated plexiform neurofibroma 0.03
Enhancer RNA–mediated transcriptional regulatory programs reveal the malignant progression of glioma 1.00
21 16.79
Genomic instability drives POSTN+ myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer 0.98
Targeting RBPMS selectively eliminates FOXO1-mediated stem cell signatures in mouse models of acute myeloid leukemia 1.00
Phase separation–based HTS identifies cobimetinib as a YAP-TEAD inhibitor that suppresses hyperactivated YAP-induced cancer progression 1.00
Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers 0.12
Site-specific methylation of SRSF2P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome 0.95
In vivo generation of CAR myeloid cells through erythrocyte-mediated mRNA delivery for cancer immunotherapy 1.00
Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenografts 0.06
A hyperactive splice variant of STAT3 promotes colonic inflammation-associated tumorigenesis in mice 1.00
A modular metalloprotein in situ vaccine for cancer immunotherapy in mouse models of breast cancer 1.00
Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiation 1.00
Cholesterol desensitizes the response of endometrial cancer to progestin by attenuating progestin signaling 1.00
USP5 inhibition enables potential therapy for t(8;21) AML through ubiquitin-mediated AML1-ETO degradation in patient-derived xenografts 1.00
Interferon-induced senescent CD8+ T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer 1.00
Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer 0.90
Targeting SIRT2 induces MLH1 deficiency and boosts antitumor immunity in preclinical colorectal cancer models 1.00
Myeloma interaction with bone marrow stromal cells suppresses ciliogenesis and osteogenic potential in myeloma bone disease 0.96
Podocyte YAP and TAZ hyperactivation drives glomerular epithelial proliferative diseases in mice and humans 0.05
OX40–heparan sulfate binding facilitates CAR T cell penetration into solid tumors in mice 0.73
Proteogenomic characterization reveals that lipid droplet formation promotes esophageal squamous cell cancer progression 1.00
Targeted suppression of glioma by ultralow-dose x-ray–induced photodynamic therapy and gold-based nanoclusters in preclinical models 1.00
Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers 0.05
8 7.08
Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial 1.00
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial 1.00
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial 1.00
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial 1.00
Targeted therapy in advanced BRAF-mutated colorectal cancer: systematic review and network meta-analysis 1.00
First mammography screening participation and breast cancer incidence and mortality in the subsequent 25 years: population based cohort study 0.08
<atl>Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in iEGFR-/i mutated non-small cell lung cancer: systematic review and network meta-analysis</atl> 1.00
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial 1.00
10 8.08
Structures of the neutral amino acid transporter LAT4 provide insights into antitumor effects of its inhibitor tubeimoside-1 1.00
Protease-mediated PRC1 dissociation promotes H2AK119ub remodeling during stress responses 0.97
Pervasive phenotypic effects of FBXO42 are promoted by regulation of PP4 phosphatase 0.08
Homeostatic control of energy metabolism by monocyte-derived macrophages 0.03
3′UTR shortening alleviates miRNA repression of mRNAs critical for muscle stem cell differentiation 1.00
Tumor-secreted clusterin promotes cachectic fat wasting via disrupting circadian gene expression and adipogenesis 1.00
Annexin A7 enhances TIA1 axonal trafficking to counteract pathological aggregation in neurons 1.00
Hemocytes facilitate interclonal cooperation-induced tumor malignancy by hijacking the innate immune system in Drosophila. 1.00
Adipose tissue-secreted Spz5 promotes distal tumor progression via Toll-6-mediated Hh pathway activation in Drosophila. 1.00
A chromatin-remodeling-independent role for ATRX in protecting centromeric cohesion 1.00
1 1.00
Role of APE1 Redox Function in Chronic Rhinosinusitis Pathogenesis: Implications for Targeted Therapy 1.00
3 3.00
Stabilizing Delocalized Charge-Transfer State in Anthraquinone-Centered TADF Emitters for Enhanced Reactive Oxygen Species Production 1.00
A Cocrystal Strategy for Harnessing UV-Responsive Endogenous Photosensitizer in Visible Light Photodynamic Therapy 1.00
Fluoro-Substitution of BODIPY Derivatives to Enhance Photothermal Conversion Efficiency for Near Infrared II Fluorescence Imaging and Immuno-photothermal Therapy 1.00
11 7.72
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial 0.54
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial 1.00
Socioeconomic inequalities in cancer survival and access to health care among children and adolescents in China, 2018–24: a prospective nationwide cohort study 0.97
Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China 1.00
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China 0.97
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial 1.00
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial 1.00
Adagrasib versus docetaxel in KRAS G12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial 0.14
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study 0.05
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial 1.00
1 0.20
Thyroid cancer in adolescents and young adults: a population-based study in 185 countries worldwide 0.20
22 11.69
Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial 0.08
Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial 0.24
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study 0.16
Evaluation of progression-free status at 24 months as a surrogate endpoint for overall survival in patients with human papillomavirus-positive oropharyngeal cancer: a retrospective cohort study 0.06
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial 1.00
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial 0.03
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial 0.17
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial 0.71
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial 0.07
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study 1.00
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial 1.00
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study 0.75
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial 1.00
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial 0.09
Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study 0.06
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial 1.00
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study 1.00
Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis 0.56
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial 0.02
Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine–oxaliplatin versus short-course radiotherapy followed by capecitabine–oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial 1.00
Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study 0.68
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial 1.00
21 5.35
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer 0.11
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy 0.04
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations 0.40
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer 0.24
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.13
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma 1.00
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer 0.27
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.05
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab 0.03
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer 0.05
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer 0.10
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer 0.06
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer 1.00
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer 0.06
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC 1.00
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.28
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC 0.14
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC 0.07
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy 0.15
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer 0.11
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer 0.08
4 3.56
The conserved spliceosomal protein AtSF3B2 controls the floral transition by regulating transcription and splicing in Arabidopsis 0.89
CCCH-type zinc finger proteins are required for meiotic progression and RNA clearance in Arabidopsis 1.00
The Arabidopsis histone methylation reader MRG2 interacts with eIF4A3 to regulate alternative splicing and circadian rhythms 0.89
ANAPHASE-PROMOTING COMPLEX/ANAPHASE-PROMOTING COMPLEX/CYCLOSOME coactivators maintain AURORA 1 kinase homeostasis during meiotic chromosome segregationcoactivators maintain AURORA 1 kinase homeostasis during meiotic chromosome segregation 0.78
1 1.00
Virtual screening of quorum sensing inhibitors with dual inhibitory effects on harmful cyanobacteria: quorum sensing interference and growth inhibition 1.00

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.